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	SUMMARY	
Gene	 therapy	 to	 cure	HIV	 is	 now	a	 reality	 and	 various	 clinical	 trials	 are	 underway.	 Since	 the	
development	of	humanized	mouse	models,	studying	human	specific	 infectious	disease	such	as	
HIV	 in	 the	 context	 of	 gene	 therapy	 has	 become	 more	 accessible,	 previously	 these	 types	 of	
studies	were	done	in	primate	models	using	SIV.	Humanized	mice	to	study	HIV	gene	therapy	has	
therefore	 gained	massive	 impetus	 over	 the	 last	 decade	 and	 there	 is	 a	 remarkable	 variety	 of	
strategies	 implemented	 thus	 far	 in	 pre‐clinical	 humanized	 mouse	 studies.	 The	 work	 of	 this	
thesis	focuses	on	an	HIV	gene	therapy	strategy	where	the	therapeutic	gene	is	a	microRNA	which	
eliminates	expression	of	a	critical	host	co‐factor	(CCR5	protein)	required	for	HIV	infection.	The	
therapeutic	microRNA	is	delivered	to	the	target	cells	with	an	HIV‐1	lentiviral	vector.		
One	first	aim	was	to	develop	a	novel	microRNA	with	superior	gene	knockdown	capabilities.	We	
looked	at	 and	modified	various	 structural	 features	of	microRNAs	such	as	 lower	 stem	 lengths,	
upper	stem	configurations	and	thermodynamics	of	 the	upper	stem	to	 try	and	come	up	with	a	
design	 that	would	 improve	processing	of	 the	microRNA	by	 the	enzymes	DROSHA	and	DICER.	
Improved	 processing	 of	 microRNAs	 by	 these	 enzymes	 translates	 into	 more	 targeting	 strand	
being	excised	from	the	microRNA	which	is	the	effector	of	gene	knockdown.	The	gene	we	aimed	
to	 knockdown	 in	 the	 initial	 studies	 was	 human	 CCR5	 (a	 critical	 co‐factor	 for	 HIV	 entry	 into	
target	 cells)	 and	 reporter	 gene	 GFP.	 The	 culmination	 of	 the	 experiments	 results	 in	 a	 new	
microRNA	 which	 we	 called	 mirGE	 and	 consisted	 of	 the	 following	 structural	 features:	 Lower	
stem	length	of	13	nucleotides,	targeting	strand	carried	on	the	5'	side	of	the	microRNA,	the	5’	end	
of	the	targeting	strand	is	thermodynamically	unstable	compared	to	the	3’	end	and	has	a	wobble	
in	 the	 middle	 of	 this	 upper	 stem.	 We	 compared	 our	 mirGE	 to	 a	 commercially	 available	
microRNA,	miR‐30.	mirGE	proved	superior	 in	 the	 following	ways:	 amount	of	 targeting	 strand	
made	 available	 for	 incorporation	 into	 RISC;	 ensuring	 the	 correct	 strand	 (targeting	 strand)	 is	
incorporation	 into	RISC	and	we	 improved	the	precision	of	DROSHA	cleavage	 from	about	21%	
inaccuracy	 to	 0.027%.	We	 could	 achieve	 an	 efficiency	 of	 over	 90%	knockdown	of	 CCR5	with	
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extremely	low	transduction	rates,	which	proved	sufficient	to	render	cells	resistant	to	infection	
with	CCR5	tropic	HIV.		
Our	 second	 aim	was	 to	 test	 this	mirGE	 CCR5	 knockdown	 lentivector	 in	 vivo	 in	 a	 humanized	
mouse	model	 to	 determine	whether	we	 can	 transduce	human	hematopoietic	 progenitor	 cells	
(CD34+	 cells),	 whether	 these	 transduced	 cells	 expressing	mirGE	 can	 engraft	 and	 give	 rise	 to	
mirGE	expressing	progeny	cells	 in	 the	periphery	of	 the	mice	and	whether	 the	HIV	target	cells	
CD4+	T	cells	in	the	mice	are	protected	against	HIV	during	chronic	infection.	We	discovered	that	
in	order	to	inhibit	HIV	viral	replication	in	the	mice	we	had	to	achieve	mirGE	expression	in	>90%	
of	HIV	target	cells	in	the	periphery	of	the	animals.	This	high	frequency	of	transduced	cells	in	the	
mice	was	 achieved	by	 sorting	 the	CD34+	 cells	 transduced	with	 the	mirGE	 lentivector	 by	 flow	
cytometry.	 These	 purified	 mirGE	 expressing	 cells	 were	 transplanted	 into	 the	 mice	 which	
showed	functional	and	persistent	resistance	to	CCR5‐tropic	HIV	for	over	6	months	and	survival	
of	human	CD4+	T	cells	despite	HIV	challenge.		
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ZUSAMMENFASSUNG	
Gentherapie	 als	 Ansatz	 zur	 Heilung	 von	 HIV	 –infizierten	 Individuen	 ist	 nun	 Wirklichkeit	
geworden	und	verschiedene	klinische	Studien	sind	zurzeit	im	Gange.	Seit	der	Entwicklung	von	
humanisierten	 Mausmodellen,	 wurden	 gewisse	 Infektionskrankheiten	 die	 spezifisch	 für	 den	
Menschen	 sind,	 wie	 HIV,	 und	 deren	 Behandlung	 durch	 Gentherapie,	 einer	 umfassenderen	
Untersuchung	 zugänglich.	 Bisher	 mussten	 solche	 Untersuchungen	 in	 Primaten	 mit	 SIV	
durchgeführt	 werden.	 Das	 erforschen	 von	 HIV	 Gentherapien	 in	 humanisierten	 Mäusen	 hat	
deshalb	einen	massiven	Auftrieb	im	letzten	Jahrzehnt	erlebt	und	es	gibt	eine	bemerkenswerte	
Vielfalt	 an	 Strategien,	 die	 bisher	 in	 diesem	 präklinischen	 Model	 erprobt	 wurden.	 Der	 Focus	
dieser	Arbeit	 ist	 eine	HIV‐Gentherapie‐Strategie,	wobei	die	Expression	eines	 zelleigenen	Gens	
(CCR5‐Protein),	welches	kritisch	 ist	 für	die	Infektion	durch	HIV,	gezielt	durch	eine	spezifische	
microRNA	eliminiert	wird.	Diese	therapeutische	microRNA	wird	durch	einen	HIV‐1	lentiviralen	
Vektor	in	die	Zielzellen	eingebracht.		
Unser	 erstes	 Ziel	 war	 es,	 eine	 neue	 microRNA	 mit	 überlegenen	 Knock‐Down‐Funktionen	 zu	
entwickeln.	Wir	haben	verschiedene	strukturelle	Eigenschaften	von	microRNAs	untersucht	und	
modifiziert,	 wie	 zum	 Beispiel	 die	 untere	 Stem‐Länge,	 die	 obere	 Stem‐Konfiguration	 oder	 die	
thermodynamische	Stabilität	des	oberen	Stems,	um	die	Verarbeitung	der	microRNA	durch	die	
Enzyme	Drosha	und	DICER	zu	verbessern.	Eine	verbesserte	Verarbeitung	von	microRNAs	durch	
diese	Enzyme	führt	zur	Exzision	von	mehr	Ziel‐Strängen	aus	der	microRNA,	welche	direkt	 für	
den	 Knock‐Down	 verantwortlich	 sind.	 Das	 Zielgen	 in	 diesen	 Knock‐Down‐Studien	 war	 das	
menschliche	 CCR5	 (ein	 wichtiger	 Ko‐Faktor	 für	 den	 HIV‐Eintritt	 in	 die	 Zielzellen)	 und	 das	
Reportergen	GFP.	Das	Endresultat	dieser	Versuche	war	eine	neue	microRNA,	welche	wir	mirGE	
bezeichnet	haben	und	die	 folgenden	Strukturmerkmale	aufweist:	Eine	untere	Stem‐Länge	von	
13	 Nukleotiden,	 eine	 Ziel‐Sequenz	 am	 5’‐Ende	 der	 microRNA,	 ein	 5'‐Ende	 des	 Ziel‐Strangs,	
welches	 thermodynamisch	 instabil	 ist	 im	 Vergleich	 zum	 3'‐Ende	 und	 eine	 Wobble‐Sequenz	
besitz	 in	 der	 Mitte	 des	 oberen	 Stems.	 Wir	 haben	 unsere	 mirGE	 mit	 einer	 kommerziell	
erhältlichen	 microRNA,	 miR‐30,	 verglichen.	 Die	 mirGE	 hat	 sich	 in	 den	 folgenden	 Arten	 und	
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Weisen	als	überlegen	 erwiesen:	Mehr	Ziel‐Strang	wurde	produziert	und	 stand	 zum	Einbau	 in	
den	RISC‐Komplex	zur	Verfügung;	Die	Spezifität	mit	welcher	der	korrekte	Strang	(Ziel‐Strang)	
in	den	RISC‐Komplex	eingebracht	wurde	war	höher	und	eine	verbesserte	Präzision	der	Drosha	
Spaltung	von	etwa	21%	Ungenauigkeit	auf		0,027%	konnte	nachgewiesen	werden.	Wir	könnten	
einen	CCR5	knock‐down	von	über	90%	erreichen	trotz	einer	niedrigen	Transduktionseffizienz.	
Dieser	 Knock‐Down	 erwies	 sich	 als	 ausreichend	 um	 Zellen	 resistent	 zu	 machen	 gegen	 eine	
Infektion	mit	CCR5	tropischem	HIV.	
Unser	zweites	Ziel	war	es,	die	mirGE	in	vivo	in	einem	humanisierten	Mausmodell	zu	testen,	um	
zu	bestimmen,	ob	wir	humane	hämatopoetische	Vorläuferzellen	(CD34+	Zellen)	 transduzieren	
können,	ob	diese	transduzierten	Zellen,	welche	die	mirGE	exprimieren,	in	vivo	anwachsen	und	
zu	mirGE	 exprimierenden	Tochterzellen	 in	den	Mäusen	 führen	und	ob	die	HIV‐Zielzellen,	 die	
CD4+	T	Zellen,	in	diesen	Mäusen	während	chronischer	Infektion	von	HIV	geschützt	bleiben.	Wir	
haben	entdeckt,	dass	die	mirGE	Expression	in	über	90%	der	HIV‐Zielzellen	im	peripheren	Blut	
vorhanden	sein	muss	um	die	HIV‐Virusreplikation	in	den	Mäusen	zu	unterdrücken.	Diese	hohe	
Frequenz	 von	 mirGE	 transduzierten	 Zellen	 im	 Blut	 der	 Mäuse	 wurde	 erzielt	 durch	 eine	
durchflusszytometrische	 Selektion	 der	 CD34+	 Zellen,	 welche	 mit	 dem	 mirGE	 lentivector	
transduziert	wurden.	Diese	aufgereinigte	Population	von	mirGE	exprimierenden	Zellen	wurde	
in	 Mäuse	 transplantiert,	 welche	 daraufhin	 eine	 funktionelle	 und	 anhaltende	 Resistenz	 gegen	
CCR5‐tropisches	 HIV	 aufwiesen.	 Diese	 Resistenz	 hat	 über	 6	 Monate	 angedauert	 und	 hat	 das	
Überleben	von	menschlichen	CD4+	T	Zellen	ermöglicht,	trotz	HIV‐Infektion.	
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INTRODUCTION	
1.1	The	Human	Immunodeficiency	Virus	
The	human	 immunodeficiency	 virus	(HIV)	 is	 a	lentivirus	 and	 can	 cause	 acquired	
immunodeficiency	 syndrome	(AIDS).	 In	 humans	 AIDS	 results	 in	 the	 progressive	 failure	 of	
the	immune	 system	 and	 people	 with	 AIDS	 suffer	 from	 constant	 opportunistic	
infections	and	cancers	 1.	 One	 of	 the	 most	 important	 aspects	 of	 the	 virus	 is	 its	 high	 rate	 of	
evolution	or	tendency	to	mutate	at	a	genetic	level	rather	quickly.	This	is	the	major	hurdle	that	
makes	effective	treatment	of	the	disease	so	difficult,	since	it	has	been	estimated	that	for	HIV‐1,	
single	 mutations	 that	 could	 render	 a	 particular	 drug	 ineffective	 can	 occur	 on	 a	 daily	 basis,	
making	the	use	of	multiple	drugs	obligatory	2.		
HIV	belongs	 to	 the	Retroviridiae	 family	of	viruses,	 the	main	characteristics	of	 these	viruses	 is	
that	 they	 are	 enveloped	 with	 a	 single	 stranded	 RNA	 genome.	 The	 RNA	 genome	 is	 reverse	
transcribed	into	DNA	which	is	stably	integrated	into	the	genome	of	the	host	or	target	cell.	This	
proviral	 genome	 serves	 as	 a	 template	 for	 the	 production	 of	 new	 viral	 RNAs,	 proteins	 and	
eventually	 the	 assembly	 of	 progeny	 virions.	 More	 specifically,	 HIV	 is	 part	 of	 the	 lentivirus	
subfamily,	 the	 hallmarks	 of	 lentiviruses	 is	 that	 their	 genomes	 are	 more	 complex	 than	 other	
retroviruses	and	lentiviruses	result	in	a	slow	and	degenerative	disease	which	can	last	decades,	
compared	 to	 other	 retroviruses	 	 such	 as	 oncoretroviruses	 which	 cause	 rapidly	 developing	
tumours.	The	HIV	genome	can	be	split	 into	 two	parts,	 the	non‐coding	or	cis‐acting	sequences	
and	 the	 coding	 sequences.	 The	 non‐coding	 sequences	 are	 responsible	 for	 replication,	
integration	and	expression	of	proviral	sequences	and	include	the	5’	cap,	the	R	(repeated)	region	
which	is	present	in	the	5’	LTR	as	well	as	the	3’	LTR	and	contains	the	TAR	sequence	which	allows	
binding	of	TAT,	the	U5	sequence	which	contains	the	att	sites	allowing	for	proviral	integration,	
the	 PBS	 site	 which	 binds	 tRNA	 which	 serves	 as	 a	 primer	 for	 reverse	 transcription,	 the	 Psi	
element	which	is	the	signal	for	encapsidation	of	viral	RNA	into	the	viral	particle,	the	central	and	
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distal	polypurine	tracts	which	are	primers	for	formation	of	plus	strand	DNA,	the	Rev‐responsive	
element	which	is	recognised	by	Rev	and	facilitates	export	of	viral	mRNAs	to	the	cytoplasm	and	
finally	 the	 U3	 region	 again	 containing	 sequences	 required	 for	 DNA	 integration.	 The	 coding	
sequences	include	the	LTRs	which	contain	regions	that	bind	host	transcription	factors,	the	Gag	
and	Env	 genes	which	 code	 for	 the	 structural	 proteins	of	 the	 virus	 such	 as	 the	matrix,	 capsid,	
nucleocapsid	 and	gp160	envelope	protein	 respectively.	 The	Pol	 gene	 codes	 for	 viral	 enzymes	
such	 as	 protease,	 reverse	 transcriptase	 and	 integrase.	 Finally,	 there	 are	 6	 regulatory	 or	
accessory	genes;	Vif,	Vpr,	Vpu,	Nef,	Tat	and	Rev	which	together	allow	the	virus	to	infect	cells	and	
replicate	3.		
	
1.2	The	HIV	pandemic,	impact	and	current	treatment	strategies		
More	 than	 39	 million	 people	 have	 died	 worldwide	 in	 the	 HIV	 pandemic	 from	 AIDS	
(http://www.unaids.org/sites/default/files/media_asset/01_PeoplelivingwithHIV.pdf).	 South	
Africa	with	~50	million	habitants	is	one	of	the	worst	affected	regions	and	is	faced	with	a	major	
HIV/AIDS	burden	with	 an	 estimated	prevalence	of	 17.9%	 (~6.1	million	HIV‐positive	people);	
the	estimated	number	of	AIDS	orphans	mounts	to	2.5	million	AIDS	orphans	(www.UNAIDS.org	
2012).	South	Africa’s	challenge	is	to	address	various	issues	surrounding	the	diseased	including	
prevention,	treatment	and	education.	Currently,	the	only	effective	treatment	for	HIV‐associated	
immunodeficiency	 is	 highly	 active	 antiretroviral	 therapy	 (HAART),	 resulting	 in	 an	 impressive	
decrease	in	HIV‐associated	morbidity	and	mortality	4,5.	However,	widespread	implementation	of	
HAART	has	 revealed	a	 large	number	of	problems,	 such	as	access	 to	HIV	clinics,	 emergence	of	
resistant	 viral	 strains	 in	 case	 of	 non‐adherence,	 and	 the	 side	 effects	 of	 lifelong	 use.	 Despite	
HAART	which	can	allow	patients	to	live	a	relatively	normal	life	with	HIV,	there	is	still	no	cure.	
There	are	 three	main	treatment	strategies	 i)	vaccines,	 ii)	development	of	drugs	 to	 induce	and	
purge	 the	 latent	 reservoir	 which	 would	 be	 used	 in	 combination	 with	 HAART	 and	 iii)	 gene	
therapy.	All	three	approaches	are	being	explored	to	provide	a	sterile	cure	(eliminating	any	trace	
11	
	
of	viremia)	or	to	provide	a	functional	cure	(persistence	of	a	low	but	stable	viremia	without	any	
impact	on	the	immune	system).		
	
1.3	Highly	active	antiretroviral	therapy	(HAART)	and	its	effect	on	HIV	decline	
HIV	can	now	be	considered	as	a	chronic	disease	 that	 can	be	managed	due	 to	 the	advances	 in	
HAART	over	the	last	three	decades.	HAART	combines	conventionally	three	drugs,	i.e.,	two	drugs	
belonging	to	the	family	of	the	nucleoside	reverse	transcriptase	inhibitors	(NRTIs)	and	a	3rd	one	
which	 is	 either	 a	 non‐nucleoside	 reverse	 transcriptase	 inhibitor(NNRTI),	 a	 protease	 inhibitor	
(PI)	or	an	integrase	inhibitor	(INSTI).	Using	a	combination	of	drugs	ensures	that	multiple	steps	
in	the	HIV	life	cycle	are	targeted	simultaneously,	minimizing	the	risk	of	emergence	of	resistant	
strains.	HAART	 is	 able	 to	decrease	 viremia	 to	 below	detection	 limits.	Once	 a	patient	 receives	
HAART,	the	decline	in	viral	load	can	be	described	in	four	stages,	where	in	each	stage	there	is	a	
smaller	 possibility	 of	 eliminating	 infected	 cells	 and	 thus	 a	 slower	 decline	 in	 viremia	 in	 each	
subsequent	 stage	 which	 is	 linked	 to	 the	 increased	 half‐life	 of	 various	 distinct	 cells	 types	
involved	in	HIV	infection.		
Stage	1:	Occurs	within	2	weeks	 from	 the	 start	of	 treatment:	 There	 is	 a	 sharp	 decline	 in	
peripheral	blood	viremia	which	has	been	attributed	to	the	elimination	of	productively	infected	
cells	due	to	the	drugs	preventing	new	rounds	of	infection;	in	parallel	we	note	a	recovery	of	CD4+	
T	cells	 in	 the	blood.	The	strikingly	 rapid	decline	 in	blood	viremia	during	stage	one	 is	directly	
related	to	the	relatively	short	half‐lives	of	free	virus	in	the	blood	(~6	hours)	and	productively	
infected	cells	(<2	days)	6,7.	Stage	2;	Occurs	much	slower	than	stage	1:	During	this	phase	the	
continued	decline	in	viremia	has	been	accounted	to	the	elimination	of	long	lived	infected	cells,	
such	 as	 macrophages	 and	 dendritic	 cells	 as	 well	 as	 partially	 activated	 CD4+	 T	 cells.	 The	
increased	 half‐life	 of	 infected	 macrophages	 compared	 to	 infected	 CD4+	 T	 cells	 is	 because	
infected	macrophages	are	less	susceptible	to	the	cytopathic	effects	of	HIV	8.	Partially	activated	
CD4+	T	 cells	have	 an	 increased	half‐life	 compared	 to	HIV‐infected	 fully	 activated	CD4+	T	 cells	
which	is	the	most	likely	reason	for	the	slower	viremia	decline	in	this	stage	8.	Indeed	the	findings	
12	
	
related	to	resting	memory	CD4+	T	cells	(the	first	definition	of	an	HIV	latent	reservoir,	9	showed	
that	these	cells	have	a	half‐life	of	over	40	months	but	when	activated	can	produce	replication	
competent	 virus.	 10,11.	 It	 is	 likely	 that	when	 such	 resting	 CD4+	 T	 cells	 are	 activated	 and	 large	
amount	 of	 viral	 replication	 occurs	 that	 the	 cells	 do	 not	 survive	 12.	 Therefore	 it	 has	 been	
suggested	that	the	pool	of	latently	infected	memory	CD4+	T	cells	is	propagated	when	these	cells	
are	infected	in	the	declining	phase	of	activation	and	progression	to	the	active	replication	phase	
is	blocked	13.	It	has	been	suggested	that	a	mechanism	that	allows	for	the	propagation	of	latently	
infected	memory	CD4+	T	cells	is	low	level	homeostatic	proliferation	of	this	pool	of	cells	caused	
by	 the	 presence	 of	 antigens	 and	 interleukin‐7	 14.	 Stage	 3	 and	 4:	 These	 stages	 have	 been	
described	as	consisting	of	a	pool	of	central	memory	(TCM)	and	transitional	memory	(TTM)	CD4+	T	
cells	 which	 can	 persist	 for	 decades	 depending	 on	 patient	 CD4+	 T‐cell	 counts	 and	 how	 early	
HAART	was	started	14.	In	fact	the	size	of	the	reservoir	depends	on	how	early	HAART	is	started,	
but	 will	 otherwise	 not	 affect	 disease	 outcome.	 To	 conclude,	 HAART	 is	 very	 effective	 and	
provides	 patients	 around	 the	 world	 with	 a	 strategy	 to	 live	 with	 the	 disease.	 However,	 the	
persistence	of	the	virus	despite	treatment	requires	lifelong	adherence	which	is	the	main	draw‐
back	of	HAART	therapy.						
	
1.4	HIV	latency		
As	outlined	above,	HAART	effectively	reduces	blood	viremia	and	productively	infected	cells	but	
has	 no	 effect	 on	 infected	 cells	 with	 a	 long	 half‐life	 and	 which	 do	 not	 enter	 into	 a	 phase	 of	
productive	infection	defined	as	a	state	where	the	HIV	promoter	is	actively	transcribing	genomic	
viral	RNA	and	producing	progeny	virus.	Instead	cells	can	be	infected	and	the	HIV	promoter	can	
exist	 in	 an	 inactive	 state	 resulting	 in	 no	 transcription	 of	 viral	 RNAs	 and	 no	 production	 of	
progeny	virus.	Latency	 is	 a	dynamic	process	whereby	HIV	 is	 able	 to	 secure	 its	 long‐term	and	
almost	sustainable	survival	 in	the	host.	Latency	is	one	of	the	ways	but	not	the	major	way	that	
HIV	escapes	immune	surveillance;	it	is	also	a	way	that	HIV	preserves	its	presence	in	the	host	by	
avoiding	the	cytopathic	effects	of	producing	progeny	virus	15	16	17.		
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i)	Establishment	of	 latency:	There	are	two	current	understandings	of	how	latency	results	 in	
viral	persistence	despite	HAART	treatment.	The	first	is	linked	to	the	normal	life	cycle	of	CD4+	T	
cells	which	upon	exposure	to	antigen	the	resting	CD4+	T	cells	become	activated,	proliferate	and	
differentiate	producing	effector	CD4+	T	cells,	some	of	which	do	not	die	but	return	to	the	resting	
stage	and	become	long	lived	memory	cells	primed	for	an	improved	response	upon	re‐exposure	
to	the	antigen.	HIV	usually	infects	activated	CD4+	T	cells,	once	the	proviral	DNA	has	integrated	
into	 the	 genome	 of	 the	 cell	 it	 comes	 under	 the	 control	 of	 host	 transcriptional	 activation	 and	
deactivation	 where	 the	 cellular	 transcription	 factor	 nuclear	 factor‐ƘB	 (NFƘB)	 and	 specificity	
protein	1	 (Sp1)	 initiate	 transcription	of	viral	 accessory	proteins	 18.	 	Once	 the	HIV	Tat	protein	
(viral	 transactivator	 of	 transcription)	 reaches	 a	 critical	 level	 in	 the	 cell,	 rate	 of	 viral	
transcription	 is	 significantly	 increased	resulting	 in	virus	particle	production	and	cell	death	 18.	
Many	newly	infected	CD4+	T	cells	die	because	of	the	cytotoxic	effect	of	the	virus	as	well	as	host	
immune	responses.	However,	a	proportion	of	these	cells	despite	being	infected	by	HIV	survive	
and	return	to	a	resting	memory	state,	and	it	is	during	this	moment	that	host	transcription	factor	
dependant	 HIV	 transcription	 falls	 silent	 in	 a	 cell	 that	 is	 now	 programmed	 to	 survive	 for	 an	
extended	period	of	time	16.	It	is	still	not	completely	clear	whether	HIV	can	infect	and	establish	
latency	 in	 resting	 CD4+	 T	 cells	 or	 whether	 it	 is	 by	 infection	 of	 activated	 CD4+	 T	 cells	 which	
survive	 and	 revert	 to	 a	 resting	 state	 as	 described	 above	 18	 –	 in	 any	 case,	 latent	HIV	 is	 found	
mostly	 in	 long‐lived	memory	CD4	 +	T	cells	 14.	These	 latently	 infected	cells	 (about	1	per	1x106	
cells)	 contain	 integrated	 but	 transcriptionally	 inactive	 proviral	 DNA	 and	 are	 the	 reason	why	
patients	 despite	 having	 access	 to	 HAART	 cannot	 be	 cured	 of	 the	 disease.	 The	 second	
understanding	is	that	HAART	in	tissues	such	as	the	gut‐associated	lymphoid	tissue	and	central	
nervous	system	drug	penetration	is	not	optimal	and	low	level	HIV	replication	continues	in	these	
tissues	 which	 results	 in	 establishment	 and	 continuous	 renewal	 of	 a	 substantial	 reservoir	 of	
latently	infected	cells	19,20.	
ii)	Maintenance	of	 latency:	 	There	are	various	mechanisms	which	have	been	elucidated	that	
explain	how	HIV	latency	is	maintained.	HIV‐1	usually	integrates	in	gene	regions	that	are	actively	
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transcribed;	 this	 it	 seems	 somewhat	 counterintuitive	 for	 the	 existence/maintenance	 of	 latent	
provirus;	 this	phenomenon	 is	 explained	by	promoter	 exclusion	and	 convergent	 transcription:	
promoter	 exclusion	 results	 in	 HIV	 expression	 being	 repressed	 by	 transcription	 factors	 being	
displaced	from	the	HIV‐1	LTR	by	read‐through	of	the	host	RNA	polymerase	II	since	the	proviral	
DNA	is	in	the	same	orientation	as	the	host	gene	21;	convergent	transcription	results	in	collisions	
of	 the	 host	 RNA	 polymerase	 II	 due	 to	 the	 HIV‐1	 provirus	 having	 integrated	 in	 the	 opposite	
orientation	 as	 compared	 to	 the	 host	 gene	 22.	 In	 addition,	 the	 chromatin	 structure	 of	 genes	
determines	 whether	 the	 particular	 genes	 are	 accessible	 to	 the	 various	 transcription	 factors.	
Posttranslational	modifications	 such	 as	 acetylation	 and	methylation	 of	 histones	 contribute	 to	
changes	in	chromatin	structure	resulting	in	either	more	repressive	or	active	chromatin	states.	
The	role	of	histone	deacytelases	(HDACs)	in	maintaining	the	transcriptionally	silent	state	of	the	
HIV‐1	genome	in	latently	infected	cells	has	been	studied	in	detail	and	they	regulate	this	process	
in	various	ways	18.	HIV	latency	is	directly	regulated	by	HDACs	through	deacytelation	of	histone	
lysine	residues	which	limits	the	access	of	transcription	factors	to	the	DNA	and	indirectly	by	non‐
histone	protein	modification	or	deacytelation	of	the	RelA	subunit	of	NF‐αB	for	example	18.	This	
repressive	state	also	recruits	further	histone‐modifying	complexes	that	contribute	to	the	silent	
state	23.	In	the	HIV	latent	state	HDACs	are	brought	proximal	to	the	integrated	HIV	proviral	DNA	
LTR	by	various	transcription	factors	of	the	cell	such	as	retinoblastoma	family	protein	2	(RBF2),	
nuclear	factor‐ƘB	p50	(NF‐ƘB),	c‐promoter‐binding	factor	1	(CBF‐1),	specificity	protein	1	(Sp1)	
and	Ying‐Yang	1	(YY1)	18.	Nuc‐1,	the	repressor	nucleosome	which	is	positioned	downstream	of	
the	 HIV	 transcriptional	 start	 site	 during	 the	 latent	 stage	 requires	 for	 its	 positioning	 the	
BRG1/brm‐associated	 factor	 (BAF)	 complex	 which	 is	 associated	 with	 HDAC1	 &	 HDAC2.	
Furthermore,	 the	methyl	 binding	 protein	 (MBD2)	 detects	methylated	DNA	proximal	 to	 nuc‐1	
and	recruits	 the	nucleosome	remodelling	and	histone	deacetylation	complex	(NURD)	which	 is	
also	 associated	 with	 HDAC1	 and	 HDAC2	 18.	 HDAC3	 also	 deacytelates	 NF‐ƘB	 (p65‐p50)	 and	
negatively	regulates	its	full	activation.												
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iii)	Activation	of	 latency:	 Activation	 of	 latently	 infected	 cells	which	would	make	 purging	 of	
these	cells	possible	is	considered	as	the	key	to	a	sterilizing	cure	for	HIV.	Patients	on	HAART,	as	
discussed,	have	latently	infected	cells	surviving	despite	long‐term	treatment.	The	strategy	is	to	
bring	latently	infected	cells	of	HAART	treated	patients	out	of	this	silent	state	which	would	make	
these	cells	visible	to	the	immune	system	and	thus	being	killed	by	HIV‐specific	CTLs	or	NK	cells,	
or	 would	 die	 due	 to	 the	 cytopathic	 effects	 of	 viral	 replication.	 The	 ongoing	 HAART	 would	
prevent	 spreading	 infection.	 Various	 strategies	 to	 block	 the	 factors	 which	 are	 involved	 in	
repression	of	HIV	provirus	have	been	proposed.	One	example	is	the	NF‐ƘB	p50/p50	homodimer	
and	HDAC	1	24.	Indeed	studies	have	used	various	HDAC	inhibitors	for	this	purpose;	valproic	acid	
25	which	was	reported	to	reduce	the	number	of	HIV‐1	infected	resting	cells,	however	this	was	
not	confirmed	in	later	studies	26,27.	A	potent	class	1	HDAC	inhibitor,	suberoylanilide	hydroxamic	
acid	 or	 SAHA	 (Vorinostat)	 induces	 HIV‐1	 transcription	 in	 resting	 CD4+	 T	 cells	 in	 patients	 on	
HAART	 23.	One	 of	 the	major	 challenges	 is	 to	 accurately	 define	 the	 size	 of	 the	 latent	 reservoir	
because	 this	would	 allow	 one	 to	 define	whether	 the	 reactivation	 and	 purging	 is	 leading	 to	 a	
decrease	in	the	size	of	the	reservoir.	It	is	very	difficult	to	estimate	the	size	of	the	latent	reservoir	
in	a	patient	and	this	is	currently	done	through	the	viral	outgrowth	assay	which	can	provides	an	
estimate	of	 the	minimum	number	of	 latently	 infected	 cells	 that	 should	be	eliminated,	 or	with	
various	PCR	assay	detecting	HIV	DNA	28.	The	main	problem	with	the	viral	outgrowth	assay	is	the	
labour	 intensiveness	 and	 high	 costs,	while	 the	 PCR	 based	 assays	 cannot	 distinguish	 between	
replication‐competent	 and	 defective	 viral	 DNAs	 ‐	 this	 results	 in	 the	 PCR	 methods	 indicating	
infected	cell	frequencies	up	to	2	fold	higher	compared	to	viral	outgrowth	assays	28.		
	
1.5	HIV	vaccines		
After	decades	of	work,	there	is	still	no	efficacious	vaccine	for	HIV	29.	A	distinction	must	be	made	
between	 prophylactic	 and	 therapeutic	 vaccines.	 	 Notably,	 there	 are	 dozens	 of	 examples	 of	
various	approaches	and	multiple	clinical	trials	at	different	stages	being	conducted	30,31.	Notably,	
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despite	a	quarter	of	a	century’s	research	there	is	still	no	evidence	that	an	effective	prophylactic	
vaccine	is	possible	30.		
Prophylactic	vaccines:	A	careful	exposure	of	an	attenuated	form	of	for	example	a	virus	prior	to	
the	 onset	 of	 an	 infection	which	will	 induce	 the	 immune	 system	 to	 produce	 specific	 antibodies	
against	the	particular	virus.	
There	has	been	only	one	phase	III	vaccine	trial	for	HIV.	The	“Thai	trial”	showed	moderate	31.2%	
efficacy,	that	is	fewer	infections	over	42	months	32.	 	This	vaccine	called	RV144	was	based	on	a	
prime‐boost	 strategy,	 i.e.,	 prime	with	 ALVAC	which	 is	 a	 canarypox‐vector	 (based	 on	 an	 inert	
canarypox	virus	which	cannot	replicate	in	humans)	containing	three	genetically	engineered	HIV	
genes;	Env,	Gag	and	Pol,	and	then	a	boost	with	AIDSVAX	which	is	a	genetically	engineered	HIV	
envelope	gp120	glycoprotein.	The	success	of	this	trial	was	correlated	with	the	induction	of	non‐
neutralizing	 IgG	antibodies	binding	to	the	envelope	V1V2	loop	33.	Careful	analysis	of	 immune‐
correlates	of	the	Thai	trial	revealed	that	Env	binding	IgA	antibodies	lessen	the	anti‐HIV	effect	of	
the	 protecting	 V1V2	 binding	 IgG	 antibodies	 33.	 This	 is	 a	 very	 positive	 indication	 that	 the	
foundation	to	a	robust	HIV	vaccine	has	been	laid,	however	this	level	of	efficacy	(32%)	is	not	an	
acceptable	success	rate	allowing	for	routine	clinical	application	of	the	vaccine.		
Therapeutic	vaccines:	These	are	treatment	vaccines,	they	are	vaccines	designed	to	treat	a	person	
already	infected	with	for	example	a	virus	and	aim	to	boost	the	immune	system	to	help	control	the	
infection.		
There	 is	now	a	 lot	of	attention	being	focused	on	the	development	of	a	 therapeutic	vaccine	for	
HIV.	 The	 main	 advantage	 of	 therapeutic	 vaccines	 is	 that	 it	 is	 being	 used	 on	 HIV	 infected	
individuals,	 this	 allows	 for	 a	 much	 quicker	 and	 more	 cost	 effective	 determination	 of	 how	
effective	 the	vaccine	 is,	which	specific	 factors	are	 resulting	 in	 the	protection	and	whether	 the	
vaccination	 can	 complement	 traditional	 HAART.	 This	 then	 allows	 for	 a	 real‐time	 assessment	
that	depending	on	the	level	of	efficacy	of	the	vaccine	HAART	could	be	scaled	down,	simplified	or	
even	 interrupted	 34.	 There	 are	 two	 main	 arms	 of	 therapeutic	 vaccine	 research,	 developing	
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vaccines	that	 induce	a	humoral	 immune	response	and	vaccines	that	 induce	cellular	 immunity.	
An	example	of	a	current	therapeutic	vaccine	intended	to	induce	a	humoral	response	is	VAC‐3S.	
In	HIV	infected	patients	the	HIV	gp41	3S	domain	induces	expression	of	NKp44L	on	uninfected	
CD4+	T–cells	which	makes	 these	 cells	more	 susceptible	 to	 lysis	by	NKp44+	activated	NK	cells.	
VAC‐3S	peptide	immunization	should	result	in	the	production	of	anti‐gp41‐3S	antibodies	which	
block	 expression	of	NKp44L	on	CD4+	T	 cells	 and	protect	 these	 cells	 against	 activated	NK	 cell	
lysis	34‐36.	The	HVTN	502	and	503	vaccines	were	designed	to	induce	a	cellular	response	to	HIV	
and	 are	 based	 on	 a	 replication	 competent	 simian	 CMV	 vector	with	 expresses	 engineered	 SIV	
Gag,	 Tat,	Rev,	Nef,	 Env	 and	Pol	 37‐39.	This	 vaccine	 induces	protective	 effector	memory	CD8+	 T	
cells	which	were	restricted	by	MHCII	antigens	in	primate	models	with	some	promising	results	
where	50%	of	vaccinated	monkeys	were	protected	37‐39.	The	main	issue	with	this	strategy	is	its	
transferability	to	humans,	one	aspect	using	an	appropriate	vector.	Finally,	approaches	are	being	
investigated	 which	 try	 to	 define	 more	 specifically	 relevant	 epitopes	 using	 bioinformatics	
technology	 to	design	mosaic	or	 conserved	antigens	 to	be	used	as	vaccines	 40‐42.	The	aim	here	
being	is	to	improve	the	extent	of	both	humoral	and	cellular	immune	responses.					
	
1.6	HIV	gene	therapy	
Gene	engineering	HIV	resistant	T	cells	got	a	marked	impetus	with	the	first	HIV‐infected	person	
supposedly	 cured	 from	 HIV	 43‐45:	 the	 patient	 received	 bone	 marrow	 from	 a	 CCR532	
homozygous	 donor	 to	 treat	 acute	 myeloid	 leukemia,	 which	 eventually	 led	 to	 the	 patient	
undergoing	 a	 complete	 genotype	 shift	 from	 heterozygous	 to	 homozygous	 CCR5∆32.	 Even	
though	 the	 patient	 stopped	 HAART	 before	 transplantation,	 he	 did	 not	 experience	 a	 viral	
rebound	45	43.	CCR5	is	the	co‐receptor	of	HIV	for	cell	entry	46‐50;	its	lack	renders	cells	resistant	to	
HIV.	 This	 anecdotal	 case	 report	 suggests	 that	 stem/progenitor	 cell‐based	 gene	 therapies	
targeting	host	and/or	HIV	genes	 is	a	promising	strategy	 for	cure	of	HIV.	More	recently	 it	was	
reported	 that	 an	 HIV	 patient	 who	 developed	 anaplastic	 large	 cell	 lymphoma	 underwent	 a	
similar	procedure	and	received	donor	CCR5∆32	(homozygous)	stem	cells.	The	tropism	of	HIV	in	
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this	 patient	 was	 determined	 prior	 to	 the	 transplantation	with	 CCR5	 deficient	 stem	 cells	 and	
confirmed	as	predominantly	CCR5	tropic.	HAART	was	discontinued	prior	to	the	transplantation	
and	had	to	be	resumed	3	weeks	after	the	transplantation	due	to	a	viral	rebound	of	up	to	93’390	
HIV	RNA	copies/ml.	Tropism	analysis	at	 this	point	revealed	 that	 there	was	predominantly	X4	
tropic	 virus	 present,	 HAART	 successfully	 supressed	 the	 viral	 load	 again.	 However,	 the	 T‐cell	
lymphoma	relapsed	and	HAART	was	again	discontinued,	two	weeks	prior	to	the	patient’s	death	
viral	 load	 was	 at	 7’582’496	 HIV	 RNA	 copies/ml.	 It	 was	 clear	 that	 there	 was	 a	 shift	 from	
predominantly	 R5	 tropic	 HIC	 to	 X4	 tropic	 HIV	 in	 this	 patient	 most	 likely	 due	 to	 the	
transplantation	of	CCR5	deficient	stem	cells	51.	There	is	also	reference	to	other	patients	who	had	
experienced	 viral	 rebound	 despite	 transplantation	 with	 CCR5	 deficient	 stem	 cells	 52.	 This	
evidence	 indicates	 that	 targeting	 only	 CCR5	 or	 only	 other	 HIV	 targets	 in	 a	 gene	 therapy	
approach	 to	 cure	HIV	might	 in	 some	 cases	 not	 be	 sufficient	 to	 prevent	 viral	 rebound	 due	 to	
tropism	 shift.	 It	 is	 important	 that	 further	 targets	 be	 identified	 and	 used	 in	 conjunction	with	
CCR5.										
The	specificity	of	HIV	to	infect	humans	means	that	only	sophisticated	models	such	as	monkeys	
or	humanized	mice	are	appropriate	 for	studying	gene	 therapies	against	HIV.	Humanized	mice	
are	generated	by	 the	 transplantation	of	human	CD34+	 cells	 into	 immunocompromised	mice	–	
these	cells	engraft	and	build	a	lymphoid	system	of	human	origin,	susceptible	to	HIV	53.	Several	
different	humanized	mouse	models	 (NSG,	BLT,	NSG‐BLT,	NOD‐RAG1‐/‐IL2rγ‐/‐)	generated	by	
manipulation	and	 transplantation	of	human	CD34+	progenitors	have	been	used	 to	 investigate	
the	gene	engineering	modality,	by	silencing	and/or	modulating	host	and	viral	co‐factors.	Gene	
transfer	was	done	using	mainly	 lentiviral	 vectors	encoding	 i)	 shRNAs	against	various	viral	or	
host	cell	targets,	ii)	broadly	neutralizing	antibodies,	iii)	HIV‐specific	T	cell	receptor,	iv)	TRIM5α	
isoforms,	 v)	 TAR	 decoys	 as	 well	 as	 using	 nucleofection	 of	 targeted	 zinc‐finger	 nucleases	
targeting	CCR5	54	55	56	57	58	59.		The	success	to	inhibit	HIV	replication	varied	greatly;	in	particular,	
partial	 viral	 load	 inhibition	 in	vivo	was	demonstrated	by	gene	engineering	CD34+	 cells	with	a	
CCR5	 targeting	 zinc	 finger	 nuclease,	 an	 HIV	 specific	 TCR	 or	 a	 broadly	 neutralizing	 antibody	
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54,57,58.	 Also	 by	 gene	 engineering	 of	 CD4+	 T	 cells	 with	 a	 CXCR4	 targeting	 zinc	 finger	 or	
knockdown/overexpression	 of	 LEDGF/LEGDF	 mutants	 60,61,	 which	 provided	 inhibition	 for		
relatively	 short	 periods	of	 infection	 (7	 ‐	 56	days	 at	 the	most).	 Several	 publications	 restricted	
their	efforts	 to	present	 the	success	of	gene	engineering	HIV	resistant	cells	 in	humanized	mice	
with	ex	vivo	experimentations	with	purified	gene	engineered	cells	such	as	splenocytes	55,56,59.	62,	
showed	that	enrichment	of	anti‐HIV	transduced	cells	in	vivo,	however	no	in	vivo	infection	data	is	
shown.	 In	 this	work	 transduced	 cells	 express	 the	MGMTP140K	 	 drug	 resistance	 gene	 alongside	
with	 various	 anti‐HIV	 genes,	 the	 MGMTP140K	 expression	 provides	 cells	 with	 resistance	 to	
combination	treatment	with	bischloroethylnitrosourea	(BCNU)	and	O6‐benzylguanine	(O6‐BG)	
62.	 Thus,	 the	 studies	 done	 in	 humanized	 mice	 reveals	 the	 potential	 of	 gene	 engineering	 HIV	
resistant	cells	but	none	targeting	cellular	or	viral	factors	resulted	in	cure	definitive	cure	of	HIV	
thus	far.		
One	 of	 the	most	 commonly	 used	 tools	 for	 anti‐HIV	 gene	 therapy	 is	 RNA	 interference	 where	
appropriate	 target	 genes	 are	 silenced	 by	 expression	 of	 shRNAs.	 Intriguingly,	 the	 less	 widely	
used	cousin	of	the	shRNA,	the	pri‐miRNA	mimic	or	miRNA	has	only	rarely	been	tested	for	gene	
engineering.	shRNA	is	considered	more	powerful	 than	miRNAs,	but	more	 toxic	and	the	use	of	
shRNA	 may	 destabilize	 cellular	 homeostasis.	 miRNAs	 mimicking	 more	 closely	 natural	 pri‐
miRNAs	have	far	less	potential	to	result	in	those	adverse	effects	63‐68.	miRNAs	can	be	expressed	
using	 inducible	 or	 tissue	 specific	 RNA	 pol	 II	 promoters,	 while	 shRNAs	 in	 most	 cases	 are		
expressed	 using	 RNA	 pol	 III	 promoters	 which	 could	 be	 linked	 to	 destabilization	 of	 cellular	
homeostasis	64.	Thus,	miRNA	may	be	better	suited	for	doing	gene	therapy	provided	an	efficient	
knockdown	of	the	gene	of	interest.		
Despite	the	huge	variation	in	techniques	employed	thus	far,	one	major	hurdle	still	has	not	been	
addressed	 which	 is	 common	 to	 all	 of	 the	 above	 mentioned	 studies.	 The	 transplantation	 of	
chimeric	 populations	 of	 gene	 engineered	 and	 non‐gene	 engineered	 CD34+	 cells	 instead	 of	 a	
homogeneous	 population	 of	 gene	 engineered	 cells	 that	 is	 the	 most	 likely	 reason	 for	 the	
20	
	
continuing	loss	of	CD4+	T	cells	when	targeting	viral	or	cellular	host	factors	by	shRNA	in	clinical	
trials	as	well	as	in	humanized	mice.	
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AIMS	OF	THE	THESIS		
Provide	 in	vitro	 and	 in	vivo	 data	 as	 the	 foundation	 to	develop	a	 gene	 therapy	 cure	 for	HIV	 in	
patients	 involving	 autologous	 bone	 marrow	 transplantation	 of	 anti‐HIV	 gene	 engineered	
hematopoietic	 progenitor	 cells.	 Notably,	 HIV	 is	 dependent	 on	 critical	 host	 factors	 for	 its	
replication;	one	critical	factor	is	the	chemokine		receptor		CCR5		which		in		concert		with		CD4		
constitutes	 	the	 	HIV’s	 	entry	 	receptor	complex	 	 for	 	the	 	majority	 	of	 	HIV		strains.	 	This	gene	
engineering	 approach	 requires	 a	 highly	 efficient	 CCR5	 targeting	 “RNA	 interference”	 miRNA	
without	off‐target	effects	that	is	safe	for	the	clinical	setting.	We	attempted	to	design	such	a	CCR5	
targeting	miRNA	system	which	we	called	mirGE	(mir‐Geneva).	mirGE	was	specifically	designed	
to	 improve	 upon	 the	 suboptimal	 knockdown	 efficiency	 achieved	 with	 an	 existing	 widely	
published	miRNA	system	based	on	miR‐30.	I	set	out	to	 i)	 test	 various	 designs	 of	 mirGE	 which	
would	provide	 insights	 into	what	 structural 	 features 	of	a	miRNA	 are	most	 important	 for	
improving	efficiency	of	recognition	and	processing	of	miRNAs	to	achieve	 the	most	 efficient	
target	 gene	 knockdown.	 ii)	 Studying	 the	 efficacy	 of	 mirGE	 to	 protect	 protect	 	 cells	 	 against		
multiple		rounds		of		HIV		infection		in		vitro	and		to	determine	whether	this	strategy	can	protect	
NOD	 SCID	 gamma	 (NSG)	 humanized	 mice	 against	 HIV	 infection	 in	 vivo	 and	 ex	 vivo.	 iii)	
Providing	 the	 proof	 of	 concept	 that	 future	 in	 vivo	or	ex	vitro	 selection	 strategies	 would	 be	
required	 for	 the	success	 of	 this	 type	of	HIV	gene	therapy	approach	since	we	hypothesise	that	
in	 order	 to	 have	 a	 significant	 effect	 on	HIV	 viral	 	 replication,	 the	majority	 of	HIV	 target	 cells	
should	be	anti‐HIV	gene	engineered.	
The	two	original	papers	that	follow	entitled	“Optimization	of	critical	hairpin	features	allows	
miRNA‐based	gene	knock‐down	upon	single‐copy	transduction”	(Published	2014:	Molecular	
Therapy	 Nucleic	 Acids	 (2014)	 3,	 e207;	 doi:10.1038/mtna.2014.58)	 and	 “Lentivector	 knock‐
down	 of	 CCR5	 in	 hematopoietic	 stem	 cells	 confers	 functional	 and	 persistent	 HIV‐
resistance	in	humanized	mice”	(In	review)	are	the	main	focus	of	this	thesis.			
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Gene	knock‐down	using	miRNA‐based	vector	constructs	is	likely	to	become	a	prominent	
gene	 therapy	 approach.	 It	was	 the	 aim	 of	 this	 study	 to	 improve	 the	 efficiency	of	 gene	
knock‐down	 through	 optimizing	 the	 structure	 of	 miRNA	 mimics.	 Knock‐down	 of	 two	
target	 genes	was	 analyzed:	 CCR5	 and	 GFP.	 	We	 describe	 here	 a	 novel	 and	 optimized	
miRNA	mimic	 design	 called	mirGE	 comprising	 a	 lower	 stem	 length	 of	 13	 base	 pairs,	
positioning	of	the	targeting	strand	on	the	5'	side	of	the	miRNA,	together	with	nucleotide	
mismatches	in	upper	stem	positions	1	and	12	placed	on	the	passenger	strand.	Our	mirGE	
proved	superior	 to	miR‐30	 in	 four	aspects:	yield	of	 targeting	strand	 incorporation	 into	
RISC;	incorporation	into	RISC	of	correct	targeting	strand;	precision	of	cleavage	by	Drosha	
and	 ratio	 of	 targeting	 strand	 over	 passenger	 strand.	 A	 triple	 mirGE	 hairpin	 cassette	
targeting	CCR5	was	constructed.	It	allowed	CCR5	knock‐down	with	an	efficiency	of	over	
90%	upon	single	copy	transduction.	Importantly,	single	copy	expression	of	this	construct	
rendered	 transduced	 target	 cells,	 including	primary	human	macrophages,	 resistant	 to	
infection	with	a	CCR5‐tropic	strain	of	HIV.	Our	results	provide	new	insights	for	a	better	
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knock‐down	 efficiency	 of	 constructs	 containing	 miRNA.	 Our	 results	 also	 provide	 the	
proof‐of‐principle	 that	 cells	 can	 be	 rendered	HIV‐resistant	 through	 single	 copy	 vector	
transduction,	rendering	this	approach	more	compatible	with	clinical	applications.		
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INTRODUCTION	
	
Micro	 RNAs	 (miRNAs)	 are	 naturally	 occurring,	 non‐coding	 small	 RNAs,	 which	 regulate	 the	
expression	of	 target	genes	69,	by	degradation	of	 their	mRNA	and/or	block	of	 their	 translation.	
The	 generation	 and	 processing	 of	 miRNA	 from	 miRNA	 genes	 follows	 a	 defined	 pattern	 70.	
Briefly,	 miRNAs	 are	 typically	 transcribed	 by	 RNA	 polymerase	 II	 as	 a	 primary	 miRNA	 (pri‐
miRNA)	 of	 several	 hundred	nucleotides	 comprising	 a	~70	 bp	 stem‐loop	 structure.	 The	 stem‐
loop	structure	 is	 then	cleaved	 from	 the	pri‐miRNA	by	a	 "microprocessor	complex"	 formed	by	
the	RNAse	III	enzyme	Drosha	and	its	subunit	protein	DGCR8,	generating	the	precursor	miRNA	
(pre‐miRNA),	 which	 is	 similar	 in	 structure	 to	 	 	 shRNAs	 (short	 hairpin	 RNA)	 71,72.	 The	 pre‐
miRNAs	are	further	processed	in	the	cytoplasm	by	the	endoribonuclease	Dicer,	which	removes	
the	loop	of	the	hairpin,	yielding	a	miRNA	duplex	of	approximately	22	base	pairs.	The	antisense	
strand	 (targeting	 strand	 in	 this	paper)	 of	 the	miRNA	duplex	will	 be	 integrated	 into	 the	RNA‐
induced	silencing	complex	(RISC),	where	it	blocks	translation	through	interaction	with	its	target	
mRNA.		
The	elegance	and	efficiency	of	RNA	interference	has	rapidly	led	to	knock‐down	vectors	designed	
from	naturally	occurring	miRNAs.	A	first	generation	of	 lentivectors	directly	expressed	shRNAs	
as	 a	 simple	 stem	 loop	 structure	 with	 no	 flanking	 sequences.	 When	 transcribed,	 they	
immediately	 form	 a	 thermodynamically	 stable	 stem	 loop	 and	 are	 directly	 exported	 to	 the	
cytoplasm	where	they	are	processed	by	DICER	bypassing	Drosha.	 In	order	to	express	shRNAs	
without	flanking	sequences,	H1	73,	or	U6	74,	RNA	Pol	III	promoters	or	snRNA	U1	Pol	II	promoters	
68,	were	initially	used.	However,	these	promoters	suffer	from	i)	their	constitutive	expression and 
ii)	potential	toxicity	due	to	competition	of	the	artificial	shRNA	with	endogenous	miRNAs	and	an	
eventual	subsequent	saturation	of	the	RNAi	machinery,	specifically	the	karyopherin	exportin‐5	
63,65.	 Also,	 overexpression	 of	 shRNAs	 may	 stimulate	 the	 innate	 immune	 system	 through	
activation	 of	 the	 RNA‐dependent	 protein	 kinase/interferon	 response	 66.	 	 On	 the	 other	 hand,	
miRNA	 mimics	 are	 compatible	 with	 expression	 from	 RNA	 pol	 II	 tissue	 specific	 or	 inducible	
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promoters	and		produce	less	processed	antisense/targeting	strand	RNA,	which	if	in	excess	can	
lead	 to	 cellular	 toxicity	 64.	 Thus,	 constructs	 reproducing	 natural	 miRNA	 synthesis	 and	
processing	for	the	purpose	of	gene	knock‐down	could	be	preferred	to	shRNA	constructs.	Indeed,	
artificial	pri‐miRNA	mimics	have	been	used	for	silencing	a	variety	of	target	genes	67,75‐77.	Most	of	
these	 constructs	were	 based	 on	 a	 naturally	 occurring	miRNA	miR‐30	 backbone	with	 various	
flanking	 region,	 stem	 and	 loop	modifications	 67,69,75‐83.	 A	 similar	 version	 of	 this	miR‐30‐based	
miRNA	mimic	 is	 also	 commercially	 available	 (GIPZ	&	TRIPZ	 shRNAmir	 lentivector	 expression	
systems,	Open	Biosystems).		
Lentiviral	vectors	containing	either	shRNA	or	miRNA	are	very	promising	tools	for	gene	therapy	
involving	 gene	 repression.	 RNA	 interference	 as	 a	 tool	 for	 gene	 therapy	 has	 been	 explored	 in	
vitro	and	in	vivo	using	both	shRNA	and	miRNA	mimics.	Focusing	on	miRNA	in	lentivectors,	the	
main	targets	involved	were	HIV	84,85,	Hepatitis	B	virus	86,	cancer	87,	Alzheimer	disease	88,	only	to	
mention	a	few.	But	the	standards	for	such	vector	systems	are	high	since	they	should	achieve	the	
required	 knock‐down	 effect	 (ideally	 at	 a	 single	 transgene	 integration	 level)	without	 affecting	
normal	cell	functions.	Indeed,	multiple	transgene	insertions	into	the	host	cell	genome	resulting	
from	high	vector‐mediated	transduction	rates	can	increase	the	risk	of	alteration	of	functionally	
relevant	parts	of	the	genome	and	in	particular	increase	the	risk	of	oncogenesis	65,89.		
In	 this	 study,	we	optimized	miRNA‐mimic	design	by	adjusting	 complementary	 sequences	and	
stem	 lengths	 (mirGE).	We	 then	 chose	 the	most	potent	 variant,	 called	mirGE	herein	 after,	 and	
compared	 it	 to	 the	original	miR‐30	 in	 its	 efficiency	 to	knock‐down	 the	CCR5	HIV	co‐receptor.	
Our	mirGE	proved	largely	more	potent	than	miR‐30.		In	particular,	high‐throughput	sequencing	
revealed	 that	 mirGE	 is	 superior	 to	 miR‐30	 in	 four	 aspects:	 yield	 of	 targeting	 strand	
incorporation	 into	 RISC;	 incorporation	 into	 RISC	 of	 correct	 targeting	 strand;	 precision	 of	
cleavage	by	Drosha	and	ratio	of	targeting	strand	over	passenger	strand.		
We	increased	mirGE	efficiency	by	expressing	it	as	a	multiple	hairpin	structure	and	found	that	a	
triple	 hairpin	 anti‐CCR5	 mirGE	 down‐regulates	 CCR5	 expression	 by	 more	 than	 90%	 with	 a	
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single	 copy	 of	 lentivector.	 This	 level	 of	 CCR5	 knock‐down	 efficiency	 by	 a	 single	 copy	 of	 anti‐
CCR5	lentivector	protected	HeLa	cells	as	well	as	primary	human	macrophages	against	 in	vitro	
infection	with	a	CCR5‐tropic	HIV	strain	.	To	the	best	of	our	knowledge,	this	is	the	most	efficient	
miRNA‐based	lentivector	described	so	far	and	the	first	demonstration	that	miRNA‐based	CCR5	
knock‐down	by	a	single	copy	of	a	lentivector	can	confer	intra‐cellular	immunization	against	HIV.	
Our	 results	 thus	 pave	 the	 way	 towards	 an	 efficient	 yet	 clinically	 compatible	 gene	 therapy	
approach	aimed	at	generating	HIV‐resistant	immune	cells	in	human	patients.	
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RESULTS	
	
Effect	of	miRNA	hairpin	features	on	green	fluorescent	protein		knockdown.	
To	 test	 miRNA	 hairpin	 features	 critical	 for	 efficient	 gene	 knock‐down,	 we	 constructed	 a	
lentivector	containing	two	independent	expression	units	(Supplementary	Fig.	S1).	One	unit	is	
expressing,	under	the	control	of	the	human	Ubiquitin	promoter,	an	mRNA	containing	the	human	
microsomal	 glutathione	 S‐transferase	 2	 (MGST2)	 gene	 ORF	 followed	 by	 a	 variable	 miRNA	
structure	 targeting	 the	 GFP	 living	 color.	 The	MGST2	 gene	was	 used	 as	 spacer	 as	we	 initially	
observed	 that	 repression	 activity	 was	 dramatically	 reduced	 when	 miRNAs	 were	 placed	
immediately	 after	 the	 transcription	 start	 site	 (data	 not	 shown).	 A	 similar	 finding	 has	 been	
reported	 that	 absence	 of	 intervening	 sequence	 between	 the	 5’	 end	 of	 the	mRNA	 and	miRNA	
hairpin	was	 detrimental	 to	 knock‐down	 activity	 67.	 The	 other	 unit	 is	 expressing	 the	mCherry	
living	color	under	the	control	of	the	human	PGK	promoter.	This	dual	cassette	design	allowed	us	
to	reliably	follow	transduced	cells	expressing	constant	amounts	of	red	mCherry	protein,	while	
green	GFP	protein	expression	was	down‐regulated	by	the	miRNA.	
We	then	transduced	a	clone	of	HeLa	cells	stably	expressing	GFP	(4.5	cells)	90,	with	lentivectors	
containing	seven	versions	of	a	composite	miRNA	backbone	containing	the	same	22	nt	segment	
targeting	the	GFP	living	color	(Fig.	1).	This	miRNA	backbone	contains	the	miR‐16	lower	stem	as	
well	as	flanking	regions,	the	target‐specific	stem	containing	a	wooble	at	position	+12	(as	in	miR‐
16)	 and	 the	 miR‐30	 loop.	 We	 kept	 the	 miR‐30	 loop	 since	 the	 terminal	 loop	 seems	 to	 be	
dispensable	 for	 pri‐miRNA	processing	 72.	 Variations	 on	 this	 backbone	were	made	 in	 order	 to	
test	 for	 two	 features,	 i.e.	 the	 length	 of	 the	 lower	 stem	 and	 the	 side	 of	 the	 mismatch	 on	 the	
targeting	strand.	D13M5	refers	to	a	13	bp	long	lower	stem	and	a	single	nucleotide	mismatch	at	
the	5’	end	of	 the	 targeting	strand,	and	 is	 thus	analogous	 to	miR‐16	72,	 in	 terms	of	 lower	stem	
length	 and	 targeting	 strand	 mismatch	 orientation.	 Other	 hairpin	 designs	 follow	 the	 same	
numbering	 code,	where	 the	 number	 after	D	 represents	 the	 length	 of	 the	 lower	 stem	 and	 the	
number	after	M	represents	 the	mismatched	end	of	 the	 targeting	strand.	GFP‐positive	4.5	cells	
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were	 transduced	 with	 similar	 MOIs	 of	 each	 vector	 and	 the	 percentage	 of	 GFP‐negative	 cells	
generated	within	the	total	of	mCherry‐positive	transduced	cells	was	analyzed	by	flow	cytometry	
(Fig.	 1b).	 Percentages	 were	 then	 plotted	 for	 statistical	 analysis	 (Fig.	 1c).	 The	 most	 obvious	
observation	is	that	the	length	of	the	lower	stem	is	critical	for	overall	efficiency,	as	hairpins	with	
13	or	15	nucleotides	in	their	lower	stem	were	the	most	potent	at	generating	GFP‐negative	cells.	
Longer	(D17)	or	shorter	(D11,	D9)	stem	lengths	show	negligible	effect	on	GFP	down‐regulation.	
Such	an	impact	of	lower	stem	length	on	knock‐down	efficiency	was	reported	previously	77,	and	
is	 likely	 due	 to	 the	 generation	 by	 Drosha	 processing	 of	 hairpins	 with	 lengths	 that	 are	
inappropriate	 for	 further	 steps	 in	 RISC	 processing	 91.	 Indeed,	 it	 was	 shown	 that	 the	 Drosha	
cleavage	 site	 is	 determined	 mostly	 by	 the	 junction	 between	 the	 flanking	 sequences	 and	 the	
lower	stem	and	that	cleavage	occurs	~11bp	(when	counting	on	the	bottom	strand,	i.e.	13	bp	on	
the	top	strand	as	we	number	in	this	paper)	up	from	this	junction	72.	Comparison	of	D13M5	and	
D13M3	 shows	 a	 difference,	 however	 not	 statistically	 significant.	 Increasing	 the	 number	 of	
experiments	may	 reveal	 a	 significant	difference	which	will	 be	 in	 accordance	with	 the	 current	
understanding	 of	 preferential	 strand	 incorporation	 into	 RISC	 92,93.	We	 thus	 chose	 the	D13M5	
hairpin	(hereinafter	called	mirGE)	as	the	best	miRNA	configuration	to	compare	to	the	miR‐30	
hairpin	in	knock‐down	experiments	targeting	CCR5.	
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Figure	 1.	Down	 regulation	 of	 GFP	 in	 4.5	 cells	 using	 lentivectors	 expressing	 various	 anti‐GFP	miRNAs	
constructs.	 (a)	 Schematic	 diagram	 of	 variations	 introduced	 in	 the	 miRNA	 design,	 based	 on	 features	
described	 in	 Supplementary	 Figure	 S2.	 (b)	 FACS	 plots	 representative	 of	 independent	 experiments:	
Control,	D9M3,	D9M5,	D11M5	and	D13M3	(n=4),	D13M5	(n=7).	D15M5,	D17M5	(n=3).		4.5	GFP	expressing	
cells	were	transduced	with	equivalent	quantities	of	 lentivectors	expressing	mCherry	alone	(GFP	control,	
upper	plot),	or	mCherry	together	with	the	corresponding	miRNA	hairpin	displayed	alongside	in	panel	A.	
For	 analysis,	 FACS	 plots	 were	 analyzed	 using	 quadrants	 to	 delineate	 Cherry‐positive	 transduced	 cells.	
Then,	 the	 ratio	 was	 calculated	 as	 the	 fraction	 of	 GFP‐negative/Cherry‐positive	 cells	 over	 the	 total	 of		
Cherry‐positive	cells.	(c)	Bar	graph	diagram	corresponding	to	the	different	experiments	as	 illustrated	in	
the	 FACS	 plots	 alongside	 in	 panl	 B,	 showing	 the	 percentage	 of	 GFP‐negative	 cells	within	 total	 	 Cherry‐
positive	 cells	 for	 each	 corresponding	 miRNA	 design.	 *p	 <	 0.05,	 **p	 <	 0.01,	 ***p	 <	 0.001,	 using	 1	 way	
ANOVA	followed	by	Bonferronis	Mulitple	Comparison	Test.		
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Effect	of	targeting	sequence	and	hairpin	context	on	CCR5	knock‐down.	
We	then	compared	the	efficiency	of	mirGE	and	miR‐30	hairpin	(for	details	see	Fig.	7),	context	
for	the	knock‐down	of	a	second	target	gene,	namely	CCR5.	Two	CCR5	targeting	sequences,	T1	
and	 T7,	 were	 identified	 in	 silico	 (see	 Supplementary	Material,	 Algorithm).	 The	 T7	 target	
sequence	has	also	previously	been	described	as	a	very	potent	target	94.	T1	and	T7	were	cloned	
as	a	single	hairpin	in	either	the	miR‐30	or	miGE	backbones.	As	shown	in	Supplementary	Fig.	
S3,	 the	 lentivector	 expression	 cassette	 transcribes	 a	 single	 mRNA	 that	 encodes	 for	 the	 GFP	
living	color	followed	by	the	CCR5	targeting	miRNAs.	Lentivectors	are	then	used	to	transduce	a	
clone	 of	 HeLa	 cells	 constitutively	 expressing	 CCR5	 (HR5	 cells),	 and	 CCR5	 knock‐down	 is	
measured	 in	 GFP‐positive	 transduced	 cells	 (Fig.	 2a).	 We	 found	 that	 T1	 as	 well	 as	 the	 T7	
targeting	sequence	were	much	more	efficient	in	down‐regulating	CCR5	in	the	mirGE	than	in	the	
miR‐30	backbone	(Fig.	2b)	and	that	the	T7	was	superior	to	the	T1	in	the	same	hairpin	context.		
Note	 that	 the	mean	 fluorescence	 intensity	 (MFI)	 of	 GFP	 decreases	more	 in	 parallel	 with	 the	
knock‐down	efficiency	(Fig.	2,	in	particular	in	mirGE‐transduced	cells).	 	This	is	due	to	the	fact	
that	 ‐	 in	 this	 construct	 ‐	 the	hairpins	are	within	 the	3'UTR	of	 the	mRNAs	coding	 for	GFP	(see	
Supplementary	Fig.	S3).	Therefore	efficient	miRNA	processing	removes	poly‐A	tail	 leading	to	
de‐stabilization	of	mRNAs	coding	for	GFP	95.	A	similar	finding	was	described	by	Sun	et	al.,	81.	
This	set	of	experiments	 indicates	 that	T7	 is	a	better	CCR5	target	 than	T1,	and	 that	 the	mirGE	
backbone	is	more	efficiently	processed	by	Drosha	than	the	miR‐30	backbone.	
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Figure	2.	Downregulation	of	CCR5	in	HR5	cells	using	lentivectors	expressing	different	anti‐CCR5	miRNA	
target	 sequences	 in	 different	 hairpin	 contexts.	 (a)	 FACS	 plots	 showing	 representative	 data	 from	 three	
independent	 experiments	 performed	 with	 three	 independent	 lentivector	 preparations.	 HR5	 cells	 were	
transduced	 with	 lentivectors	 expressing	 either	 GFP	 alone	 (GFP	 control	 vector,	 not	 shown),	 or	 GFP	
followed	by		miR‐30	or	mirGE	hairpins	containing	the	T1	or	the	T7	targeting	sequence	(see	Results	and	
Materials	 and	 Methods	 for	 details).	 For	 determination	 of	 MFI	 (mean	 of	 fluorescence	 intensity)	 of	
transduced	versus	untransduced	cells,	square	gates	were	used	by	default	and	polygonal	gates	were	used	
when	populations	were	overlapping	in	one	or	2	axes.	MFI	of	GFP	for	the	transduced	population	(R3)	for	
the	 miR‐30	 T1	 condition	 was:	 	 150	 (percentage	 transduction	 66%),	 miR‐30	 T7	 condition:	 103.5	
(percentage	trandsuction	46%),	mirGE	T1	condition:	47.8	(percentage	transduction	48%)	and	mirGE	T7	
condition:	30.4	(percentage	transduction	23%).	(b)	Bar	graph	analysis	of	data	in	A.	CCR5	downregulation	
was	 calculated	 by	 dividing	 the	 CCR5	MFI	 value	 of	 GFP‐positive	 cells	 (transduced	 cells,	 gate	R3)	 by	 the	
CCR5	MFI	value	of	GFP‐negative	cells	(untransduced	cells,	gate	R2),	within	each	sample.	This	allows	for	
compensation	of	 sample‐to‐sample	variations	due	 to	slight	changes	 in	CCR5	antibody‐to‐cell	 ratios.	The	
relative	 CCR5	 expression	 in	 transduced	 cells	 was	 then	 displayed	 as	 percentage	 of	 CCR5	 expression	
normalized	 to	 the	 internal	 control	 provided	by	untransduced	 cells.	 Values	 represent	 average	 from	N=3	
independent	 experiments.	 ***p	 <	 0.001,	 ****p	 <	 0.0001	 using	 1	 way	 ANOVA	 followed	 by	 Bonferronis	
Mulitple	Comparison	Test.		
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Effect	of	miRNA	backbone	and	hairpin	number	on	CCR5	knock‐down.	
We	then	analyzed	the	knock‐down	potential	of	T7	targeting	sequence	in	HR5	cells	when	miRNA	
hairpins	are	expressed	as	multiple	copies	on	a	single	mRNA,	either	in	miR‐30	or	mirGE	context.	
For	this,	we	used	a	system	that	allowed	us	to	clone	several	copies	of	miRNA	hairpins	in	tandem	
in	a	 single	 lentivector	backbone.	This	 strategy,	depicted	 in	Supplementary	Fig.	S3,	 is	 largely	
inspired	from	Sun	et	al.,	81.		
Since	 our	 ultimate	 goal	 is	 to	 apply	 miRNA‐based	 gene	 silencing	 for	 clinical	 applications,	 we	
analyzed	experiments	performed	in	conditions	which	represent	the	safest	transduction	rate	for	
gene	therapy,	i.e.	one	copy	of	transgene	per	cell.	According	to	Poisson's	law,	when	less	than	20%	
of	cells	are	transduced,	the	majority	of	transduced	cells	contain	only	one	copy	of	the	lentivector	
transgene.	So,	not	only	it	reproduces	the	most	desirable	situation	for	clinical	application	but	it	
also	facilitates	the	comparison	of	different	constructs	between	each	other.	
We	 first	 assessed	 the	efficiency	of	 the	miR‐30	backbone	 containing	one	or	 two	T7	 constructs	
(Fig.	 3).	 They	 gave	 unsatisfactory	 results	 with	 a	 knock‐down	 of	 CCR5	 of	 16%	 or	 33%,	
respectively.	In	contrast,	a	single	hairpin	of	T7	in	the	mirGE	context	was	already	more	efficient	
than	 two	 copies	 of	 miR‐30	 with	 a	 knock‐down	 of	 45%	 compared	 to	 33%.	 Increasing	 the	
numbers	 of	 hairpins	 in	 mirGE	 to	 two	 or	 three	 resulted	 in	 80%	 and	 91%	 knock‐down,	
respectively.	
As	observed	in	Fig.	2,	higher	knock‐down	efficiency	of	mirGE	backbones	was	correlated	with	a	
more	important	decrease	in	GFP	fluorescence	as	measured	by	MFI	of	GFP,	again	suggesting	that	
a	better	Drosha	processing	results	in	fewer	copies	of	translatable	mRNA.	When	the	mRNA	only	
contains	the	GFP	coding	sequence,	GFP	MFI	is	195.	When	containing	GFP	and	one	copy	of	miR‐
30	hairpin,	the	GFP	MFI	drops	to	99	and	when	containing	GFP	and	one	copy	of	mirGE,	GFP	MFI	
drops	 to	 36.	 From	 this,	 one	 can	 estimate	 that	 only	 50%	 of	 all	mRNA	 containing	 one	miR‐30	
hairpin	 is	 processed	 and	 available	 for	RNA	 interference,	whereas	when	one	 copy	 of	mirGE	 is	
present,	more	than	80%	of	mRNAs	are	processed	and	available	for	RNA	interference.	
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Figure	3.	Downregulation	of	CCR5	 in	HR5	cells	using	 lentivectors	containing	various	copies	of	different	
anti‐CCR5	 miRNA	 constructs.	 (a)	 FACS	 plots	 showing	 representative	 data	 from	 four	 independent	
experiments	 (n=4).	 HR5	 cells	 were	 transduced	 with	 various	 concentrations	 of	 lentivectors	 expressing	
either	 GFP	 alone	 (GFP	 control	 vector),	 or	 GFP	 followed	 by	 one	 or	 several	 copies	 of	 a	 given	 miRNA	
backbone	 containing	 the	T7	 targeting	 sequence.	The	T7	 targeting	 sequence	was	 inserted	 in	one	or	 two	
copies	 in	 the	miR‐30	context,	 and	 in	one,	2	or	3	 copies	 in	 the	mirGE	context.	For	 further	analysis,	 only	
FACS	plots	displaying	less	than	20%	transduced	cells	(hence	mostly	single‐copy	GFP‐positive	cells)	were	
retained.	For	determination	of	MFI	(mean	of	 fluorescence	 intensity)	of	 transduced	versus	untransduced	
cells,	 square	 gates	 were	 used	 by	 default	 and	 polygonal	 gates	 were	 used	 when	 populations	 were	
overlapping	in	one	or	2	axes.	MFI	of	GFP	for	the	transduced	population	(R3)	for	the	GFP	control	condition	
was:	195.7	(percentage	transduction	38.3%),	miR‐30	single:	98.8	(percentage	transduction	7.6%),	miR‐30	
double:	62.37	(percentage	transduction	19.7%),	mirGE	single:	36	(percentage	transduction	13.7%),	mirGE	
double:	18.5	(percentage	transduction	7.1%)	and	mirGE	triple:	12.9	(percentage	transduction	9.1%).	(b)	
Bar	graph	analysis	of	data	in	A.	CCR5	downregulation	was	calculated	as	described	in	Figure	3.	The	relative	
CCR5	expression	in	transduced	cells	is	displayed	as	percentage	of	CCR5	expression	normalized	to	internal	
control	untransduced	cells.	Values	represent	average	from	N=4	independent	experiments.	****p	<	0.0001	
using	1	way	ANOVA	followed	by	Bonferronis	Mulitple	Comparison	Test.	
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High‐throughput	sequencing	of	mirGE	and	miR‐30	small	RNA	products.	
The	 lower	 Drosha	 processing	 of	 miR‐30	 could	 suffice	 to	 account	 for	 its	 lower	 knock‐down	
efficiency	as	 compared	 to	mirGE.	However,	 another	 scenario	 can	also	 contribute	 to	 the	 lower	
efficiency	of	miR‐30.	As	discussed	for	Fig.	1,	if	Drosha	processes	miR‐30	after	~13	base	pair	of	
lower	 stem	 structure,	 it	 will	 generate	 a	 targeting	 strand	 that	 will	 miss	 two	 nucleotides	
complementary	 to	 the	 target	 sequence	 at	 its	 3’	 end	 and	will	 also	 have	 an	 extra	 AU	 artificial	
sequence	at	its	5’	end.		
To	investigate	this	cleavage	issue,	we	performed	a	high‐throughput	sequencing	analysis	of	the	
small	RNAs	generated	by	miR‐30	and	mirGE	constructs.		As	described	in	Materials	and	Methods,	
we	purified	 fragments	 in	 the	range	of	15	to	40	nt	 long	before	sequencing,	 in	order	 to	analyze	
mostly	RNAs	that	are	incorporated	into	RISC.	The	raw	counts	of	reads	from	this	sequencing	are	
shown	in	Supplementary	Table	S1	and	can	also	be	downloaded	as	described	in	Materials	and	
Methods.	 As	 shown	 in	 Supplementary	Table	 S2,	 the	 percentage	 of	 reads	 assigned	 to	 either	
miR‐30	 or	 mirGE	 are	 comparable,	 i.e.	 2.33%	 vs.	 2.21%,	 respectively.	 Since	 mirGE	 cells	 are	
transduced	at	23%	and	miR‐30	cells	are	transduced	at	43%,	and	according	to	Poisson’s	law,	the	
average	copy	number	in	mirGE	cells	can	be	estimated	at	0.23	whereas	the	average	copy	number	
in	 miR‐30	 cells	 can	 be	 estimated	 at	 more	 than	 0.4.	 This	 indicates	 that	 mirGE	 can	 produce	
approximately	 2‐times	 more	 targeting	 strands	 than	 miR‐30.	 This	 is	 in	 accordance	 with	 GFP	
intensities	observed	 in	Figure	3,	 suggesting	 that	Drosha	 cleavage	 is	more	efficient	 on	mRNAs	
containing	mirGE	hairpins	than	on	mRNAs	containing	miR‐30	hairpins.	
Moreover,	the	percentage	of	reads	where	the	targeting	strand	has	an	incorrect	start	position	is	
7.53	 for	 miR‐30	 and	 0.16	 for	 mirGE,	 indicating	 that	 overall	 processing	 of	 RISC‐incorporated	
targeting	strands	is	approximately	50‐times	better	for	mirGE	than	for	miR‐30.	This	is	confirmed	
in	 the	 mirGE_triple	 sample,	 where	 the	 transduction	 rate	 is	 high,	 90%	 positive	 cells	
corresponding	to	an	estimated	average	copy	number	of	more	than	5.	In	this	case,	even	though	
the	reads	assigned	to	mirGE	represent	more	than	two	thirds	of	all	cellular	reads	(69.8%),	 the	
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percentage	of	reads	with	an	incorrect	start	position	is	even	lower	than	in	mirGE_single	(0.06%	
vs.	0.16%,	respectively).	This	suggests	that	the	mirGE	backbone	can	be	processed	with	higher	
efficiency	and	higher	precision	than	miR‐30,	even	when	representing	the	majority	of	all	Drosha‐
processed	miRNAs.	We	further	investigated	the	issue	of	cleavage	accuracy	for	the	mirGE	or	miR‐
30	 backbone.	 As	 shown	 in	Fig.	4,	 the	 Drosha	 cleavage	 occurs	 at	 the	 correct	 position	 both	 in	
mirGE	 and	 miR‐30	 although	 the	 accuracy	 with	 which	 this	 occurs	 is	 very	 different	 when	
comparing	the	two	backbones	(discussed	below).	This	is	surprising	for	miR‐30	since	its	 lower	
stem	 is	 two	 nucleotides	 shorter	 than	 usually	 seen	 in	 miRNAs	 72.	 	 Also,	 Dicer	 cutting	 occurs	
mostly	 at	 the	 expected	 site	 so	 the	 vast	 majority	 of	 the	 reads	 covers	 the	 targeting	 strand,	
whether	it	is	generated	by	mirGE	or	by	miR‐30.		
However,	this	analysis	identified	two	further	points	where	mirGE	was	superior	to	miR‐30.	First,	
there	is	a	10‐fold	difference	in	the	ratio	of	RISC	incorporation	of	targeting	vs.	passenger	in	favor	
of	 mirGE	 over	 miR‐30.	 As	 shown	 in	 Supplementary	 Table	 S1	 and	 Fig.	 4,	 for	 mirGE_single	
sample,	there	is	a	count	of	18253	reads	at	position	26	vs.	no	read	at	position	65	or	around.	Thus,	
a	 ratio	 of	 14’823	 could	 only	 be	 calculated	 with	 the	 mirGE_triple	 sample	 (2’638’464	 reads	
starting	 at	 position	 26	 over	 178	 reads	 starting	 at	 position	 65).	 For	miR‐30,	 there	 are	 44’853	
reads	of	starting	at	position	72	over	33	reads	starting	at	position	33,	giving	a	ratio	of	targeting	
strand/passenger	strand	of	1359.	Second,	Drosha	cutting	 is	500	to	1’000	fold	more	precise	 in	
mirGE	 than	 in	 miR‐30.	 As	 shown	 in	 Supplementary	Table	 S1	 and	 Fig.	 4,	 for	 mirGE_single	
sample,	 there	 is	 a	 count	 of	 18253	 reads	 at	 position	 26	 and	 a	 total	 of	 5	 reads	 proximal	 but	
outside	position	26,	giving	a	ratio	of	0.00027	of	incorrect	cuts.	A	similar	ratio	was	obtained	from	
the	mirGE_triple	sample,	with	2’638’464	reads	at	position	26	and	a	total	of	1194	reads	proximal	
but	outside	position	26,	 giving	a	 ratio	of	0.00045.	Of	note,	 even	when	reads	are	 coming	 from	
mirGE	processing	of	a	triple	hairpin	and	amount	to	more	than	two	thirds	of	all	trimmed	reads,	
Drosha	 still	 manage	 to	 be	 extremely	 accurate	 in	 mirGE	 processing.	 On	 the	 contrary,	 miR‐30	
processing	by	Drosha	is	500	to	1’000	times	less	precise	with	a	ratio	of	0.21	of	incorrect	cuts	(33	
reads	 at	 position	 33	 and	 7	 reads	 at	 position	 34).	 When	 applying	 this	 calculation	 to	 Dicer	
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processing,	miR‐30	 appears	 to	 be	 processed	with	 an	 accuracy	 that	 is	 6‐times	higher	 than	 for	
mirGE,	with	ratios	of	 incorrect	cuts	of	0.08	and	0.49,	respectively.	Such	a	difference	is	hard	to	
explain	since	both	hairpins	have	the	same	loop	to	present	to	Dicer.	
Taken	together,	this	high‐throughput	sequencing	analysis	shows	that	mirGE	is	superior	to	miR‐
30	 in	 four	 aspects:	 yield	 of	 targeting	 strand	 incorporation	 into	 RISC;	 percentage	 of	 RISC‐
incorporated	targeting	strands	with	the	correct	sequence;	precision	of	cleavage	by	Drosha	and	
ratio	of	targeting	strand	over	passenger	strand.	It	thus	provides	molecular	basis	to	account	for	
the	superiority	of	mirGE	over	miR‐30	in	knock‐down	efficiency.	
	
37	
	
	
Figure	 4.	 High‐throughput	 sequencing	 of	 short	 RNAs	 generated	 by	 miR‐30	 and	 mirGE	 and	 miRNA	
constructs.	(a)	Schematic	diagram	of	the	miR‐30	miRNA	containing	the	CCR5	T7	target.	Targeting	strand	is	
in	red	(bottom	strand).	Position	and	numbering	of	reads	major	starts	and	reads	major	ends	of	coverage	
(see	 Supplementary	Table	 S1	 for	details)	 are	 indicated	by	 arrows.	 (b)	 Schematic	 diagram	of	 the	mirGE	
miRNA	containing	the	CCR5	T7	target.	Targeting	strand	is	in	red	(top	strand).	Position	and	numbering	of	
reads	 major	 starts	 and	 reads	 major	 ends	 of	 coverage	 (see	 Supplementary	 Table	 S1	 for	 details)	 are	
indicated	 by	 arrows.	 (c)	 Coverage	 plot	 of	 reads	 aligning	 to	 the	 targeting	 strands	 of	 miR‐30	 or	 mirGE	
hairpins	sequences.	Base	1	corresponds	to	nucleotide	72	for	miR‐30		and	to	nucleotide	26	for	mirGE.		(d)	
Summary	 of	 analysis	 of	 reads	 covering	 the	 targeting	 or	 passenger	 strand	 sequences	 (see	 text	 and	
Supplementary	Table	S1	for	details).			
38	
	
Effect	of	CCR5	knock‐down	on	HIV	infection	in	vitro.		
Finally,	 we	 wanted	 to	 determine	 whether	 the	 CCR5	 knock‐down	 induced	 by	 transduction	 of	
cells	with	 a	 single	 copy	 of	 lentivector	 containing	 an	 optimized	 anti‐CCR5	miRNA	 design	was	
efficient	enough	 to	 render	 cells	 resistant	 to	HIV	 infection.	For	 this,	we	used	a	HIV‐permissive	
clone	 of	 HeLa	 cells	 expressing	 both	 CD4	 and	 CCR5	 (HR5	 cells,	 see	 Materials	 and	 Methods	
section).	We	transduced	the	HR5	cells	with	varying	amounts	of	lentivectors,	containing	GFP	and	
triple	hairpin	anti‐CCR5	mirGE,	or	GFP	only	as	negative	control	(Fig.	5a).	Again,	we	included	a	
condition	with	<20%	of	the	cells	transduced	(mirGE	2	µl	=	13%	and	1	µl	=	6%),	hence	observing	
the	effect	of	 single‐copy	 transgene	expression.	 	Cells	were	seeded	at	20%	confluence	one	day	
prior	 to	 infection	 with	 the	 CCR5	 tropic	 HIV	 strain,	 YU‐2.	 All	 cells	 which	 were	 either	 mock‐
transduced	or	 transduced	with	 the	GFP	 control	 lentiviral	 vector	were	 either	 dead	 or	 showed	
massive	syncytia	induction	5	days	post	infection	(Fig.	5a).	In	contrast,	a	sub‐population	of	the	
cells	previously	transduced	with	the	anti‐CCR5	mirGE	lentivector	survived	the	HIV	infection	and	
further	 proliferated.	 Monitoring	 of	 the	 HIV	 p24	 antigen	 in	 the	 supernatants	 reflected	 the	
microscopic	findings	with	lower	levels	of	p24	antigen	in	the	cells	transduced	with	the	anti‐CCR5	
mirGE	 (Fig.	 5b).	 At	 day	 5,	 we	 observed	 syncytia	 induction	 in	 close	 proximity	 to	 apparently	
healthy	cells.	At	day	7,	 the	positive	selection	 for	 the	HIV	resistant	cells	 is	evident.	Phenotypic	
analysis	of	these	surviving	cells	shows	that	they	have	lost	CCR5	expression	(Fig.	5g).	The	cells	
which	 survived	 this	 first	 infection	with	 R5‐tropic	HIV	were	 re‐challenged	with	 the	 same	HIV	
strain.	 Corroborating	 our	 observation	 that	 these	 cells	 have	 lost	 CCR5	 expression,	 they	 were	
entirely	HIV‐resistant	(Fig.	5c).	Finally,	we	wanted	to	verify	that	the	2	rounds	of	R5‐tropic	HIV	
infection	 did	 not	 select	 for	 cells	 that	were	 resistant	 to	 HIV	 infection	 in	 general.	 For	 this,	 we	
infected	 the	 surviving	 cells	with	an	X4‐tropic	HIV	 strain.	As	 shown	 in	Fig.	5d,	 these	 cells	 can	
support	X4‐tropic	HIV	replication	at	the	same	level	as	naïve	HR5	cells.	Thus,	no	non‐specific	HIV	
resistance	appears	to	have	developed	in	the	process.	We	also	performed	a	phenotypic	analysis	
of	 cells	 that	 survived	 R5‐tropic	 infection	 and	 compared	 them	 to	 the	 sub‐population	 of	 cells	
transduced	with	the	anti‐CCR5	lentivector	before	infection.	As	shown	in	Fig.	5f,	the	transduced	
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cells	represent	6%	of	the	total	population,	which	implies	that	the	vast	majority	contain	only	one	
copy	 of	 the	 transgene.	 When	 compared	 to	 the	 internal	 negative	 control	 provided	 by	 the	
untransduced	cells	whose	CCR5	MFI	is	114,	the	knock‐down	ratio	is	more	than	10	fold,	as	also	
shown	 in	Fig.	3b.	The	same	phenotypic	analysis	performed	seven	days	after	HIV	R5	 infection	
shows	 a	 dramatic	 enrichment,	 yielding	 to	 a	 population	 where	 CCR5	 expression	 is	 virtually	
absent	(Fig.	5g).		
To	further	check	if	our	anti‐CCR5	lentivector	could	inhibit	HIV	infection	in	natural	target	of	the	
virus,	we	performed	HIV‐R5	infection	in	human	monocyte‐derived	macrophages	(MDMs)	with	
or	without	prior	transduction	with	the	anti‐CCR5	T7	triple	hairpin	lentivector	described	above.	
MDMs	were	matured	in	culture	for	8	days	as	described	in	the	Materials	and	Methods	section.	In	
order	to	maximize	R5‐tropic	HIV	infection,	MDMs	were	treated	with	VPX‐virus	like	particles	for	
two	hours	prior	 to	 transduction,	as	described	previously	 96.	The	MDMs	were	 then	 transduced	
with	various	quantities	of	either	a	control	GFP	vector	or	the	anti‐CCR5	lentivector,	followed	four	
days	 after	 by	 infection	with	 R5‐tropic	 HIV‐Luciferase	 virions	 (see	Materials	 and	Methods	 for	
details).	 As	 shown	 in	Fig.	6,	 we	 can	 see	 a	 strong	 inhibition	 of	 HIV	 infection	 using	 anti‐CCR5	
lentivector	 at	 a	 MOI	 of	 1.7.	 Other	 conditions	 using	 lentivectors,	 i.e.	 lower	 MOI	 of	 anti‐CCR5	
lentivector	 or	 control	 GFP	 lentivector	 display	 a	 moderate	 inhibition	 of	 HIV	 infection,	 as	
compared	 to	 the	 no	 vector	 condition.	 This	 is	 most	 likely	 due	 to	 the	 triggering	 by	 defective	
particle	of	cell‐autonomous	innate	immune	systems	independent	of	SAMHD1	(see	97	for	review).		
Altogether,	these	data	show	that	our	anti‐CCR5	lentivector	can	efficiently	block	HIV	infection	at	
low	copy	number	in	both	artificial	and	natural	target	cells.	
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Figure	5.	Resistance	to	R5‐tropic	HIV	infection	of	HR5	cells	transduced	with	anti‐CCR5	mirGE	lentivector.	
(a)	 Representative	 images	 of	 control	 parental	 HeLa	 cells	 (HeLa),	 untransduced	 HR5	 (HR5),	 HR5	 cells	
transduced	with	 a	 lentivector	 expressing	GFP	alone	 (GFP),	 and	HR5	 cells	 transduced	with	 a	 lentivector	
expressing	GFP	and	3	hairpins	of	anti‐CCR5	mirGE	(mirGE).	Pictures	of	these	four	cell	lines	were	taken	at	
day	0,	day	5	and	day	7	of	HIV‐R5	infection.	Only	parental	HeLa	cells	and	mirGE‐transduced	cells	survive	
the	 infection.	 Note	 that	 mirGE	 1µl	 indicates	 cells	 transduced	 with	 the	 lowest	 volume	 of	 vector	
corresponding	to	a	7%	transduction	rate.	(b)	Values	of	HIV	p24	antigen	in	supernatants	of	cells	showed	in	
Figure	5a,	collected	over	6	days	post	R5	HIV	infection.	(c).	Values	of	HIV	p24	antigen	collected	over	6	days	
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post	R5	HIV	 infection,	 in	 supernatants	of	mirGE	cells	 that	survived	 the	 first	HIV	challenge	 in	Figure	5b.	
Negative	 and	 positive	 controls	 for	 HIV	 replication	 were	 provided	 by	 naïve	 HeLa	 and	 HR5	 cells,	
respectively.	(d)	Values	of	HIV	p24	antigen	collected	over	6	days	post	X4	HIV	infection,	in	supernatants	of	
mirGE	cells	that	survived	the	first	and	second	HIV	challenges	in	Figure	5b	and	c.	Negative	control	for	X4	
HIV	infection	was	provided	by	naïve	CD4‐negative	parental	HeLa	cells	and	a	fresh	batch	of	naïve	HR5	cells	
served	 as	 the	 positive	 control	 for	 infection.	 (e)	 Phenotypic	 analysis	 of	 HR5	 cells	 transduced	with	 GFP	
control	 lentivector	 (no	 miRNA).	 (f)	 Phenotypic	 analysis	 of	 HR5	 cells	 transduced	 with	 GFP‐anti‐CCR5	
mirGE	 lentivector	prior	 to	R5‐tropic	HIV	 infection.	Within	 the	untransduced	cells	 in	gate	R2	(89%),	 the	
CCR5	and	GFP	MFIs	are	144	and	2.4,	respectively.	Within	the	transduced	cells	in	gate	R3	(6%),	the	CCR5	
and	 GFP	 MFIs	 are	 14	 and	 18,	 respectively.	 (g)	 Phenotypic	 analysis	 of	 HR5	 cells	 from	 (F)	 7	 days	 post	
infection	with	R5‐tropic	HIV.	The	majority	of	cells	(81%)	are	CCR5‐negative.	The	CCR5	and	GFP	MFIs	in	
this	population	(gate	R3)	are	3	and	48,	respectively.	
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Figure	6. Resistance	 to	 R5‐tropic	HIV	 infection	 of	Monocyte‐derived	Macrophages	 (MDMs)	 transduced	
with	anti‐CCR5	mirGE	lentivector.	(a)	Bar	graphs	showing	the	level	of	infection	of	MDMs	by	recombinant	
R5‐tropic	 HIV	 particles	 encoding	 luciferase	 (see	Materials	 and	Methods	 for	 details).	 Prior	 to	 infection,	
MDMs	were	either	not	 transduced	(no	vector)	or	 transduced	with	various	amounts	of	anti‐CCR5	mirGE	
lentivector	(CCR5	KD)	or	with	a	control	vector	expressing	only	GFP	(GFP).	Vector	stocks	(CCR5	KD	and	
GFP)	 were	 normalized	 and	 1	 µl	 of	 vector	 corresponds	 to	 a	 MOI	 of	 1.7.	 Experiments	 consisted	 of	 a	
minimum	of	3	technical	replicates.	Luciferase	activity:	No	vector	1250	(sem	±	248),	0.1ul	CCR5	KD	vector	
811	(sem	±	195),	0.1ul	GFP	vector	711	(sem	±	137),	1ul	CCR5	KD	vector	69	(sem	±	44)	and	1ul	GFP	vector	
791	 (sem	 ±	 18).	 P	 values	 (**p<0.0099,	 **p<0.0038,	 ***	 p<0.0004)	 were	 obtained	 using	 a	 two‐tailed	
unpaired	t‐test.	(b‐c)	Light	microscope	images	of	macrophages	4	days	post	transduction	with	1µl	of	anti‐
CCR	mirGE	vector	or	1µl	of	GFP	vector,	respectively	(20x	magnification).	
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Figure	 7.	 Schematic	 representations	 of	 miR‐30	 and	 mirGE	 designs.	 (a)	 miR‐30	 design	 as	 it	 has	 been	
previously	 described	 [1]	 [17]	 [14].	Main	 features	 include	 11	 bp	 lower	 stem,	 upper	 double‐strand	 stem	
composed	 of	 the	 fully	 complementary	 targeting	 strand	 (bottom	 strand,	 dotted	 line),	 3’	 mismatch	 of	
targeting	 strand	 as	 well	 as	 a	 weak	 AU	 bond	 on	 the	 5’	 of	 the	 targeting	 strand.	 (b)	 mirGE	 backbone	
developed	 in	 this	 study.	 Main	 features	 include	 miR‐16	 flanking	 regions,	 upper	 double‐strand	 stem	
composed	of	 the	 fully	 complementary	 targeting	strand	 (top	strand,	dotted	 line),	 	 a	13bp	 lower	stem	 ,	 a	
wobble	 at	 position	 12	 of	 the	 upper	 stem	 (position	 1	 is	 the	 first	 5’	 base	 of	 the	 targeting	 strand),	 a	 5’	
mismatch	and	no	3’	mismatch		on	the	targeting	strand.	
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DISCUSSION	
The	work	presented	in	this	paper	is	the	result	of	an	ambitious	goal:	Efficient	gene	knock‐down	
with	a	single	copy	of	miRNA‐containing	lentivector.	We	could	achieve	this	goal	by	optimization	
of	 critical	 miRNA	 features,	 combined	 with	 multimerization	 of	 miRNA	 hairpins	 in	 a	 single	
cassette.	When	applied	to	human	CCR5,	we	reached	a	knock‐down	efficiency	which	provides	the	
ground	for	a	clinically‐applicable	approach	towards	cellular	immunization	against	HIV.			
When	 we	 designed	 our	 knock‐down	 lentivector	 constructs	 by	 implementing	 the	 miR‐30	
protocols	 from	 institutional	on‐line	 tools	 (http://hannonlab.cshl.edu),	 these	 constructs	hardly	
reduced	the	level	of	CCR5	expression	by	one	third	(Fig.	2,	miR‐30	T1	and	miR‐30	T7).	This	was	
surprising	and	disappointing	since	T7	has	been	described	as	one	of	the	most	potent	CCR5	RNAi	
targets	94.	Notably,	cells	with	multiple	copies	of	anti‐CCR5	T7	miR‐30	did	show	efficient	CCR5	
knock‐down.	 Clearly,	 one	 cannot	 expect	 any	 phenotype	 with	 this	 level	 of	 knock‐down,	 and	
therefore	no	clinical	applicability.		
A	 careful	 review	 of	 articles	 about	Drosha	 processing	 and	RISC	 incorporation	 identified	 three	
potential	 features	critical	 for	optimal	miRNA‐based	silencing:	(1)	 length	of	 the	 lower	stem	for	
optimal	Drosha	processing,	(2)	destabilization	of	the	5’	end	of	the	targeting	strand	for	optimal	
RISC	 incorporation,	 and	 (3)	 a	 mismatch	 in	 the	 middle	 of	 the	 upper	 stem	 to	 avoid	 abortive	
processing	by	Drosha	67,72,77,81,82,98‐100.	
When	 these	 three	 features	 were	 incorporated	 in	 our	 mirGE	 hairpin	 design,	 the	 knockdown	
efficiency	 improved	 dramatically	 compared	 to	 miR‐30‐based	 hairpin	 designs,	 whether	 we	
targeted	 GFP	 or	 CCR5	 (Fig.	 1	 and	 2).	 The	 level	 of	 knock‐down	 with	 a	 single	 mirGE	 hairpin	
construct,	 however	 still	 did	 not	 reach	 a	 level	 of	 down‐regulation	 compatible	 with	 clinical	
applications	 i.e.	 >	 90%.	We	 reached	 this	 threshold	 by	 tandem	 addition	 of	 hairpins,	 achieving	
90%	 knock‐down	 with	 a	 single	 copy	 of	 a	 lentivector	 containing	 a	 triple	 anti‐CCR5	 mirGE	
construct	(Fig.	3).	These	tandem	repeats	do	not	seem	to	be	subject	to	recombination	(data	not	
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shown)	and	are	thus	a	safe	alternative	to	the	accumulation	of	integrated	proviral	copies	in	the	
target	cell	genome.		
To	investigate	the	mechanisms	underlying	the	superiority	of	mirGE	over	miR‐30,	we	performed	
a	high‐throughput	sequencing	of	short	RNAs	generated	by	the	two	miRNA	backbones	(Fig.	4).	
We	 found	 that	 mirGE	 performed	 better	 than	 miR‐30	 in	 terms	 of	 yield	 of	 targeting	 strand	
incorporation	 into	 RISC	 as	 well	 as	 percentage	 of	 correct	 targeting	 strands	 incorporated	 into	
RISC.	Also,	the	ratio	of	targeting	strand	over	passenger	strand	is	higher	for	mirGE	than	for	miR‐
30	.	We	also	found	that	Drosha	cutting	on	miR‐30	was	quite	imprecise,	with	21%	of	cuts	outside	
of	 the	 correct	 position.	 On	 the	 contrary,	 Drosha	 cutting	 on	 mirGE	 was	 very	 precise	 (500	 to	
1’000‐fold	more	precise	than	miR‐30)	and	keeps	the	same	level	of	accuracy	even	when	mirGE	is	
expressed	at	high	levels	and	in	a	triple	hairpin	context.		
Surprisingly,	Dicer	cutting	was	not	very	precise,	ranging	from	8%	to	49%	of	incorrect	cuts	for	
miR‐30	 and	mirGE,	 respectively.	 This	 level	 of	 inaccuracy	 is	 comparable	 to	Drosha	 cutting	 on	
miR‐30	(21%).	One	possibility	is	that	the	miR‐30	loop	that	we	kept	in	our	mirGE	design	is	also	
not	 optimal.	We	 plan	 on	 testing	 other	 loop	 sequences	 based	 on	 features	 affecting	 enzymatic	
processing	of	hairpin	transcripts	as	described	elsewhere	101.		
Taken	 together,	 our	 results	 show	 a	 clear	 superiority	 of	 mirGE	 over	 miR‐30	 in	 terms	 of	
processing,	 cleavage	 accuracy,	 targeting	 strand	 incorporation	 and,	 most	 of	 all,	 knockdown	
efficiency.	Also,	in	mirGE,	the	upper	strand	is	incorporated	in	RISC,	whereas	in	miR‐30	it	is	the	
lower	strand.	In	mirGE,	Drosha	cutting	generates	the	5’	end	of	the	guide	strand	and	is	extremely	
precise,	 whereas	 in	 miR‐30,	 the	 terminal	 loop	 processing,	 whether	 done	 by	 Dicer	 or	 single‐
strand	RNAses,	generates	the	5’	end	of	the	guide	strand	and	is	 imprecise	and	requires	further	
optimization.	Finally,	in	the	meantine,	we	have	applied	the	mirGE	design	to	other	target	genes	
(Caveolin‐1,	 VEGF	 and	 Wnt5a,	 data	 not	 shown)	 and	 found	 equally	 efficient	 knock‐down	
efficiency,	 allowing	 gene	 repression	 at	 low	 copy	 number.	We	 thus	 propose	 to	 use	 the	mirGE	
design	as	default	design	for	miRNA‐based	knock‐down	applications.	
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Using	a	triple	anti‐CCR5	mirGE	construct	to	protect	Hela	R5	cells		against	HIV	infection	in	vitro,	
we	showed	 that	 a	 sub‐population	of	 cells	 transduced	at	 levels	 lower	 than	10%,	hence	mostly	
containing	 only	 one	 copy	 of	 anti‐CCR5	 mirGE	 89,	 could	 resist	 HIV	 R5	 infection	 (Fig.	 5).	 Re‐
challenging	these	surviving	cells	with	HIV	R5	did	not	show	any	virus	replication,	whereas	the	
same	 cells	 remained	 permissive	 to	 HIV	 X4	 infection,	 proving	 the	 specificity	 of	 the	 anti‐CCR5	
cellular	immunization.	To	further	validate	the	protective	effect	of	our	anti‐CCR5	constructs,	we	
tested	 it	 in	 natural	 targets	 of	 HIV	 R5,	 i.e.	 human	 macrophages	 (Fig.	 6).	 We	 found	 that	 our	
construct,	 even	at	 low	MOI,	efficiently	and	specifically	protected	macrophages	against	HIV‐R5	
infection.	This	protective	effect	in	primary	human	cells	was	later	confirmed	in	humanized	mice	
(Myburgh	et	al.,	2014	manuscript	in	preparation).	
Altogether,	these	results	can	be	compared	in	terms	of	efficiency	to	the	work	of	Ringpis	et	al.,	55.	
However,	they	used	an	shRNA‐based	vector	which	may	be	less	desirable	for	clinical	application	
due	to	potential	adverse	effect	of	shRNA‐related	toxicity	63‐65.	
In	conclusion,	this	work	provides	the	ground	to	ultimately	build	a	genetic	tool	that	can	be	used	
to	confer	HIV‐resistance	in	patients.		Also,	the	efficiency	of	our	system	provides	a	universal	tool	
to	 knock‐down	 any	 clinically‐relevant	 target	 gene	 without	 sacrificing	 safety	 by	 requiring	
multiple	 transgene	 integrations.	 Finally,	 we	 provide	 here	 an	 algorithm	 (see	 Supplementary	
Material:	Algorithm	for	mirGE	design)	as	well	as	a	set	of	genetic	tools	for	everyone	to	design	
“optimized”	miRNA	against	any	target	gene.	
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MATERIALS	AND	METHODS	
	
Construction	 of	 miRNA‐containing	 plasmids	 and	 lentiviral	 vectors:	 To	 construct	 the	
plasmid	 intermediates	containing	 the	various	miRNA	hairpins,	we	 followed	a	protocol	 largely	
inspired	by	 Sun	et	 al.	with	 the	 following	modifications	 81.	An	amplicon	 containing	 the	miRNA	
hairpin	 flanked	 by	 sequences	 for	 digestion	 with	 restriction	 enzymes	 was	 generated	 by	 high	
fidelity	PCR	using	Herculase	II	polymerase	(Agilent).	The	oligos	for	PCR	template	and	primers	
were	 obtained	 from	 Microsynth	 then	 Sigma.	 The	 templates	 for	 miR‐30	 hairpins	 had	 inside	
sequences	specific	for	gene	targeting	and	common	outside	sequences	for	annealing	with	miR‐30	
primers	 (see	 Supplementary	 Material).	 The	 mirGE	 hairpins	 were	 amplified	 from	 similar	
templates	 but	 with	 common	 outside	 sequences	 for	 annealing	 with	 mirGE	 primers	 (see	
Supplementary	 Material).	 PCR	 products	 were	 digested	 with	 BamHI	 and	 XbaI	 restriction	
enzymes	(New	England	Biolabs),	and	ligated	into	a	pENTR‐derived	plasmid	(Invitrogen)	using	
BamHI	and	XbaI	sites	located	directly,	either	downstream	of	the	MGST2	gene	(Genbank	Access	
U77604.1	 )	 for	miRNAs	 targeting	GFP	(see	Supplementary	Figure	S1a),	or	downstream	of	 the	
GFP	 gene	 for	miRNAs	 targeting	 hCCR5	 (Supplementary	 Figure	 S3a).	 Ligation	was	 performed	
using	T4	DNA	ligase	(New	England	Biolabs).	The	pENTR‐GFPmir	plasmid	maps	and	sequences	
are	 available	 at	 our	 institutional	 website	 (http://medweb2.unige.ch/salmon/lentilab).	 The	
amplicon	parts	of	 each	clone	were	verified	by	 sequencing.	For	 constructs	 containing	multiple	
hairpins,	PCR	products	were	inserted	using	BamHI	and	SpeI	sites	as	depicted	in	Supplementary	
Figure	S3a	and	described	before	by	Sun	et	al.	(CCR5	knockdown)	81.	This	allows	for	the	insertion	
of	multiple	miRNAs	where	each	new	addition	was	verified	by	sequencing.	The	final	lentivector	
plasmid	was	generated	by	an	LR	Clonase	 II	 (Invitrogen)	mediated	 recombination	of	 a	pENTR	
plasmid	containing	the	human	ubiquitin	promoter	(pENTR‐L4‐UBI‐L1R)	and	a	pCLX‐R4‐DEST‐
R2	lentivector	destination	cassette	(Supplementary	Figure	S1b	and	S3b).	For	GFP	knock‐down	
experiments,	 a	 specific	 lentivector	 destination	 cassette	 (pCWX‐R4‐DEST‐R2‐PC)	 was	 used,	
containing	an	additional	transcription	unit	with	the	human	PGK	promoter	driving	the	mCherry	
living	color,	as	described	in	the	text.	All	maps	and	sequences	of	the	plasmids	used	in	this	study	
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are	available	at	our	institutional	website	(http://medweb2.unige.ch/salmon/lentilab).	The	GFP	
target	sequence	–AAGAACGGCATCAAGGTGAACT‐	was	taken	from	previous	publication	102.	The	
human	 CCR5	 (Genbank	 NM_000579.3)	 target	 sequences	 were	 chosen	 using	 the	 online	
webserver	at	http://rna.tbi.univie.ac.at/cgi‐bin/RNAxs,	and	 from	published	article	 94.	The	 two	
CCR5	 target	 sequences	 retained	were	 named	 Target	 1	 (T1)	 5’‐TTTCCATACAGTCAGTATCAAT	
and	Target	 7	 (T7)	 5’‐AAGTGTCAAGTCCAATCTATGA.	 Sequences	 of	 templates	 for	 various	 anti‐
GFP	miRNA	 and	 anti‐	 CCR5‐T1,	 anti‐CCR5‐T7,	 used	 for	 PCR	 amplification,	 as	 well	 as	 the	 full	
algorithm	 used	 to	 design	 optimized	 upper	 and	 lower	 strands,	 are	 given	 in	 Supplementary	
Material	section.	
Lentiviral	 vector	 production	 and	 titration:	 Lentiviral	 vector	 stocks	 were	 generated	 using	
transient	 transfection	of	HEK	293T/17	cells	with	the	specific	 lentivector	 transfer	plasmid,	 the	
psPAX2	 plasmid	 encoding	 gag/pol	 and	 the	 pCAG‐VSVG	 envelope	 plasmid,	 as	 previously	
described	103,104.	Lentivector	titer	was	performed	using	transduction	of	HT‐1080	cells	followed	
by	 flow	 cytometry	 quantification	 of	 GFP‐positive	 (or	 mCherry	 positive)	 cells	 5	 days	 after	
infection,	as	previously	described	103,104.	
Cell	culture	and	knock‐down	analysis:	All	cell	lines	were	cultured	in	High‐Glucose	Dulbecco’s	
modified	 eagle	 medium	 (DMEM,	 Sigma)	 supplemented	 with	 10%	 FCS,	 1%	 Penicillin,	 1%	
Streptomycin	and	1%	L‐Glutamine.	For	GFP	knock‐down	studies,	the	4.5	cell	line	90,	containing	
one	 copy	 of	 a	 GFP‐expressing	 lentivector	 was	 used.	 For	 each	 knock‐down	 assay,	 cells	 were	
analyzed	5	days	after	 transduction.	For	CCR5	knock‐down	studies,	a	subclone	of	Hela‐derived	
TZM‐bl	 cells	 (AIDS	Repository),	 expressing	 CD4	 and	 high	 levels	 of	 human	CCR5,	 named	here	
HR5,	was	used.	CCR5	and	CD4	quantification	was	performed	using	an	APC	and	PE	Cy7‐labelled	
antibody,	 respectively	 (BD	 Pharmingen	 550856,	 Biolegend	 300511),	 followed	 by	 flow	
cytometry	 analysis	 using	 FACS	 Vantage	 (Becton	 Dickinson)	 or	 MoFlow	 Astrios	 (Beckman	
Coulter).		
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High‐throughput	 sequencing	 of	miRNA	 cleavage	 products:	 The	 samples	 were	 processed	
following	the	 illumina	TruSeq	Small	RNA	protocol	(www.illumina.com).	 In	short,	 total	RNA	(2	
µg	per	sample)	from	R5	cells	transduced	with	lentivectors	expressing	either	mirGE‐T7	or	miR‐
30	T7	miRNAs	was	extracted	using	TRIzol	(Life	Technologies).	After	validation	of	RNAs,	1µg	of	
total	RNA	from	each	sample	was	ligated	to	specific	3'	and	5'	adapters.	In	a	subsequent	reverse	
transcription	step,	single	stranded	cDNA	was	generated,	followed	by	PCR	amplification	and	gel	
purification	 that	 selecting	 constructs	 holding	 specific	 RNA	 fragments	 with	 an	 approximate	
length	 of	 22nt	 (range	 15‐40).	 Reads	 were	 sequenced	 on	 the	 illumina	 HiSeq	 platform	with	 a	
length	of	50bp.	Partial	adapter	sequences	were	trimmed	using	Flexbar.	The	trimmed	reads	were	
aligned	to	the	hairpin	sequences	of	miRBase	v20	and	the	sequences	of	 the	mirGE	and	miR‐30	
constructs.	Alignment	was	done	with	Bowtie	with	the	options	"‐‐chunkmbs	1024	‐e	50	‐a	‐m	50	
‐‐best	 ‐‐strata	 ‐‐nomaqround	 –y".	 We	 counted	 only	 the	 number	 of	 reads	 that	 aligned	 to	 the	
positive	strand	of	 the	sequences.	Raw	data	of	 this	study	have	been	uploaded	 to	 the	European	
Nucleotide	 Archive	 and	 can	 be	 accessed	 at	 this	 link;	
http://www.ebi.ac.uk/ena/data/view/PRJEB7175	
R5‐tropic	 and	 X4‐tropic	 HIV	 infection	 of	 HR5	 cells:	 Viral	 stocks	 were	 obtained	 by	
Polyethylenimine	(PEI)	mediated	transfection	(Polysciences)	of	293T	cells	with	pYU‐2	or	pNL4‐
3	(provided	through	the	NIH	AIDS	Research	and	Reference	Reagent	Program).	Forty‐eight	hours	
after	 transfection,	 virus	was	harvested,	 filtered	 (0.45µm),	 and	 frozen	at	 ‐80°C	until	use.	Virus	
titers	were	 determined	 as	 previously	 described	 105.	 Briefly,	 TCID50	 (tissue	 culture	 infectious	
dose	50%)	was	determined	by	infecting	human	CD8+	T	cell	depleted	PBMC	from	three	donors	
which	were	 stimulated	by	PHA	and	anti‐CD3	beads	 (Dynal	11131D,	Life	Technologies).	Then,	
viral	stocks	were	adjusted	to	1x106	TCID50/ml,	aliquoted	and	frozen	at	‐80°C	before	use.	HR5	
cells	were	infected	for	6	hours	at	an	MOI	of	2.5,	washed	3	times	with	PBS	and	then	cultured	in	
DMEM	(Invitrogen)	with	10%	FCS	(PAA	laboratories),	1%	Penicillin/Streptomycin	(Invitrogen	
Life	 Technologies)	 and	 1%	 L‐glutamine	 (Invitrogen	 Life	 Technologies).	 Assays	 for	 HIV	 p24	
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antigen	 levels	 in	 cell	 culture	 supernatants	 were	 performed	 using	 an	 in‐house	 ELISA	 as	
described	106. 
R5‐tropic	 HIV‐Luciferase	 infection	 of	 Monocytes‐derived	 Macrophages:	 VPX‐encoding	
virus‐like	particles	 (VPX‐VLPs)	were	produced	essentially	 as	described	previously	 107.	Briefly,	
293T	 cells	 were	 transfected	 using	 polyethylenimin	 (PEI)	 (Sigma‐Aldrich)	 with	 the	 Vpx‐
containing	pSIV3+	plasmid	(provided	by	A.	Cimarelli,	Lyon)	and	the	pMD2.G	(VSV‐G	envelope)	
plasmid.	 The	medium	was	 changed	 after	 16	 hours,	 and	 supernatants	were	 collected	 after	 48	
hours	 and	 filtered	 through	 0.45um	 low	 protein	 binding	 syringe	 filters.	 Monocyte‐derived	
Macrophages	(MDMs)	were	prepared	as	follows.	Monocytes	from	HIV	seronegative	donors	were	
isolated	 from	 total	 peripheral	 blood	 after	 ACK	 lysis	 (Lonza)	 by	 CD14	 micro‐beads	 (Miltenyi	
Biotec).	The	isolated	monocytes	were	matured	to	produce	macrophages	for	6	days	with	X‐vivo‐
10	medium	 (Lonza)	 supplemented	with	1000U/ml	GMCSF	and	100ng/ml	MCSF.	After	6	days,	
the	medium	was	changed	to	X‐vivo‐10	w/o	Cytokines	for	2	days.	VPX‐VPLs	were	added	onto	the	
cells	for	2	hours,	cells	were	washed	and	then	transduced	overnight	with	the	anti‐CCR5	mirGE	or	
control	GFP	lentivectors.	The	next	day	the	cells	were	washed	and	kept	in	culture	for	4	days	prior	
to	infection	with	R5	tropic	NL4‐3/luciferase	virus	pseudotyped	with	ADA	envelope	virus	for	6	
hours.	After	6	hours	cells	were	washed	and	new	medium	added.	Cells	were	lysed	24	hours	after	
infection	with	the	Cell	Culture	 lysis	reagent	(Luciferase	assay	System	Promega)	and	luciferase	
was	measure	with	the	MLX	microplate	luminometer	(Dynex	technologies).	
Statistical	 Analysis:	 The	 statistical	 analyses	 were	 performed	 using	 GraphPad	 Prism	 5.04	
(GraphPad	Software).	We	used	One	Way	ANOVA	followed	by	Bonferronis	Multiple	Comparison	
Test	as	well	as	t‐test	(Non	parametric,	Mann‐Whitney	U).	In	Supplementary	Table	2,	significant	
difference	of	 incorrect	 targeting	strand	processing	was	determined	using	a	proportion	 test	(R	
prop.test;	2‐sample	 test	 for	equality	of	proportions	with	continuity	correction).For	all	 tests,	p	
0.05	was	taken	as	statistically	significant.	
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SUPPLEMENTARY	MATERIAL	
	
Primer	 sequences:	 The	 sequences	 annealing	 to	miR‐30	 or	mirGE	 templates	 templates	 are	
underlined.		The	sequences	for	restriction	sites	BamHI,	SpeI	and	XbaI	are	in	bold	lower	case.	
 
miR‐30 5’ primer:  5’‐CAGAAGGggatccATCGATactagtGATCCAAGAAGGTATATTGCTGTTGACAGTGAGCG 
miR‐30 3’ primer:  5’‐CTAAAGTAGCCCCTTtctagaATCGTAGCCCTTGAAGTCCGAGGCAGTAGGCA 
mirGE 5’ primer:  5’‐CAGAAGGggatccATCGATactagtGGTGATAGCAATGTCAGCAGT 
mirGE 3’ primer:  5’‐AGTAGCTtctagaGTAGAGTATGGTCAACCTT	
	
Template	Sequences:	Sequences	are	shown	as	they	were	received,	ready	to	serve	as	template	
to	 PCR	 amplify	 with	 the	 corresponding	 primers	 shown	 above.	 Targeting	 strands	 are	 in	 blue,	
passenger	strands	are	in	red. 
 
miR‐30 T1 template: 
5’‐
GATCCAAGAAGGTATATTGCTGTTGACAGTGAGCGCTTCCATACAGTCAGTATCAATTAGTG
AAGCCACAGATGTAATTGATACTGACTGTATGGAAATGCCTACTGCCTCGGACTTCAAGGGC
TACGAT 
miR‐30 T7 template: 
 5’‐
GATCCAAGAAGGTATATTGCTGTTGACAGTGAGCGCAGTGTCAAGTCCAATCTATGATAGTG
AAGCCACAGATGTATCATAGATTGGACTTGACACTTTGCCTACTGCCTCGGACTTCAAGGGC
TACGAT 
mirGE T1 template: 
5’‐
GGTGATAGCAATGTCAGCAGTGCCTATTGATACTGACTGTATGGAAAGTGAAGCCACAGATG
TTTCCATACAATCAGTATCAACAAGTAAGGTTGACCATACTCTAC 
mirGE T7 template: 
5’‐
GGTGATAGCAATGTCAGCAGTGCCTTCATAGATTGGACTTGACACTTGTGAAGCCACAGATG
AAGTGTCAAGCCCAATCTATGCAAGTAAGGTTGACCATACTCTAC 
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D9M3 GFP template:  
5’‐
GGTGATAGCAATGTCAGCAGTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACAGATGCAGA
ACGGCACCAAGGTGAACTAAGGTTGACCATACTCTAC 
D9M5 GFP template:  
5’‐
GGTGATAGCAATGTCAGCAGTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACAGATGAAGA
ACGGCACCAAGGTGAACCAAGGTTGACCATACTCTAC 
D11M5 GFP template:  
5’‐
GGTGATAGCAATCAGCAGTGCCTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACAGATGAA
GAACGGCACCAAGGTGAACCAAGTAAGGTTGCATACTCTAC 
D13M3 GFP template:  
5’‐
GGTGATAGCAATGTCAGCAGTGCCTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACAGATG
CAGAACGGCACCAAGGTGAACTAAGTAAGGTTGACCATACTCTAC 
D13M5 GFP template:   
5’‐
GGTGATAGCAATGTCAGCAGTGCCTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACAGATG
AAGAACGGCACCAAGGTGAACCAAGTAAGGTTGACCATACTCTAC 
D15M5 GFP template:  
5’‐
GGTGATAGCAATCAGTCAGCAGTGCCTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACAGA
TGAAGAACGGCACCAAGGTGAACCAAGTAAGGTTGACTGCATACTCTAC 
 
D17M5 GFP template:  
5’‐
GGTGATAGCAATCAGTGTCAGCAGTGCCTAGTTCACCTTGATGCCGTTCTTGTGAAGCCACA
GATGAAGAACGGCACCAAGGTGAACCAAGTAAGGTTGACACTGCATACTCTAC 
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Algorithm	 for	 the	 design	 of	 mirGE‐based	 amplicons	 for	 cloning:	 This	 algorithm	 is	 a	
compilation	of	several	published	and	on‐line	references	including	108,109.	
	
1. Copy your target sequence (ORF, 3'UTR, etc). 
2. Use the three following web tools to select at least ten target sequences 
(http://www5.appliedbiosystems.com/tools/siDesign/; http://www.med.nagoya‐
u.ac.jp/neurogenetics/i_Score/i_score.html;  http://rna.tbi.univie.ac.at/cgi‐bin/RNAxs 
3. Select candidates that are in overlapping pools. 
4. Blast each 19mer to check that they are targeting no other gene other than your target gene. 
5. Exclude “bad” candidates by following instructions of 108, page 12. 
6. Extend 19mer to 22mer by adding nucleotides from the original target sequence, either upstream or 
downstream, favoring a resulting complementary sequence that will have a T on the 5’ end 109 . This 
22mer is the basis for the following shRNA design. 
7. Make a complementary strand to this 22mer. 
8. To favor incorporation of the targeting strand into RISC, it needs to have one flapping nucleotide at its 
5’ end. For human CCR5 mRNA (GenBank: NM_000579.3), the result is 
TTTCCATACAGTCAGTATCAAT (22mer). 
9. Make an antiparallel strand, which will be the top strand of mirGE context, i.e the targeting strand. To 
be efficiently incorporated into RISC, the 5’ terminus A needs to flap, thus make a wobble on the 
complementary strand (Z)  
5’-ATTGATACTGACTGTATGGAAA  
3’-ZAACTATGACTGACATACCTTT 
10. Make another wobble on the complementary strand corresponding to position +12 of the targeting 
strand, to suppress abortive processing As a general rule: Antiparallel (targeting) sequence being in 
blue, 100% complimentary to target mRNA (in red)  
5’- NNNNNNNNNNNNNNNNNNNNNN  
3’- ZNNNNNNNNNNZNNNNNNNNNN 
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11. Then choose Z to add to bottom oligo according to the N in top oligo facing Z. If N is T, make Z a C. If N 
is C, make Z a A. If N is A, make Z a C. If N is G, make Z a A 
12. Replace NNN stretches by sense and antisense oligos to make the PCR template oligo 
13. Amplify this template with the 5' and 3' PCR oligos, as described in Materials and Methods. 
 
 
 
	
Supplementary	Figure	1.	 Schematic	 diagram	of	 the	 lentiviral	 vector	 plasmid	 used	 for	 the	 GFP	 knock‐
down	 experiments.	 (a)	 A	 PCR	 amplicon	 containing	 the	 miRNA	 hairpin	 is	 generated	 as	 described	 in	
Materials	 and	 Methods,	 cut	 with	 BamHI	 and	 XbaI	 restriction	 enzyme	 and	 inserted	 in	 a	 pENTR‐L1L2	
plasmid	 downstream	 of	 the	 human	 MGST2	 gene.	 (b)	 After	 LR	 recombination	 cloning,	 the	 lentivector	
plasmid	 contains	 one	 cassette	 expressing	 the	 MGST2‐miRNA	 unit	 under	 the	 control	 of	 the	 human	
Ubiquitin	promoter	(UBI)	and	the	mCherry	living	color	under	the	control	of	the	human	PGK	promoter.	
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Supplementary	Figure	2.	 Schematic	 representations	GFP	knock‐down	miRNA	designs.	Four	out	of	 the	
seven	 anti‐GFP	 miRNA	 hairpins	 used	 in	 Fig.	 1	 are	 depicted	 here	 for	 illustration.	 The	 22	 nt	 segment	
targeting	GFP	is	on	the	top	strand	and	is	identical	in	all	constructs.	Mismatches	are	generated	by	altering	
sequence	of	the	lower	passenger	strand.	The	number	after	D	represents	the	length	of	the	lower	stem	and	
the	number	after	M	represents	 the	mismatched	end	of	 the	 targeting	strand.	For	example,	D13M5	 lower	
stem	 is	13bp	 in	 length	and	 the	 targeting	strand	has	a	mismatch	on	 its	5’.	This	design	 is	 the	one	named	
mirGE	in	this	paper.	
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Supplementary	Figure	3.	Cloning	strategy	used	 to	easily	 clone	multiple	miRNA	hairpins	 in	a	 lentiviral	
expression	cassette.	 (a)	A	pENTR‐L1L2	plasmid	containing	GFP	 followed	by	BamHI	and	XbaI	restriction	
sites	is	used	as	recipient	for	miRNA	hairpin	cloning	(see	Materials	and	Methods	section).	The	first	hairpin	
PCR	 amplicon	 (see	Materials	 and	Methods	 section)	 is	 cut	 with	 BamHI	 and	 XbaI	 and	 introduced	 in	 the	
pENTR	 plasmid	 opened	 by	 BamHI	 and	 XbaI.	 Subsequent	 hairpins	 are	 cut	 by	 BamHI	 and	 XbaI	 and	
introduced	 in	 front	 of	 the	 previous	 hairpin	 using	 BamHI	 and	 SpeI.	 (b)	 The	 final	 lentiviral	 plasmid	 is	
constructed	using	LR	recombination	between	a	destination	lentiviral	plasmid	(see	Materials	and	Methods	
section),	a	pENTR	plasmid	providing	the	ubiquitin	promoter	(UBI)	and	the	pENTR	plasmid	containing	GFP	
followed	by	miRNA	hairpins.	
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Supplementary	Table	1	
(http://www.nature.com/mtna/journal/v3/n10/suppinfo/mtna201458s1.html):	Positions of starts 
and ends of coverage of short RNAs generated by mirGE and miR‐30 miRNAs. Sequences from high‐throughput 
sequencing of short RNAs generated from mirGE and miR‐30 miRNAs (called reads after illumina®) were aligned 
to their cognate miRNA sequence (see Figure 4). Results are from cells transduced with lentivector expressing a 
single hairpin of miR‐30 (mir‐30_single, 43 % transduced cells), a single hairpin of mirGE (mirGE_single, 23 % 
transduced cells), or a triple hairpin of mirGE (mirGE_triple, 90 % transduced cells). Numbering after 
corresponding miRNA sequence is in white horizontal lines. Counts of reads are in yellow horizontal lines. 
Positions of major starts and ends of reads are indicated in red cells. Orange cells indicate the position of “off‐
site” reads which are present only in mirGE construct and align to the lower stem. These reads were counted 
for the score of total reads aligning to miRNA in Supplementary Table 2 and not counted for the score of 
Drosha cleavage accuracy in Figure 4C.  	
	
	
Supplementary	Table	2:	Numbers	of	total	reads,	reads	assigned	to	miRNAs	and	reads	aligned	to	miR‐30	
or	mirGE.	
Sample  Total 
number 
of 
reads 
[Mio] 
Number of 
reads that 
can be 
assigned to 
a miRNA* 
[Mio]  
 
Number of 
reads that can 
be assigned to 
miR‐30 or 
mirGE hairpins 
Percentage of 
reads that can 
be assigned to 
miR‐30 or mirGE 
from total 
miRNA reads 
Percentage of 
targeting 
strand reads 
with incorrect 
start 
position** 
miR‐30_Single 
(Transduction 
rate 43%) 
4.58  2.07  48’506  2.33 
 
7.53 
mirGE_Single 
(Transduction 
rate 23%) 
1.54  0.83  18’282  2.21  0.16 
mirGE_Triple 
(Transduction 
rate 90%) 
5.20  3.78  2’640’128  69.8 
 
0.06 
HeLa_R5  4.14  2.34  46***  0.002***  NA 
 
*	 Total	 reads	 were	 screened	 to	 determine	 number	 of	 reads	 that	 can	 be	 aligned	 to	 either	 endogenous	
miRNA	 (mirbase	 v20)	 or	 to	 introduced	 constructs	 miR‐30	 or	 mirGE.	 Untransduced	 HeLa	 cells	 stably	
expressing	CCR5	(HeLa_R5	cells,	see	Materials	and	Methods)	were	used	as	negative	control.	
**	 All	 reads	 starting	 outside	 of	 position	 72	 (miR‐30)	 or	 position	 26	 (mirGE)	 (see	 Figure	 4	 A‐B)	 were	
considered	 incorrect.	 The	 7.63%	 incorrect	 5’	 ends	 of	 miR‐30	 is	 significantly	 more	 than	 the	 0.16%	
incorrect	5’	ends	of	mirGE	according	to	an	R	prop.test	(p	<	2.2e‐16).	
***These	values	were	considered	as	background.	
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Gene‐engineered	CD34+	hematopoietic	stem	and	progenitor	cells	(HSPCs)	can	be	used	to	
generate	an	HIV‐1‐resistant	immune	system.	However,	a	certain	threshold	of	transduced	
HSPCs	 might	 be	 required	 for	 an	 effective	 therapy,	 and	 thus,	 improved	 transduction	
procedures	or	 in	vitro/in	vivo	selection	strategies	might	be	necessary.	Here,	to	obtain	a	
more	 effective	 population	 for	 transplantation,	 we	 combined	 CCR5	 knock‐down	 by	 a	
highly	 efficient	 miRNA	 lentivector	 with	 pre‐transplantation	 selection	 of	 transduced	
HSPCs.	 Low‐level	 transduction	 of	 HSPCs	 and	 subsequent	 sorting	 by	 flow	 cytometry	
yielded	>70%	transduced	cells.	Mice	transplanted	with	these	cells	showed	functional	and	
persistent	resistance	to	a	CCR5‐tropic	HIV	strain:	viral	 load	was	significantly	decreased	
over	months,	 and	human	CD4+	T‐cells	were	preserved.	 In	one	mouse,	 viral	mutations,	
resulting	 presumably	 in	 a	 CXCR4‐tropic	 strain,	 overcame	 HIV	 resistance.	 Our	 results	
suggest	 that	HSPC‐based	CCR5	knock‐down	may	 lead	 to	efficient	control	of	HIV	 in	vivo.	
We	overcome	a	major	limitation	of	previous	HIV	gene	therapy	in	humanized	mice	studies	
in	which	only	a	proportion	of	the	cells	in	chimeric	mice	in	vivo	are	anti‐HIV	engineered.	
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Our	 strategy	underlines	 the	promising	 future	of	 gene	engineering	HIV‐resistant	CD34+	
cells	that	produce	a	constant	supply	of	HIV	resistant	progeny.		
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IMPORTANCE	
	
Major	 issues	 in	experimental	 long‐term	 in	vivo	HIV	gene	therapy	have	been	(i)	 low	efficacy	of	
cell	transduction	at	the	time	of	implantation	and	(ii)	transduction	resulting	in	multiple	copies	of	
heterologous	 DNA	 in	 target	 cells.	 In	 this	 study,	 we	 demonstrated	 the	 efficacy	 of	 a	
transplantation	approach	with	a	selection	step	for	transduced	cells	that	allows	transplantation	
of	an	enriched	population	of	HSPCs	expressing	a	single	(low)	copy	of	a	CCR5	miRNA.	Efficient	
maintenance	of	CD4+	T‐cells	 and	a	 low	viral	 titer	 resulted	only	when	at	 least	70%	of	 the	HIV	
target	cells	were	genetically	modified.	These	findings	imply	that	clinical	protocols	of	HIV	gene	
therapy	require	a	selective	enrichment	of	genetically	targeted	cells	because	positive	selection	of	
modified	cells	is	likely	to	be	insufficient	below	this	threshold.	This	selection	approach	may	not	
only	 be	 beneficial	 for	 HIV	 patients,	 but	 also	 other	 patients	 requiring	 transplantation	 of	
genetically	modified	cells.		
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INTRODUCTION	
	
Combined	anti‐retroviral	therapy	(cART)	changed	the	face	of	HIV	medicine:	patients	have	a	life‐
expectancy	 close	 to	uninfected	people	 110.	However,	 cART	has	major	disadvantages,	 including	
adverse	events,	emergence	of	drug‐resistant	strains	in	patients	with	poor	adherence,	a	need	for	
life‐long	 intake,	psychological	dependence,	 and	cost.	Thus,	 cART	has	not	halted	 the	pandemic	
(http://www.who.int/hiv/en/),	and	alternative	therapies	are	needed	to	cure	HIV.		
Gene	therapy	has	been	widely	discussed	as	a	possible	strategy	to	cure	HIV	and	has	been	tested	
in	 phase	 I/II	 clinical	 trials.	 Autologous	 CD4+	 T‐cells	 111,112	 or	 CD34+	 cells	 113,114	 were	 gene	
engineered	 to	express	various	anti‐HIV	moieties,	 including	a	combination	of	 three	RNA‐based	
anti‐HIV	moieties	 (tat/rev	shRNA,	TAR	decoy,	and	CCR5	ribozyme)	 113,	 a	 tat‐vpr‐specific	anti‐
HIV	ribozyme	114,	and	a	conditionally	replicating	lentiviral	vector	expressing	long	anti‐sense	to	
HIV	 111	or	were	gene	edited	by	zinc‐finger	nucleases	 for	CCR5	knockout	 112.	Gene	engineering	
also	generated	HIV‐specific	CD4+	or	CD8+	T‐cells	115,116.	Overall,	the	effects	on	HIV	infection	were	
modest,	but	importantly,	gene	engineering	proved	to	be	safe	in	humans.		
The	 concept	 of	 engineering	 an	HIV‐resistant	 immune	 system	 received	 new	 impetus	 from	 the	
“Berlin	 patient,”	 who	 was	 treated	 with	 hematopoietic	 stem	 cell	 transplantation	 for	 acute	
myeloid	 leukemia.	 He	 received	 bone	 marrow	 from	 a	 donor	 homozygous	 for	 the	 Δ32	 CCR5	
mutation,	and	thus,	the	progeny	cells	did	not	express	CCR5.	He	was	the	first	documented	cure	
for	HIV	 44	 and	provided	hope	 that	eliminating	CCR5	 from	 the	 cell	 surface	would	be	 the	 “Holy	
Grail”	for	the	cure	of	HIV.	However,	another	HIV‐infected	patient	suffering	from	anaplastic	large	
cell	 lymphoma	 also	 received	 a	 stem	 cell	 transplant	 from	 a	 homozygous	 CCR5‐null	 donor.	
Unfortunately,	in	that	case,	X4‐tropic	HIV	strains	emerged	that	necessitated	the	re‐initiation	of	
cART	51.		
In	 view	 of	 the	 modest	 success	 of	 phase	 I/II	 clinical	 trials	 and	 the	 data	 from	 stem	 cell	
transplantation,	 pre‐clinical	 studies	 are	 needed	 to	 define	 the	 best	 anti‐HIV	moieties	 and	 the	
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minimal	number	of	gene	engineered	cells	required	to	advance	gene	therapy	in	HIV.	Humanized	
(hu)	mice,	which	are	generated	by	the	transplantation	of	CD34+	cells,	are	of	particular	value	in	
this	context.	Hu	mice	excel	in	their	multi‐lineage	hematopoiesis	117,	are	highly	permissive	to	HIV	
118,	and	allow	for	the	gene	engineering	of	human	CD34+	cells	before	transplantation	119.	Indeed,	
various	anti‐HIV	moieties	have	been	investigated	in	hu	mice	as	gene	therapy	options,	including	
cellular	 factors,	boosting	 the	anti‐HIV‐immune	response,	 and	 the	HIV	genome	 itself	 119.	These	
mice	were	used	in	extenso	to	investigate	the	effects	of	targeting	CCR5	by	shRNA	55,56,59	or	ZNF	54.	
All	 these	studies	 reported	a	decrease	 in	CCR5	expression	 in	circulating	and	 tissue	 leukocytes,	
which	were	not	permissive	to	HIV	ex	vivo,	but	only	the	study	by	Holt	et	al.	reported	a	significant	
decrease	of	HIV	RNA	copy	number	in	vivo	54.	The	other	studies	either	did	not	analyse	the	effects	
on	HIV	 infection	 in	vivo	55	or	demonstrated	no	effect	on	viral	 load	56.	The	results	of	Holt	et	al.	
revealed	disruption	of	CCR5	in	only	~20%	of	all	CD4+	T‐cells.	The	follow‐up	in	that	study	was	
only	8	weeks.	Gene	engineering	HSPCs	with	a	lentiviral	vector	encoding	the	broadly	neutralizing	
anti‐HIV	human	antibody	2G12	showed	suppression	of	HIV	RNA	but	was	only	studied	7	days	
after	a	challenge	with	a	virus	containing	the	corresponding	epitope	58;	gene	engineering	an	HIV‐
specific	 T‐cell	 receptor	 also	 lowered	 the	HIV	RNA	but	 only	modestly	 57.	 A	 very	 elegant	 study	
with	CD34+	cells	edited	with	an	HIV‐1	LTR	specific	Tre‐recombinase	showed	a	potent	lowering	
of	HIV	RNA	activity	after	HIV	challenge	in	hu	mice	120.	All	these	data	are	promising;	however,	we	
lack	a	long‐term	follow‐up	of	the	effects	of	anti‐HIV	gene	therapy	in	hu	mice,	the	number	of	gene	
engineered	CD34+	cells	needed	in	the	various	studies	to	obtain	an	HIV	RNA	lowering	effect,	and	
a	 detailed	 characterization	 of	 the	 hematopoietic	 system.	 A	 major	 advance	 was	 recently	
presented	by	Barclay	et	al.,	who	purified	the	gene	engineered	CD34+	cells	via	the	expression	of	a	
truncated	version	of	CD25	121.				
Various	means	 are	 available	 for	 gene	 engineering	 CD34+	 cells;	 each	 has	 its	 pros	 and	 cons.	 A	
great	deal	of	experience	exists	with	shRNA	122;	potential	cons	may	be	its	potential	to	trigger	the	
innate	immune	system	66	and	its	less	than	absolute	downregulation	of	the	target	gene.	Targeted	
gene	disruption	by	 ZFN,	Talen	or	Crispr/cas	has	 the	 advantage	of	 complete	disruption	of	 the	
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gene	 of	 interest	 123‐125;	 however	 the	 modest	 rate	 of	 gene	 engineering	 CD34+	 cells	 126,	 the	
potential	 of	 off‐target	 effects	 126‐128	 and	 the	 lack	 of	 clinical	 experience	 represent	 substantial	
hurdles	for	wider	use	in	vivo.	
We	 recently	 reported	 a	 novel	 microRNA‐based	 gene	 knock‐down	 strategy	 with	 improved	
knock‐down,	 relative	 to	 methods	 conventionally	 used	 129.	 A	 triple	 hairpin	 cassette	 targeting	
CCR5	resulted	in	>90%	CCR5	knock‐down	upon	single‐copy	transduction	in	HeLa	cells.	The	aim	
of	 the	 present	 study	 was	 to	 assess	 whether	 gene	 engineering	 CD34+	 cells	 with	 this	 vector	
construct	results	in	down‐regulation	of	CCR5	in	progeny	cells	in	hu	mice	and	whether	it	could	
protect	 against	HIV	 challenge	ex	vivo	 as	well	 as	 in	vivo.	 Since	 some	evidence	 in	 the	 literature	
exists	that	the	number	of	gene	engineered	CD34+	cells	is	a	major	determinant	of	the	success	of	
the	anti‐HIV	moieties	 54,56,	we	also	made	a	major	 effort	 to	 generate	hu	mice	with	a	 very	high	
number	of	gene	engineered	CD34+	cells.	Finally,	we	characterised	in	extenso	the	hematopoietic	
system	subsequent	to	HIV	infection	in	hu	mice	with	gene‐engineered	CD34+	cells.		
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RESULTS	
	
Transplanting	 CD34+	 cells	 with	 partial	 CCR5	 knock‐down	 does	 not	 hinder	 HIV	
replication.		
We	previously	developed	a	highly	efficient	microRNA	called	“mirGE”	(	30)	that	allows	efficient	
knock‐down	by	 single‐copy	 transduction	 (Fig.	 S1a).	Here	we	explore	 the	potential	of	 a	mirGE	
lentivector	 targeting	 CCR5	 to	 produce	 an	 HIV‐resistant	 immune	 system	 in	 hu	 mice.	 The	
construct	consists	of	a	triple	hairpin,	and	the	vector	cassette	contains	GFP	driven	by	the	same	
promoter	 as	 the	 miRNA	 that	 allows	 transduced	 cells	 to	 be	 identified	 directly.	 To	 minimize	
possible	cellular	perturbations	from	multiple	vector	inserts,	we	established	a	protocol	that	gave	
us	 a	 transduction	 rate	 of	 20–30%.	 This	 transduction	 rate	 was	 based	 on	 previous	 work	 and	
should	 correlate	 with	 single‐copy	 integration	 89.	 In	 a	 first	 series	 of	 experiments,	 mice	 were	
transplanted	with	mirGE‐transduced	CD34+	cells	without	further	manipulation	(R5	knock‐down	
mice);	 the	 CD34+	 cells	were	 a	mixture	 of	 transduced	 (20–30%)	 and	 untransduced	 (70–80%)	
cells	 (data	 not	 shown).	 As	 controls,	 we	 used	 either	 mice	 transplanted	 with	 CD34+	 cells	
transduced	 with	 a	 control	 GFP	 lentivector	 (control‐transduced	 mice;	 Fig.	 S1b)	 or	 with	
untransduced	CD34+	cells	(untransduced	mice).	Upon	infection	with	a	R5‐tropic	HIV	(YU‐2),	the	
percentage	and	absolute	number	of	GFP‐positive	CD4+	T‐cells	were	increased	in	R5	knock‐down	
cohorts	 and	 not	 in	 control‐transduced	 cohorts	 (Fig.	 1a,	 and	 Fig.	 3g	 and	 h).	 The	 CD4+	 cell	
population,	however,	remained	the	same	over	the	observation	period	of	92	days	(cohort	1),	or	
showed	a	CD4+	T‐cell	loss	only	at	day	134	days	(cohort	2)			(Fig.	1b).	We	explain	this	increase	in	
GFP+	 HIV‐resistant	 CD4+	 cells	 as	 the	 result	 of	 preferential	 expansion	 at	 the	 cost	 of	
untransduced	 CD4+	 T‐cells,	 while	 the	 lymphoid	 system	 tries	 to	 keep	 the	 lymphoid	 T‐cell	
number	 constant.	However,	HIV	 replication	was	 similar	 in	R5	 knock‐down	mice	 and	 control‐
transduced	mice	over	the	observation	period	at	92	and	134	days	(Fig.	1c).	Analysis	of	absolute	
numbers	of	CD4+	T‐cells	(cohort	2)	indicated	that	the	control‐transduced	mice	lost	CD4+	T‐cells;	
whereas,	they	were	more	or	less	maintained	in	the	R5	knock‐down	mice	(data	not	shown).		
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In	 the	 R5	 knock‐down	mice,	 CCR5	was	 down‐regulated	 in	 the	 GFP‐positive	 CD4+	 T‐cells,	 but	
CCR5	was	detected	on	the	GFP‐negative	CD4+	T‐cells	in	blood	and	spleen	(Fig.	1d	and	Fig.	S2).	In	
the	control‐transduced	mice,	CCR5	was	detected	on	GFP‐negative	and	‐positive	CD4+	T‐cells.	We	
verified	 the	 efficacy	 of	 our	 gene	 engineering	 approach	 by	 separating	 transduced	 from	
untransduced	splenocytes	(R5	knock‐down	mice)	by	FACS	and	infected	the	populations	ex	vivo	
with	R5	tropic	HIV.	GFP‐positive	splenocytes	had	no	HIV	replication	(Fig.	1e).		
These	 results	 suggest	 that	 CCR5	 knock‐down	 efficiently	 protects	 CD4+	 T‐cells	 from	 HIV	
infection,	while	CCR5‐expressing	CD4+	T‐cells	are	eradicated.	In	our	mice,	despite	HIV	challenge,	
at	 least	 a	 proportion	 of	 the	 ~70–80%	 untransduced	 hematopoietic	 stem	 cells	 survive	 and	
continue	 to	produce	HIV‐permissive	CD4+	T‐cells,	which	sustains	high	HIV	 titers.	 It	 is	still	not	
entirely	clear	what	effect	HIV	infection	has	on	CD34+	cells	and	to	what	extent	they	are	depleted,	
if	at	all	130.		
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Figure	1.	Homeostatic	 expansion	of	GFP‐positive	CD4+	T‐cells	 in	R5	knock‐down	mice	despite	
sustained	R5‐tropic	 (YU‐2)	HIV	 infection.	 (a)	 The	 percentage	 change	 of	 GFP‐positive	 CD4+	T‐
cells	 in	 the	 peripheral	 blood	 of	 control‐transduced	 and	 R5	 knock‐down	 mice.	 Control‐
transduced	mice	(Cohort	1,	n=8;	Cohort	2,	n=4)	and	R5	knock‐down	mice	(Cohort	1,	n=6;	Cohort	
2,	n=5).	Mean	±	sem.;	*P	=	0.0152,	**P	=	0.0034,	***P	=0.0002.	P	values	determined	by	two‐tailed	
unpaired	t‐test.	(b)	HIV	RNA	copies	per	ml	of	blood	plasma	collected	for	the	control‐transduced	
and	R5	 knock‐down	mice	 cohort	 1	 and	 cohort	 2	 over	 92	 and	 134	 days,	 respectively.	 Time	 of	
termination	 was	 chosen	 at	 random	 for	 the	 various	 groups.	 The	 dashed	 line	 indicates	 400	
copies/ml,	detection	limit	of	the	HIV	RNA	assay.	Mean	±	sem.	(c)	Frequency	of	total	CD4+	T‐cells	
(percentage	of	total	CD3	T‐cells)	for	the	control‐transduced	and	R5	knock‐down	cohorts	1	and	2.	
Mean	 ±	 sem.;	 *P	 =	 0.0146.	 P	 values	 determined	 by	 two‐tailed	 unpaired	 t‐test.	 (d)	 Percentage	
CCR5	expression	on	total	CD4+	T‐cells	in	peripheral	blood	and	spleen	of	various	cohorts	of	mice.	
Blood:	mean	 ±	 sem	 .;	 *P	 =	 0.0237,	 *’P	 =	 0.0121,	 **P	 =	 0.0035,	 ***P	 =	 0.0007,	 ****P	 =	 0.0001.	
Spleen:	mean	±	sem.;	*P	=	0.041,	***P	=	0.0003.	P	values	determined	by	two‐tailed	unpaired	t‐
test.	(e)	HIV	replication	is	 inhibited	ex	vivo	in	GFP‐positive	sorted	splenocytes	from	R5	knock‐
down	mice.	 Splenocytes	 were	 isolated	 from	 R5	 knock‐down	mice	 20	 weeks	 after	 CD34+	 cell	
injection.	Splenocytes	were	sorted	into	GFP‐positive	(n=5)	and	GFP‐negative	(n=5)	fractions	at	
99%	 purity	 and	 challenged	with	 R5	 tropic	 HIV	 (YU‐2).	 The	 amount	 of	 HIV	 production	 in	 the	
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culture	supernatant	was	monitored	by	HIV	p24	ELISA.	Viral	loads	were	normalized	to	the	peak	
viral	load	in	each	condition	(mean	±	sem).		
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	Transplantation	 of	 purified	 CCR5	 knock‐down	 CD34+	 cells	 results	 in	mice	with	 “pure”	
populations	of	transduced	cells	in	vivo.		
The	 lack	 of	 resistance	 to	 HIV	 infection	 was	 likely	 due	 to	 the	 chimerism	 of	 transduced	 and	
untransduced	CD34+	cells	in	our	initial	experiments.	Therefore,	we	sorted	the	CD34+	cells	after	
transduction	 into	 CCR5	 knock‐down,	 GFP‐positive	 and	 ‐negative	 fractions	 obtaining	 a	 >90%	
pure	 population	 of	 GFP‐positive	 CD34+	 cells	 (Fig.	 S3a‐d).	 Mice	 transplanted	 with	 GFP‐sorted	
cells	were	called	“FACS‐sorted	R5	knock‐down	mice.”	Analysis	of	the	peripheral	blood	in	six	of	
the	FACS‐sorted	R5	knock‐down	animals	showed	a	single	GFP‐positive	peak	for	human	CD45+	
and	CD4+	T‐cells,	suggesting	that	only	transduced	CD34+	cells	engrafted	in	these	mice	(Fig.	2);	
the	 level	 of	 GFP‐positive	 cells	 was	 a	 major	 criterion	 for	 successful	 gene	 engineering	 and	
engraftment.	 Mice	 transplanted	 with	 the	 GFP‐negative	 fraction	 were	 called	 “FACS‐sorted	
negative	mice.”	They	developed	CD4+	and	CD8+	T‐cell	populations	with	no	GFP	expression	(Fig.	
2).	 In	 contrast,	 the	 control‐transduced	 mice	 had	 two	 distinct	 GFP‐negative	 and	 ‐positive	
populations	 for	 CD45+	 and	 CD4+	 T‐cells	 (Fig.	 2).	 A	 summary	 of	 mice	 used	 in	 this	 study	 is	
indicated	 in	 (Table	 1).	 Mice	 with	 less	 than	 5%	 human	 engraftment	 in	 the	 peripheral	 blood	
before	HIV	infection	were	excluded.		
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Figure	2.	GFP‐positive	CCR5	knock‐down	sorted	CD34+	HSPCs	produced	mice	with	“pure”	populations	of	
transduced	cells	in	vivo.	(a)	FACS	plots	showing	the	percentage	human	engraftment	CD45+	(percentage	of	
live	 cells)	 and	 GFP‐positive	 CD45+	 (percentage	 of	 human	 CD45)	 cells	 for	 representative	 control‐
transduced,	FACS‐sorted	R5	knock‐down	and	FACS‐sorted	negative	mice	before	HIV	 infection.	 (b)	FACS	
plots	 showing	 the	 percentage	 CD4+	 T‐cells	 (percentage	 of	 CD3+),	 CD8+	 (percentage	 of	 CD3+)	 and	 GFP‐
positive	CD4+	T‐cells	(percentage	of	CD4+)	in	the	peripheral	blood	before	HIV	infection	of	the	same	mice	as	
in	(a).	For	all	cell	subset	analysis,	the	sub‐gating	was	done	as	follows,	total	 live	cells,	CD45+,	CD3+,	CD4+,	
CD8+.	Mean	fluorescence	intensity	(MFI)	for	GFP	is	indicated.		
	
	
Table	1:	Mice	used	in	the	study.		
	
%GFP+ CD34+	
cells;	[Pre‐	
transplantatio
n]	
Total	
mice	
%	
Engraftment	
(>5%	
hCD45+)	
%	GFP+CD4+	
T‐cells	
(>70%)	
%	GFP+CD4+		
T‐cells	(20‐
70%)	
%	GFP+CD4+	
T‐cells	
(<20%)	
Untransduced	 n/a	 15	 11	 n/a	 n/a	 n/a	
Control‐transduced	 15‐40	 17	 12	 0	 5	 7	
R5	knock‐down	 17‐20	 15	 11	 0	 0	 11	
FACS	GFP‐positive	 12‐32	 20	 10	 6	 4	 0	
FACS	GFP‐negative	 n/a	 26	 15	 n/a	 n/a	 n/a	
	
Number	of	mice	with		
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	Transplanting	 purified	 CCR5	 knock‐down	 CD34+	 cells	 dramatically	 lowered	 viral	 load	
and	protected	HIV	target	cells	in	vivo.	
The	 FACS‐sorted	 R5	 knock‐down	mice	 had	markedly	 lower	 viral	 loads	 than	 the	 FACS‐sorted	
negative	mice	over	28	weeks	(Fig.	3a).	Peak	viremia	for	the	FACS‐sorted	R5	knock‐down	mice	
was	on	average	4.2x103	copies/ml,	and	FACS‐sorted	negative	mice	had	3.5x105	copies/ml.	Viral	
loads	for	the	untransduced,	control‐transduced,	R5	knock‐down,	and	FACS‐sorted	negative	mice	
were	 similar	 (Fig.	 S4a).	 The	 FACS‐sorted	R5	 knock‐down	mice	 had	 lower	 viral	 loads	 than	 all	
cohorts	(Fig.	S4b).		
CD4+	 T‐cells	 (percentage	 of	 total	 CD3+	 T‐cells)	 from	 the	 FACS‐sorted	 negative	mice	 declined	
steadily	upon	infection	(day	0:	55%;	day	134:	20%)	(Fig.	3b).	 In	contrast,	 the	FACS‐sorted	R5	
knock‐down	 mice	 showed	 a	 steady	 increase	 in	 CD4+	 T‐cells	 (day	 0:	 33%;	 day	 196:	 65%).	
Furthermore,	 the	 absolute	 numbers	 of	 CD4+	 T‐cells	 increased	 for	 the	 FACS‐sorted	 R5	 knock‐
down	mice	but	decreased	for	the	FACS‐sorted	negative	mice	(data	not	shown).		
At	euthanasia,	for	the	FACS‐sorted	R5	knock‐down	mice,	70%	of	CD4+	T‐cells	in	the	blood	and	
83%	of	CD4+	T‐cells	in	the	spleen	were	GFP‐positive	(Fig.	3c‐d).	In	the	control‐transduced	and	
R5	knock‐down	groups,	this	was	on	average	20%	and	18%	in	the	blood	and	21%	and	20%	in	
the	spleen,	respectively	(Fig.	3c,d).	Similarly,	the	CD4+/CD8+	T‐cell	ratios	in	the	blood	and	spleen	
(end/pre‐infection)	were	very	low	in	the	various	groups	except	for	the	FACS‐sorted	R5	knock‐
down	group	 (Fig.	 3e,f).	Absolute	numbers	of	GFP‐positive	CD4+	T‐cells	 expanded	significantly	
upon	HIV	challenge	 in	the	FACS‐sorted	R5	KD	mice	(Fig.	3i),	and	CCR5	expression	was	down‐
regulated	in	the	blood	and	spleen	of	the	FACS–sorted	R5	knock‐down	mice	(Fig.	1d	and	Fig.	S5).		
In	summary,	transplantation	of	GFP‐positive	sorted	CD34+	cells	produced	mice	with	high	levels	
of	gene‐engineered	CCR5	knock‐down	CD4+	T‐cells	in	vivo.	This	resulted	in	long‐term	inhibition	
of	HIV	replication	in	vivo	and	preservation	of	HIV	target	cells	in	the	blood	and	spleen.		
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Figure	3.		Sustained	HIV	viral	load	inhibition	in	FACS‐sorted	R5	knock‐down	mice.	(a)	HIV	RNA	copies	per	
ml	in	blood	plasma	from	FACS‐sorted	R5	knock‐down	n=5	(YU‐2)	and	FACS‐sorted	negative	n=15	(YU‐2	
n=9	or	 JRCSF	n=6)	mice	collected	over	134	and	196	days,	 respectively.	The	viral	 load	detection	 limit	 is	
indicated	by	the	dashed	line	(400	copies/ml).	Mean	±	sem.;	Day	57	*P	=	0.0486,	day	92	*P	=	0.0188,	and	
day	134	*P	=	0.0391.	P	values	determined	by	a	two‐tailed	unpaired	t‐test.	(b)	Percentage	CD4+	T‐cells	of	
FACS‐sorted	R5	 knock‐down	 (n=5)	 and	 FACS‐sorted	 negative	 (n=15)	mice.	Mean	 ±	 sem.;	 Day	 92	 **P	 =	
0.0017	and	day	134	**P	=	0.0018.	P	values	determined	by	two‐tailed	unpaired	t‐test.	(c)	Percentage	GFP‐
positive	 CD4+	 T‐cells	 in	 the	 peripheral	 blood	 at	 termination.	 Mean	 ±	 sem.;	 ****P	 =	 0.0001.	 P	 values	
determined	 by	 two‐tailed	 unpaired	 t‐test.	 (d)	 Percentage	 GFP‐positive	 CD4+	 T‐cells	 in	 the	 spleen	 at	
termination.	Mean	±	sem.;	****P	=	0.0001.	P	values	determined	by	two‐tailed	unpaired	t‐test.	(e)	Change	of	
CD4+/CD8+	 T‐cell	 ratio	 in	 the	 peripheral	 blood,	 comparing	 the	 CD4+/CD8+	 T‐cell	 ratio	 of	 each	 cohort	
end/pre‐infection.	 Mean	 ±	 sem.;	 **P	 =	 0.0026.	 P	 values	 determined	 by	 two‐tailed	 unpaired	 t‐test.	 (f)	
CD4+/CD8+	T‐cell	ratio	at	termination	in	the	spleen	of	various	cohorts	of	mice.	Mean	±	sem.;	**P	=	0.0059,	
*P	=	0.039.	P	values	determined	by	two‐tailed	unpaired	t‐test.	(g‐i)	Absolute	numbers	of	GFP+	CD4+	T‐cells	
or	 total	 CD4+	 T‐cells/µl	 of	 blood	 of	 representative	mice	 from	 the	 control‐transduced	 (n=5),	 R5	 knock‐
down	 (n=8)	 and	 FACS‐sorted	 R5	 knock‐down	 (n=5)	 cohorts.	 Mean	 ±	 sem.;	 *P	 =	 0.0194,	 *P	 =	 0.0369,	
respectively.	P	values	determined	by	paired	t‐test.	
73	
	
Outlier	analysis	and	follow‐up	of	mice	that	did	not	meet	acceptance	criteria.	
The	 FACS‐sorted	 R5	 knock‐down	 mice	 typically	 controlled	 the	 virus	 long‐term	 (titers	 <	 104	
copies/ml)	while	maintaining	a	high	level	of	GFP‐positive	CD4+	T‐cells	in	the	blood	(Fig.	4a).	In	
contrast,	a	single	FACS‐sorted	R5	knock‐down	mouse	(#954)	showed	an	unexpected	decline	in	
GFP‐positive	CD4+	T‐cells	with	high	HIV	copy	numbers,	>105	copies/ml	on	days	57	and	92	(Fig.	
4a).	We	performed	an	outlier	analysis	(see	methods	section),	and	at	 four	different	times,	viral	
loads	detected	in	animal	#954	were	statistical	outliers	(Fig.	4a).	Based	on	this,	animal	#954	was	
not	included	in	the	mean	values	and	was	analyzed	separately	(see	below).	At	termination,	this	
mouse	had	much	lower	splenic	engraftment	of	total	human	splenocytes	with	31%	human	cells	
(Fig.	S6a,b)	compared	to	 the	FACS‐sorted	R5	knock‐down	mice	which	had	54%	(mean	±	sem:	
11%).	GFP‐positive	CD4+	T‐cells	were	barely	detected	in	the	spleen	of	mouse	#954	(6%),	while	
the	 FACS‐sorted	 R5	 knock‐down	mice	 had,	 on	 average,	 83%	 (mean	 sem	 ±	 2%)	 GFP‐positive	
CD4+	T‐cells	in	the	spleen	(Fig.	3d	and	Fig.	S6a,b).		
The	inclusion	criterion	we	defined	as	successful	reconstitution	for	FACS‐sorted	R5	knock‐down	
mice	was	 70%	GFP+	 CD4+	 T‐cells	 in	 the	 peripheral	 blood	 before	 infection.	 Four	mice	 did	 not	
meet	 these	 criteria	despite	being	 transplanted	with	GFP‐positive	 sorted	CD34+	 cells	 (Fig.	 4b).	
Mouse	#1113	had	no	protection	against	HIV	and	had	a	limited	expansion	of	GFP‐positive	CD4+	
T‐cells	(23%	on	day	0	to	43%	on	day	137).	Mice	#958	and	#1115	had	massive	expansions	of	
GFP‐positive	 cells	 reaching	 close	 to	 100%	 of	 the	 total	 CD4+	 T‐cell	 population	which	 went	 in	
parallel	 with	 a	 decrease	 in	 the	 viral	 load	 (Fig.	 4b,	 and	 Fig.	 S7a,b).	 For	 mouse	 #1608,	 the	
dynamics	 of	 GFP‐positive	 CD4+	 T‐cell	 recovery	 and	 viral	 load	were	 slower,	 and	 GFP‐positive	
CD4+	T‐cell	recovery	on	day	134	was	less	extensive.	However,	the	GFP‐positive	CD4+	T‐cells	had	
increased	 substantially	 from	36%	at	 (day	0)	 to	63%	at	day	60	post‐infection	 (Fig.	 4b).	These	
three	mice	(#958,	#1115,	#1608)	maintained	a	high	CD4/CD8	ratio,	as	well	as	high	percentage	
of	GFP‐positive	CD4+	T‐cells	in	the	blood	and	spleen	(Fig.	S7a‐c).		
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Strikingly,	 we	 observed	 this	 level	 of	 expansion	 (Fig.	 4b	 and	 Fig.	 S7)	 of	 HIV‐resistant	 GFP‐
positive	CD4+	T‐cells	cells	and	a	concomitant	inhibitory	effect	on	HIV	only	in	mice	transplanted	
with	CCR5	knock‐down	GFP‐sorted	CD34+	cells	(these	animals	had	30±4%	GFP+	CD4+	T‐cells	on	
day	0).	This	degree	of	expansion	was	not	seen	in	R5	knock‐down	mice	(which	had	5±2%	GFP+	
CD4+	T‐cells	before	HIV	infection).	Based	on	these	results,	we	estimate	that	at	least	20%	of	CD4+	
T‐cells	 need	 to	 be	 CCR5	 repressed	 to	 observe	 homeostatic	 expansion	 and	 relevant	 effects	 on	
viremia.		
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Figure	4.	Outlier	analysis	and	examples	of	viral	load	control	due	to	homeostatic	expansion	of	transduced	
cells.	 (a)	Left	panel,	viral	 load	of	 the	FACS‐sorted	R5	knock‐down	mice	 (YU‐2)	and	viral	 load	of	 “outlier	
FACS‐sorted	R5	knock‐down	mouse	#954”	 (YU‐2).	Right	panel,	percentage	GFP‐positive	CD4+	T‐cells	of	
the	 FACS‐sorted	 R5	 knock‐down	 mice	 and	 mouse	 #954.	 Percentage	 GFP‐positive	 CD4+	 T‐cells	 as	 a	
percentage	of	total	CD4+	T‐cells.	P	values	determined	by	GraphPad	Outlier	calculator.	*P	<	0.001.	(b)	Viral	
load	 and	 percentage	 GFP‐positive	 CD4+	 T‐cells	 of	 three	 individual	 FACS‐sorted	 R5	 knock‐down	 mice	
(mouse	 #1113,	 JRCSF,	 #958,	 YU‐2,	 #1115,	 JRCSF	 and	 #1608,	 JRCSF)	 that	 were	 excluded	 due	 to	 not	
reaching	the	inclusion	criteria	of	over	70%	GFP‐positive	CD4+	T‐cells	before	HIV	infection.	
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Preserved	 engraftment	 and	preferential	 expansion	of	 central	memory	T‐cells	 in	 FACS‐
sorted	R5	knock‐down	mice	upon	HIV	infection.	
Engraftment	as	reflected	 in	peripheral	blood	decreased	 in	all	control	cohorts	but	 increased	 in	
the	FACS‐sorted	R5	knock‐down	mice	(Fig.	5a).	This	effect	on	total	engraftment	was	even	more	
impressive	 in	 the	 spleen.	 FACS‐sorted	 R5	 knock‐down	mice	 had	 10	 times	more	 human	 cells	
than	control	cohorts	(Fig.	5b).		
We	evaluated	 the	CD4+	 and	CD8+	 effector	 (CD45RApos;	 CCR7neg),	 effector	memory	 (CD45RAneg;	
CCR7neg),	naive	(CD45RApos;	CCR7pos)	and	central	memory	(CD45RAneg;	CCR7pos)	T‐cell	subsets	in	
the	 blood	 and	 spleen	 of	 the	 FACS‐sorted	 R5	 knock‐down	 and	 representative	 FACS‐sorted	
negative	 mice	 (Fig.	 5c‐f).	 In	 the	 peripheral	 blood	 of	 the	 FACS‐sorted	 negative	 mice,	 the	
frequency	 of	 central	 memory	 CD4+	 T‐cells	 was	 significantly	 decreased,	 and	 the	 CD8+	 central	
memory	T‐cell	subset	was	unchanged	(Fig.	5c,e).	In	contrast,	central	memory	CD4+	and	CD8+	T‐
cells	were	 increased	 in	 the	FACS‐sorted	R5	knock‐down	mice.	Similarly,	more	CD4+	and	CD8+	
central	memory	T‐cells	were	present	 in	 the	 spleens	 of	 the	 FACS‐sorted	R5	 knock‐down	mice	
(Fig.	5d,f).	We	observed	no	differences	between	 the	cohorts	 for	effector	and	effector	memory	
cells	(data	not	shown).	Notably,	however,	there	was	a	trend	towards	a	decrease	in	naive	CD4+	
and	CD8+	T‐cells	in	all	cohorts	(data	not	shown).	
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Figure	 5.	 Increased	 engraftment	 and	 central	 memory	 T‐cells	 in	 blood	 and	 spleen	 of	 FACS‐sorted	 R5	
knock‐down	mice.	 (a)	 Change	 in	 level	 of	 peripheral	 blood	 engraftment	 expressed	 as	 the	 ratio	 of	 total	
CD45+	end/pre‐infection.	Mean	±	sem.;	**P	=	0.0031,	***P	=	0.0006,	****P	<	0.0001.	P	values	determined	
by	two‐tailed	unpaired	t‐test.	(b)	Absolute	numbers	of	human	cells	(CD45+)	in	the	spleen	at	termination.	
Mean	±	sem.;	*P	=	0.0229,	**P	<	0.0019.	P	values	determined	by	two‐tailed	unpaired	t‐test.	(c,e)	Percentage	
of	CD4+	and	CD8+	central	memory	T‐cells	in	the	peripheral	blood,	pre‐infection	and	at	the	end	time	point.	
Mean,	sem.;	*P	=	0.0153,	**P	=	0.0042,	***P	=	0.0004.	P	values	determined	by	paired	t‐test.	(d,f)	Percentage	
CD4+	and	CD8+	central	memory	T‐cells	in	the	spleen	at	termination.	Mean	±	sem.;	*’P	=	0.0472,	*P	=	0.0106,	
**P	=	0.0022,	***P	=	0.0001,	****P	<	0.0001.	P	values	determined	by	two‐tailed	unpaired	t‐test.	
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Evidence	of	shift	from	R5	to	X4	tropic	strain	in	one	mouse.	
As	 described	 above	 (Fig.	 4),	 FACS‐sorted	 R5	 knock‐down	 mice	 had	 a	 low	 viral	 load	 and	
maintained	high	levels	of	CCR5	knock‐down	CD4+	T‐cells.	Mouse	#954	was	clearly	an	outlier:	it	
had	 high	 viral	 titers	 and	 lost	 GFP‐positive	 CD4+	 T‐cells	 (Fig	 6a).	 We	 hypothesized	 that	 this	
mouse	might	have	had	a	tropism	shift	of	the	virus	from	R5	to	X4.	We	performed	HIV	population	
sequencing	(from	plasma)	on	days	57	and	196.	As	a	control,	we	analyzed	mouse	#958	(Fig.	6b	
and	Fig.	S7a).	Sequencing	revealed	no	mutations	in	mouse	#958.	Mouse	#954	had	mutations	in	
the	V3	loop	of	the	HIV	envelope	sequence	(Fig.	6c),	resulting	in	amino	acid	substitutions	to	basic	
amino	acids	as	indicated	(Fig.	6d).	Substitutions	in	the	V3	loop	to	basic	amino	acids	have	been	
reported	to	result	in	a	switch	from	R5	to	X4	tropism	131.	
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Figure	6.	Population	sequencing	of	HIV	in	plasma:	evidence	for	gene‐therapy	failure.	(a,b)	Plots	showing	
the	percentage	of	GFP‐positive	CD4+	T‐cells	 in	peripheral	blood	(as	a	percentage	of	CD3+	T‐cells)	on	the	
left	Y	axis	and	HIV	viral	load	on	the	right	Y	axis	for	mice	#954	and	#958,	respectively.	Mouse	#954	had	a	
high	 and	 sustained	 viral	 load	 overtime	with	 a	 complete	 loss	 of	 GFP‐positive	 CD4+	 T‐cells.	Mouse	#958	
experienced	an	expansion	of	GFP‐positive	CD4+	T‐cells	from	less	than	30%	on	day	19,	to	over	80%	on	day	
196.	(c)	On	day	57,	both	animals	had	a	homogenous	HIV	population	in	the	peripheral	blood,	sequencing	
data	of	HIV	envelope	V3	loop	is	consistent	with	an	R5	tropic	HIV	strain.	On	day	196,	animal	#954,	which	
experienced	 a	 complete	 loss	 of	GFP‐positive	CD4+	T‐cells	 (blood	and	 spleen),	 had	detectable	mutations	
within	 the	 V3	 loop	 of	 HIV.	 For	 mouse	 #958,	 no	 mutations	 were	 detected	 in	 the	 V3	 loop	 on	 day	 196,	
indicating	the	presence	of	a	homogenous	HIV	population.	(d)	Amino	acid	changes	to	basic	amino	acids	H	
and	R.	According	to	a	Geno2Pheno	(http://www.geno2pheno.org/)	analysis	of	the	obtained	sequence	in	
(c),	there	is	only	18%	confidence	that	the	virus	at	day	196	of	mouse	#954	was	not	an	X4	variant.	
80	
	
DISCUSSION	
Here	we	investigated	a	lentiviral	vector–based,	CCR5‐targeting	miRNA	as	a	tool	for	engineering	
an	HIV‐resistant	 human	 immune	 system.	We	 show	 that	 i)	 the	miRNA‐based	 vector	was	 very	
efficient	in	down‐regulating	CCR5	from	T‐cells	and	prevented	their	infection	by	HIV	ex	vivo,	 ii)	
only	mice	that	were	transplanted	with	a	pre‐selected	population	of	transduced	CD34+	cells	and	
maintained	 gene	 engineered	 CD4+	 T‐cells	 had	 a	 dramatically	 reduced	 viral	 load	 (functional	
cure),	 and	 iii)	 the	HIV‐infected	mice	 transplanted	with	miRNA	 CCR5	 gene‐engineered	 CD34+	
cells	 showed	 a	 dramatic	 expansion	 of	 memory	 T‐cells	 (i.e.,	 the	 miRNA	 edited	 T‐cells	 were	
mainly	 of	 this	 phenotype).	 Thus,	 we	 provide	 here	 pre‐clinical	 proof‐of‐concept	 for	 gene	
engineering	 of	 an	 HIV‐resistant	 immune	 system	 through	 the	 use	 of	 vector‐mediated	 miRNA	
expression	and	the	need	for	a	certain	threshold	of	gene	engineered	CD34+	cells	 for	 functional	
cure	of	HIV.		
While	gene	engineering	HIV‐resistant	cells	is	a	viable	option	to	cure	of	HIV,	major	issues	remain	
to	 be	 solved.	 These	 include	 finding	 the	 best	 anti‐viral	 moiety	 or	 combination,	 the	 most	
efficacious	way	to	gene	engineer	the	CD34+	cells,	and	the	threshold	of	gene	engineered	CD34+	
cells	needed	for	functional	cure.		
Lentivirus‐based	transduction	has	been	supplemented	by	gene‐targeting	methods,	such	as	ZNF‐
or	Talen	nucleases,	or	 the	Crispr/Cas	 system	 for	 gene	editing	 123‐125.	However,	 these	methods	
are	still	in	their	infancy,	and	off‐target	effects	are	unknown.	Gene	engineering	in	primary	cells	is	
only	modestly	effective,	 and	even	 though	no	adverse	events	have	been	 reported,	 there	 is	 less	
experience	 in	 clinical	 trials	 than	 with	 lentivirus‐based	 transduction.	 Thus,	 we	 opted	 for	
lentivirus‐based	 gene	 engineering	 132‐134.	 Furthermore,	 we	 are	 the	 first	 to	 engage	 in	 miRNA	
technology	for	knocking	down	the	HIV	co‐receptor	CCR5	in	CD4+	T‐cells	via	gene	engineering	
CD34+	cells.	miRNAs	closely	mimic	naturally	occurring	pri‐miRNAs	and,	thus,	are	less	likely	to	
cause	oversaturation	of	 the	RNA	interference	pathway	and	to	affect	cellular	homeostasis	 than	
the	widely	used	shRNAs	63,65.	However,	miRNAs	are	thought	to	have	a	lower	capacity	to	down‐
regulate	 target	 genes	 than	 shRNAs.	 Here	 we	 used	 a	 miRNA	 we	 developed	 with	 optimized	
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features	 that	efficiently	knock‐down	target	genes	upon	single‐copy	vector	 transduction	 129.	Ex	
vivo	sorted	cells	were	 indeed	resistant	to	a	challenge	with	CCR5‐tropic	strains.	However,	bulk	
transplantation	of	transduced	CD34+	cells	into	mice	resulted	in	a	human	lymphoid	system	that	
replicated	HIV	similar	to	untransduced	hu	mice	but	preserved	CD4+	T‐cell	counts.	Similar	data	
have	been	reported	56.		
We	hypothesized	that	a	threshold	of	gene	engineered	cells	would	be	required	to	see	an	effect	on	
the	HIV	load;	otherwise,	the	HIV	permissive	CD4+	T‐cells	that	originated	from	the	untransduced	
CD34+	cells	would	“outnumber”	the	HIV‐resistant	cells.	Thus,	we	used	GFP	to	allow	for	efficient	
sorting	of	transduced	CD34+	cells	before	transplantation.	By	doing	so,	we	found	that,	to	achieve	
long‐term	 suppression	 of	 viral	 load,	 more	 than	 70%	 of	 CD34+	 transplanted	 should	 be	 gene	
engineered.	 Walker	 et	 al.	 obtained	 an	 average	 engraftment	 (±STD)	 level	 of	 anti‐HIV	 vector	
transduced	 cells	 of	 17.5±8%	 in	 the	 peripheral	 blood	 and	 argued	 that	 these	 numbers	 of	 cells	
were	 insufficient	 to	 see	 any	 decrease	 in	 plasma	 viremia	 56.	 Furthermore,	 a	 very	 recent	
publication	 sorted	 the	 gene	 engineered	CD34+	 cells	with	 a	 truncated	 version	 of	 CD25	before	
their	 transplantation	 into	 2–5‐day‐old	NRG	mice	 121.	 They	 found	 that	mice	 transplanted	with	
tCD25	 purified	 CD34+	 cells	 had	 normal	 multi‐lineage	 hematopoiesis	 similar	 to	 mice	
transplanted	with	untransduced	CD34+	cells.	Upon	HIV	challenge,	tCD25	transplanted	mice	did	
not	 suffer	 from	HIV	 induced	 CD4+	 T‐cell	 depletion	 as	 did	 the	 untransduced	mice	 and	 tCD25	
mice	had	a	1.5	 log	 inhibition	 in	plasma	viremia,	 compared	 to	mice	with	untransduced	CD34+	
cells.	 Our	 data	 nicely	 complement	 the	 data	 provided	 by	Walker	 et	 al.	 and	 Barclay	 et	 al.	 and	
underline	the	importance	of	the	number	of	transduced	cells	that	are	required	for	efficient	HIV	
gene	 therapy.	 Notably,	 two	 hu	mice	 transplanted	 with	 purified	 gene	 engineered	 CD34+	 cells	
showed	at	baseline	23	and	40%	GFP+	cells	which	expanded	substantially	upon	HIV	infection;	the	
expansion	went	 along	with	 a	 decrease	 in	 viral	 load.	 These	 two	mice	were	 reminiscent	 of	 the	
data	reported	by	Holt	et	al	where	disruption	of	CCR5	by	zinc‐finger	nucleases	was	achieved	in	
~20%	of	CD34+	cells	and	resulted	in	viral	repression	over	time	54.		
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Obviously,	in	humans,	GFP‐based	sorting	would	not	be	an	option,	given	the	xenogeneic	nature	of	
the	 protein.	 However,	 novel	 strategies	 for	 sorting	 of	 transduced	 CD34+	 cells	 based	 on	 the	
expression	 of	 truncated	 cellular	 surface	 receptors,	 such	 as	 CD25	 121,	 the	 epidermal	 growth	
factor	receptor	135	or	the	nerve	growth	factor	receptor	136,	are	very	promising	for	achieving	high	
numbers	 of	 engrafted	 gene	 engineered	 cells.	 An	 alternative	 approach	 to	 pre‐transplantation	
sorting	would	be	in	vivo	selection	of	transduced	cells	137,138.	Regrettably,	current	in	vivo	selection	
methods	 use	 potentially	 carcinogenic	 compounds,	 such	 as	 mycophenolate,	 methotrexate	 or	
alkylating	agents	(i.e.,	O6‐benzylguanine/bis‐chloroethylnitrosourea),	 that	offset	 their	use	 in	a	
disease,	 such	 as	 HIV,	 that	 is	 amenable	 to	 an	 efficient	 and	 well‐tolerated	 cART.	 We	 want	 to	
emphasize	that,	in	our	gene‐engineering	efforts,	we	aimed	for	single	lentiviral	copy	integration.	
The	 two	 recent	phase	 I	 clinical	 trials	 used	 gene	 engineering	protocols	 that	 resulted	 in	 vector	
copy	numbers	of	 ranging	 from	2‐4	per	genome	of	bone	marrow	cells	prior	 to	 transplantation	
without	 documenting	 any	 adverse	 events	 over	 an	 observation	 period	 of	 >20	 months	 132,133.	
Thus,	 ensuring	 CD34+	 transduction	 might	 present	 another	 alternative	 for	 increasing	 the	
number	 of	 gene	 engineered	 CD34+	 cells.	 These	 protocols	 appear	 not	 to	 affect	 the	 long‐term	
engraftment	negatively	in	these	phase	I	clinical	trials.		
While	the	data	on	a	critical	threshold	in	our	set	of	mice	are	quite	evident	in	the	hu	mouse	model,	
we	 do	 not	 know	 what	 the	 threshold	 would	 need	 to	 be	 in	 humans.	 HIV	 certainly	 by	 killing	
untransduced	cells	via	its	cytopathic	effects	will	promote	the	expansion	of	HIV	resistant	cells.	To	
what	 extent	 the	HIV‐resistant	 cells	will	 foster	 an	 efficient	HIV‐specific	 immune	 response	 and	
thereby	constrain	HIV	remains	unknown.		
White	blood	cell	counts	from	HIV‐infected	mice	generated	with	FACS	sorted	R5	KD	cells	showed	
an	 expansion	 of	 central	 memory	 CD4+	 and	 CD8+	 T‐cells,	 while	 all	 other	 groups	 showed	 a	
progressive	loss	of	these	CD4+	memory	T‐cells	and	no	change	in	CD8+	T‐cells.	This	pattern	was	
also	 evident	 when	 looking	 at	 the	 splenocytes.	 These	 memory	 CD8+	 T‐cells	 might	 have	
contributed	 to	 the	 control	 of	HIV.	 There	was	 a	 decrease	 in	 the	 frequency	 of	 naive	 CD4+	 and	
83	
	
CD8+	T‐cells	in	the	peripheral	blood	in	both	FACS‐sorted	negative	and	FACS‐sorted	R5	KD	mice,	
whereas	in	the	spleen,	the	naive	CD4+	and	CD8+	T‐cells	in	the	FACS‐sorted	R5	KD	mice	tended	
to	be	higher	 (data	not	shown).	The	expansion	of	central	memory	T‐cells	 is	 reminiscent	of	 the	
immune	reconstitution	seen	in	HIV‐infected	patients	on	ART	139.	
HIV	is	known	for	its	high	mutational	rate.	In	this	respect,	we	observed	one	mouse	(#954)	with	
an	escape	mutation.	Despite	high	levels	(day	0)	of	engraftment	of	CCR5	knock‐down	cells,	this	
mouse	 had	 a	 high	 viral	 load	 and	 a	 complete	 loss	 of	 circulating	 CD4+	 T‐cells.	 Population	
sequencing	 of	 the	 V3	 loop	 indicated	 a	 likely	 shift	 to	 X4	 tropism	 which	 might	 explain	 the	
uncontrolled	infection.	The	mutations	were	detectable	in	the	blood	only	at	relatively	late	time	
points.	This	might	be	due	to	an	initial	compartmentalized	replication	of	the	X4‐tropic	strains	in	
the	thymus.	We	previously	showed	that	X4‐HIV	NL4‐3	severely	depleted	the	thymus,	whereas	
YU‐2	only	had	minor	effects	53.	However,	we	do	not	know	whether	the	potential	emergence	was	
due	 to	 the	 CCR5	 knock‐down	 or	 was	 just	 a	 coincidence.	 Indeed,	 emergence	 of	 CXCR4‐tropic	
strains	may	occur	without	any	immune	or	drug	pressure	in	hu	mice	infected	with	CCR5‐tropic	
strains	 140.	 In	any	case,	CCR5	knock‐down	should	be	done	 in	concert	with	another	strategy	 to	
constrain	HIV	(i.e.,	 including	another	anti‐HIV	moiety,	combining	with	efficient	antiretrovirals,	
or	 boosting	 the	 immune	 response	 in	 parallel	 to	 transplantation).	 Indeed,	 the	 solidness	 of	
successful	gene	engineering	by	the	expression	of	more	than	one	antiviral	moiety	may	prevent	
HIV	evolution	141.	Gene	engineering	could	be	combined	with	conventional	ART:	combining	two	
treatment	 modalities	 was	 efficient	 as	 induction	 therapy	 142	 or	 with	 anti‐PD1	 antibodies	 that	
decrease	viral	load	and	increase	the	level	of	CD4+	T‐cells	in	HIV‐infected	mice	143.	In	any	case,	
gene	engineering	efforts	 cannot	promote	more	virulent	HIV	strains,	neither	 for	 the	 individual	
patient	nor	for	the	general	population.		
In	 summary,	 our	 results	 provide	 the	 first	 preclinical	 proof	 of	 concept	 that	 transplantation	 of	
miRNA	CCR5	knock‐down	CD34+	cells	can	lead	to	long‐term	control	of	HIV	viremia.	Translation	
of	 our	 results	 to	 the	 clinical	 setting	 is	 relatively	 straightforward,	 but	 will	 require	 the	
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implementation	 of	 existing	 strategies	 for	 pre/post‐transplantation	 selection	 compatible	 with	
human	use.	At	this	point,	our	strategy	demonstrates	long‐term	viral	control,	but	not	yet	a	cure.	
However,	 while	 a	 cure	 remains	 the	 ultimate	 goal,	 long‐term	 viral	 control	 independent	 of	
antiretrovirals	 is	 a	 relevant	 intermediate	 step,	 worth	 translating	 to	 the	 clinical	 setting.	 We	
believe	 that	 a	 definitive	 cure	 of	 HIV	 might	 indeed	 come	 from	 a	 combination	 of	 different	
approaches	such	as	CCR5	knock‐down	combined	with	drug	therapy	or	vaccination	and	a	second	
gene	therapy	target.		
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MATERIALS	AND	METHODS	
Ethics	statement		
The	procurement	and	use	of	CD34+	cells	from	human	cord	blood	was	approved	by	the	Cantonal	
Ethical	Committee	of	Zurich	(EK‐1103).	All	adult	subjects	provided	written	 informed	consent.	
Animal	care	and	experimental	protocols	were	in	accordance	with	the	“Swiss	Ethical	Principles	
and	 Guidelines	 for	 Experiments	 on	 Animals,”	 and	 approved	 by	 the	 Veterinary	 office	 of	 the	
Canton	 of	 Zurich,	 permit	 26/2011.	 Manipulations	 of	 mice	 were	 in	 accordance	 with	 the	
regulations	 of	 the	 Veterinary	 office	 of	 the	 Canton	 of	 Zurich.	
(http://www.veta.zh.ch/internet/gesundheitsdirektion/veta/de/home.html).	
	
Lentiviral	vector	production	and	titration	
Lentiviral	vector	stocks	were	generated	using	transient	transfection	of	HEK	293T/17	cells	with	
the	self‐inactivating	vector,	pCLX‐R4‐DEST‐R2	encoding	the	microRNA	to	CCR5	129,	the	psPAX2	
plasmid	encoding	gag/pol,	and	the	pCAG‐VSVG	envelope	plasmid,	as	described	104.	Lentivector	
titration	was	performed	using	transduction	of	HT‐1080	cells,	followed	by	quantification	of	GFP‐
positive	(or	mCherry	positive)	cells	5	days	after	infection	by	flow	cytometry	as	described	104.		
	
Generation	of	humanized	mice		
NOD.scid.IL2R	 −/−	 (NSG)	mice	were	 bred	 and	maintained	 in	 individual	 ventilated	 cages	 and	
were	fed	autoclaved	food	and	water.	Mice	with	a	human	immune	system	(humanized	(hu)	mice)	
were	generated	as	described	118.	Briefly,	newborn	(<5	days	old)	NSG	mice	received	sub‐lethal	
(1Gy)	 total	 body	 irradiation	 with	 a	 Cs	 source,	 and	 then	 received	 2×	 105	 transduced	 or	
untransduced	 CD34+	 human	 HSPCs	 with	 a	 50μl	 Hamilton	 syringe	 via	 the	 intrahepatic	 (i.h.)	
route.	For	the	FACS‐sorted	R5	knock‐down	animals,	CD34+	cells	were	sorted	post‐transduction	
into	 green‐fluorescent	 protein	 (GFP)	 positive	 and	 ‐negative	 fractions,	 and	 then,	 2x105	 CD34+	
GFP‐positive	or	GFP‐negative	cells	were	injected	i.h.	 into	respective	cohorts.	All	manipulations	
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of	hu	mice	were	performed	under	laminar	flow.	Cell	suspensions	of	the	hu	mouse	organs	were	
prepared	in	RPMI1640	medium	supplemented	with	2%	fetal	calf	serum.		
	
HIV	virus	stock	and	infection	of	mice	
Viral	stocks	were	obtained	by	polyethylenimine	(PEI)‐mediated	 transfection	(Polysciences)	of	
293T	cells	with	either	pYU‐2	(R5	tropic)	or	JRCSF	(R5	tropic)	(provided	through	the	NIH	AIDS	
Research	and	Reference	Reagent	Program).	At	48	hours	after	transfection,	virus	was	harvested,	
filtered	(0.45	µm),	and	frozen	at	‐80°C	until	use.	Viral	titers	were	determined	as	described	105.	
Briefly,	TCID50	(tissue	culture	infectious	dose	50%)	was	determined	by	infecting	human	CD8+	
T‐cell‐depleted	 peripheral	 blood	 mononuclear	 cells	 (PBMCs)	 from	 three	 donors	 that	 were	
stimulated	by	adding	IL‐2,	phytohaemagglutinin	(PHA)	and	anti‐CD3	beads	(Dynal	11131D,	Life	
Technologies).	 Mice	 were	 infected	 intraperitoneally	 (i.p.)	 with	 either	 HIV	 YU‐2	 or	 JRCSF	 at	
2x105	 TCID50	 per	 mouse.	 HIV	 RNA	 plasma	 levels	 were	 measured	 by	 RT‐PCR	
(AmpliPrep/COBAS	TaqMan	HIV‐1	Test,	Roche)	at	various	times	after	infection.	
		
Flow	cytometry	
The	 cells	 in	 whole	 blood	 were	 counted	 in	 a	 Beckman	 Cell	 Counter.	 Cell	 suspensions	 were	
labelled	 with	 anti‐human	 monoclonal	 antibodies	 (mAb)	 targeting	 the	 following	 cell‐surface	
markers:	CD45‐PerCP,	CD3	ACP,	CD4‐Pe	Cy7,	CD8‐BVa,	CCR5‐PE,	CD34‐APC,	CD45RA‐APC,	and	
CCR7‐PE	(all	from	BD	Biosciences	or	Biolegend).	Washing	and	reagent	dilutions	were	done	with	
FACS	buffer	(PBS	containing	2%	fetal	calf	serum	and	0.05%	sodium	azide.	All	acquisitions	were	
performed	on	a	Cyan	ADP	(Beckman	Coulter)	flow	cytometer.	Data	were	analyzed	with	FlowJo	
software	 (Ashland,	OR).	Cellular	debris	and	dead	cells	were	excluded	by	 their	 light‐scattering	
characteristics.	Transduced	CD34+	cells	were	 sorted	according	 to	 intrinsic	GFP	expression	as	
measured	by	a	BD	FACSARIATM	III	cell	sorter.		
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HIV	challenge	ex	vivo		
Spleens	of	five	hu	mice	transplanted	with	HSPCs	gene	engineered	with	the	microRNA	to	CCR5	
were	dissociated	through	a	nylon	mesh,	and	red	blood	cells	were	 lysed	with	ACK	buffer	 for	3	
minutes	(LONZA).	Cells	were	sorted	(≥99%	pure)	with	an	ARIA	sorter	(BD	Bioscience)	into	GFP‐
positive	and	‐negative	cells,	and	were	subsequently	activated	for	24	hours	with	PHA	(4	mg/ml)	
in	 RPMI	 culture	 medium	 supplemented	 with	 IL‐2	 (100	 U/ml)	 and	 10%	 fetal	 calf	 serum.	
Thereafter	cells	were	infected	with	a	TCID	of	3.3	x105/ml	of	YU‐2	for	6	hours	and	washed	three	
times.	The	supernatant	of	the	last	wash	was	used	as	the	base	line	p24	antigen	level	measured	by	
an	in	house	ELISA	106.	Virus	spread	was	then	monitored	at	day	1,	4,	6,	8	and	10	post‐infection.		
	
Analysis	of	HIV	envelope	sequences	
Nucleic	Acid	Extraction:	For	viral	envelope	sequencing,	total	nucleic	acid	was	extracted	from	60	
µL	 of	 mouse	 plasma	 on	 an	 EasyMag	 extractor	 (BioMerieux,	 Switzerland)	 according	 to	 the	
manufacturer’s	instructions.	The	elution	volume	was	50	µL.		
Reverse	Transcription	and	PCR:	For	cDNA	synthesis,	9	µL	of	extracted	nucleic	acid	was	reverse‐
transcribed	in	a	total	reaction	volume	of	20	µL	at	42°C	for	30	min.	using	a	shorted,	sequence‐
specific	 primer	MSR5	 144	 and	 the	 PrimeScript	 One	 Step	 RT‐PCR	 kit	 (Takara	 Bio	 Europe/SAS,	
France).	 After	 heat	 inactivation	 at	 96°C	 for	 5	 min.	 amplification	 primers	 were	 added	 to	 the	
reaction	mixture,	and	DNA	corresponding	to	positions	5956	to	8535	in	isolate	HXB2	(Accession	
K03455,	M38432)	was	amplified	for	20	cycles.	Nested	PCR	in	a	total	reaction	volume	of	40	µL	
with	Phusion	Hot	Start	II	DNA	polymerase	(Thermo	Scientific,	Switzerland)	was	carried	out	to	
amplify,	respectively,	gp120	(positions	6817	to	7812)	and	gp41	(positions	7789	to	8382).	
DNA	 Sequencing:	Before	 sequencing,	 amplified	 DNA	was	 treated	 with	 Illustra	 ExoStar	 1‐step	
reagent	(Fisher	Scientific,	Switzerland).	For	cycle	sequencing,	the	BigDye	Terminator	v3.1	Cycle	
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Sequencing	 Kit	 (LifeTechnologies,	 Switzerland),	 and	 specific	 sequencing	 primers	 were	 used.	
Twenty‐five	 cycles	 of	 heat	 denaturation	 at	 96°C	 for	 10	 sec,	 annealing	 at	 50°C	 for	 5	 sec,	 and	
synthesis	 60°C	 for	 4	 min	 were	 carried	 out	 on	 a	 2720	 Thermal	 Cycler	 (Life	 Technologies,	
Switzerland).	 Samples	were	 further	 processed	 by	 ethanol	 precipitation,	 followed	 by	 capillary	
electrophoresis	on	a	3130xl	Genetic	Analyzer	(Applied	Biosystems,	Switzerland).	The	sequences	
were	assembled	and	edited	with	SeqMan	Pro	from	the	Lasergene	11	package	(DNAStar).	
	
Statistical	analyses		
The	statistical	analyses	were	performed	using	GraphPad	Prism	5.04	(GraphPad	Software).	Data	
were	subjected	to	either	unpaired	t‐tests	or	paired	t‐tests,	as	indicated	in	the	figure	legends.	The	
P	values	obtained	were	 considered	 significant	when	 *P	<	0.05.	The	 statistical	 outlier	 analysis	
was	 performed	 using	 the	 GraphPad	 Outlier	 calculator	 with	 an	 alpha	 of	 0.01	
(http://graphpad.com/quickcalcs/Grubbs1.cfm).	
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SUPPLEMENTARY	MATERIAL	
	
	
	
	
Supplementary	 Figure	 1.	 Schematic	 representation	 of	 the	 two	 self‐inactivating	 (SIN)	 lentivector	
constructs	used	 in	 this	 study.	 (a)	GFP‐CCR5	knock‐down	 lentivector	 in	which	 the	human	UBI	promoter	
drives	 expression	 of	 GFP,	 followed	 by	 a	 triple	 CCR5‐targeting	miRNA	 cassette.	 (b)	 Control	 lentivector,	
human	UBI	promoter	driving	expression	of	GFP.	
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Supplementary	Figure	2.	CCR5	expression	was	not	detected	on	GFP‐positive	CD4+	T‐cells	in	blood	of	R5	
knock‐down	mice.	FACS	plots	showing	the	percentage	human	engraftment	as	quantified	by	the	percentage	
of	 CD45+cells,	 as	 well	 as	 percentages	 of	 CD4+	 T‐cells	 and	 CCR5‐positive	 CD4+	 T‐cells	 in	 a	 non‐infected	
untransduced	 mouse	 (a),	 control	 (b)	 and	 R5	 knock‐down	 mouse	 (c).	 MFI	 of	 CCR5	 on	 CD4+	 T‐cells	 is	
indicated.	
	 	
91	
	
	
	
Supplementary	Figure	3.	Obtaining	pure	populations	of	GFP‐positive	CD34+	progenitors	transduced	with	
the	CCR5	knock‐down	lentivector.	(a)	The	untransduced	fraction	after	3	days	of	culture.	(b)	Cells	from	the	
same	donor	 as	 in	 (a)	 3	 days	post‐transduction.	 The	gating	 for	 sorting	 of	 the	GFP‐negative	 and	positive	
populations	is	show	in	(b);	we	sorted	only	for	the	GFP	high	population	(9%	of	the	total	live	population	in	
green)	 to	 ensure	 high	 purity	 and	 high	 transduction.	 (c)	 GFP‐negative	 fraction	 post‐sorting	 of	 the	 cells	
sorted	 in	(b).	 (d)	The	GFP‐positive	 fraction	post‐sorting	of	the	cells	 in	(b).	The	cells	 in	the	GFP‐negative	
fraction	showed	a	very	high	purity	of	99%;	the	cells	in	the	GFP‐positive	fraction	were	also	very	pure	with	
94%	of	purity.			
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Supplementary	Figure	4.	Grouped	viral	loads	of	various	cohorts.	(a)	control‐transduced	n=12	(YU‐2),	R5	
knock‐down	 group	 1	 n=6	 (YU‐2)	 and	 group	 2	 n=5	 (YU‐2),	 untransduced	 n=11	 (YU‐2)	 and	 FACS‐sorted	
negative	n=15	(YU‐2	n=9	and	JRCSF	n=6).	(b)	The	viral	loads	of	the	control‐transduced,	untransduced	and	
FACS‐sorted	negative	mice	combined	to	 form	the	combined	control	group	as	well	as	 the	 two	R5	knock‐
down	cohorts	 compared	 to	 the	FACS‐sorted	R5	knock‐down	mice	n=5	 (YU‐2).	Mean	±	 sem.;	 *P	 =	0.019	
(day	134).	P	values	determined	by	two‐tailed	unpaired	t‐test.	
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Supplementary	Figure	5.	CCR5	 knock‐down	 on	 CD4+	 T‐cells	 in	 peripheral	 blood	 and	 spleen	 of	 FACS‐
sorted	R5	knock‐down	mice.	FACS	plots	of	peripheral	blood	and	spleen	showing,	percentage	engraftment	
(CD45+)	and	CD4+	T‐cells,	CD8+,	CCR5‐positive	CD4+	T‐cells	of	a	FACS‐sorted	negative	mouse	(a,	b)	and	of	a	
FACS‐sorted	R5	knock‐down	mouse	(c,	d).	
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Supplementary	Figure	6.	Analysis	of	cell	subsets	in	the	spleen	of	FACS‐sorted	R5	knock‐down	mice.	(a)	
Mouse	#959	maintained	over	90%	GFP‐positive	CD4+	T‐cells	in	the	spleen	resulting	in	long	term	control	of	
viremia.	(b)	Mouse	#954	had	very	low	frequency	of	gene	engineered	CD4+	T‐cells	in	the	spleen.	CD3+	T‐
cells	are	of	total	human	CD45+	cells.	
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Supplementary	Figure	7.	Detailed	analysis	of	various	FACS‐sorted	R5	knock‐down	mice.	(a)	#958(YU‐2),	
(b)	#1115(JRCSF)	and	(c)	#1608(JRCSF).	FACS	plots	show	percentage	CD45+	(spleen	only),	CD4+	T‐cells,	
CD8+	T‐cells	and	GFP‐positive	CD4+	T‐cells	(blood	and	spleen).	
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VARIA	
	
In	 parallel	 I	 have	 published,	 contributed	 to	 and	 in	 certain	 cases	 initiated	 various	 other	
publications,	reviews	or	projects:	
	
i)	Original	article	(In	review)	
	
Discovery	and	characterization	of	an	endogenous	CXCR4	antagonist	
The	author	list	contains	over	40	authors,	the	affiliations	is	one	page,	this	is	not	indicated	
here.*	
This	 original	 article	 is	 in	 review.	 I	 am	 a	 contributing	 author	 and	 conducted	 various	 in	 vivo	
humanized	mouse	experiments	which	 involved	 the	oral	 inoculation	of	HIV	viruses	 to	address	
certain	of	the	reviewers’	comments.	
	
Abstract		
Endogenous	 factors	 controlling	 HIV‐1	 replication	 and	 transmission	 1	 are	 poorly	 defined.	 To	
discover	such	factors,	we	screened	a	blood‐derived	peptide	library	and	identified	a	16‐residue	
fragment	(ALB408‐423)	of	human	serum	albumin	(HSA)	as	a	specific	inhibitor	of	CXCR4	(X4)‐
tropic	HIV‐1	strains.	We	found	that	ALB408‐423	is	an	endogenous	antagonist	of	X4	that	inhibits	
cancer	 cell	 migration,	 mobilizes	 hematopoietic	 stem	 cells	 and	 suppresses	 inflammatory	
responses	 in	 mice.	 ALB408‐423	 is	 highly	 conserved	 in	 mammals	 and	 generated	 by	 limited	
proteolysis	 of	 HSA	 by	 pepsin	 and	 cathepsins	 D	 and	 E.	 ALB408‐423	 is	 present	 in	 acidified	
plasma,	breast	milk,	gastric	fluid	of	newborns,	vaginal	secretions,	as	well	as	in	oral,	vaginal	and	
rectal	 tissues	 suggesting	 that	 it	 may	 represent	 the	 long‐sought	 gatekeeper	 of	 X4	 HIV‐1	
transmission.	 Our	 study	 identified	 an	 endogenous	 X4	 antagonist	 and	 demonstrates	 that	
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proteolytic	 cleavage	 of	 the	 highly	 abundant	 HSA	 precursor	 generates	 an	 effective	 HIV‐1	
inhibitor	and	anti‐inflammatory	agent.	
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ii)	Original	article	(In	review)	
	
T	Cell	Engaging	Bispecific	Antibody	Constructs	Targeting	HIV‐1	Env‐
expressing	Cells	Show	Significant	Antiviral	Efficacy	
Johannes	Brozy*,	Erika	Schlaepfer‡,	Mary‐Aude	Rochat‡,	Renier	Myburgh‡,	Tobias	Raum*,	Peter	
Kufer*,	Patrick	A.	Baeuerle*,	Markus	Muenz*,	#,	Roberto	F.	Speck‡,	#	
#	M.M.	and	RF.S.	contributed	equally	to	this	work	
*	Amgen	Research	Munich	GmbH,	Staffelseestr.	2‐4,	81477	Munich,	Germany,	‡	Division	
of	 Infectious	Diseases	and	Hospital	Epidemiology,	University	Hospital	of	Zurich,	Zurich,	
Switzerland	
	
This	 original	 article	 has	 been	 submitted,	 I	 am	 a	 contributing	 author.	My	 contribution	was	 to	
assist	and	conduct	some	of	 the	 in	vivo	humanized	mouse	experiments	that	were	conducted	at	
the	University	of	Zurich.	
	
Abstract	
Today’s	gold	standard	in	HIV	therapy	is	the	combined	antiretroviral	therapy	(cART).	It	requires	
strict	 adherence	 by	 patients	 and	 life‐long	 medication,	 which	 can	 lower	 the	 viral	 load	 below	
detection	 limits	and	prevent	 the	onset	of	AIDS,	but	 cannot	 cure	patients.	The	bispecific	T	 cell	
engaging	 (BiTE®)	 antibody	 technology	 has	 demonstrated	 long‐term	 relapse‐free	 outcomes	 in	
clinical	 studies	 with	 relapsed	 and	 refractory	 acute	 lymphocytic	 leukemia	 patients.	 We	 here	
explored	 this	 technology	 for	 the	 treatment	of	 infectious	diseases	as	a	potential	means	 to	cure	
patients	by	redirecting	T	cells	 to	effectively	 lyse	virus‐infected	cells.	BiTE	antibody	constructs	
were	 generated	 that	 target	 the	 HIV‐1	 envelope	 protein	 (env)	 by	 using	 variable	 domains	 of	
antibodies	B12	and	VRC01	or	by	 the	 first	 two	extracellular	domains	 (1+2)	 of	 human	CD4.	All	
BiTE	antibody	constructs	showed	single‐digit	nM	affinities	for	HIV	env	and	human	CD3e	as	well	
as	 engagement	 of	 unstimulated	 and	 pre‐stimulated	 T	 cells	 for	 in	 vitro	 lysis	 of	 HIV	 env‐
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transfected	 CHO	 cells	 at	 pM	 concentrations.	 Furthermore,	 anti‐HIV‐1	 env	 BiTE	 antibody	
constructs	 completely	 inhibited	 HIV‐1	 replication	 in	 cultured	 PBMC	 and	 monocyte‐derived	
macrophages	in	the	presence	of	autologous	CD8+	T	cells	at	nM	concentrations.	Antiviral	activity	
was	 also	 observed	 in	 NSG	 mice	 engrafted	 with	 HIV+	 human	 PBMC	 by	 virtue	 of	 significantly	
lowering	HIV	RNA	copies	 in	blood.	HIV	env‐specific	BiTE	antibody	constructs	warrant	 further	
development	as	novel	antiviral	therapy	with	curative	potential.		
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iii)	Original	article	(In	preparation)			
	
Studying	HIV‐triggered	EBV‐associated	lymphoproliferative	diseases	
in	a	humanized	mouse	model	
Donal	McHugh*	 a,	Renier	Myburgh*	 b,	Nicola	Caduff	 a,	 Bithi	Chatterjee	 a,	 Roberto	F.	 Speck	 +b,	
Christian	Münz	+a	
*These	authors	contributed	equally,	co‐first	authors	
+These	authors	are	co‐senior	author	
	
This	 is	 a	 project	 that	 I	 initiated	 with	 my	 good	 friend	 Donal	 McHugh	 at	 the	 Institute	 of	
Experimental	 Immunology,	Viral	 Immunobiology	 also	at	 the	University	of	Zurich.	We	decided	
combine	our	expertise	and	go	for	this	dual	infection	(HIV/EBV)	model	in	humanized	mice.	
	
Abstract	
The	ubiquitous	gamma	herpes	virus	Epstein‐Barr	Virus	(EBV)	latently	infects	the	vast	majority	
of	 the	 human	 adult	 population.	 Despite	 EBV’s	 strong	 B	 cell	 transforming	 capacity,	 only	 few	
infected	individuals	develop	EBV‐associated	lymphomas,	because	of	continuous	restriction	by	T	
cell	mediated	 immune	 responses.	 In	HIV	 infected	 individuals,	 the	drastic	 loss	of	 CD4+	 T	 cells	
can	 therefore	 lead	 to	 EBV‐associated	Non‐Hodgkin	 lymphomas	 (NHL).	 It	 has	been	 suggested	
that	 the	 HIV	 induced	 loss	 of	 EBV	 specific	 CD4+	 T	 cells	 results	 in	 an	 exhausted	 CD8+	 T	 cell	
population	 that	 can	 no	 longer	 control	 EBV	 mediated	 lymphoproliferation	 resulting	 in	 a	
progression	 toward	 NHLs,	 a	 hypothesis	 not	 yet	 tested	 experimentally.	 Furthermore	 EBV	 is	
highly	 associated	 with	 the	 development	 of	 central	 nervous	 system	 lymphoma	 (CNSL)	 in	
patients	with	AIDS,	a	NHL	in	the	brain	rarely	encountered	outside	the	context	of	HIV	infection.	
To	 investigate	aspects	of	 pathogenesis	 and	mechanisms	of	 immune	 control	 in	 a	 small	animal	
model,	 mice	 with	 human	 immune	 system	 components	 have	 been	 successfully	 used	to	 study	
HIV	and	EBV	infection	in	isolation.	Recent	advances	in	sophisticated	humanized	mouse	models	
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have	enabled	 researchers	to	 closely	mimic	 the	biology	 of	 viruses	 such	 as	 EBV	or	HIV	 in	vivo.	
EBV	and	HIV	co‐infection	is	usually	found	 in	patients	since	the	vast	majority	of	healthy	adults	
are	 already	 latently	 infected	with	 EBV	 prior	 to	 HIV	 infection.	 For	 this	 reason	we	propose	 to	
establish	a	 stable	 in	 vivo	model	 of	 dual	 infection	 for	HIV‐1	 and	 EBV.	With	 this	model	we	aim	
to	determine	whether	loss	of	EBV	immune	control	via	HIV	mediated	immune	suppression	 leads	
to	 the	 enhanced	 emergence	of	 lymphomatous	 tumors.	 Furthermore	we	intend	to	characterize	
the	 resulting	 EBV	 lymphoproliferative	disease	with	 regard	 to	 clonality,	 viral	 gene	 expression	
and	spread	to	different	anatomical	sites	 including	the	CNS.	 Finally,	we	aim	to	characterize	the	
mechanism	 by	 which	 HIV	 abrogates	 EBV	 immune	 control.	 The	 study	 of	 EBV	 and	 HIV	 co‐
infection	 in	 humanized	 mice	 is	 a	 novel	 concept,	 which	 will	 pool	 the	 expertise	 of	 two	
laboratories	 already	 independently	 experienced	 in	 EBV	 and	HIV	infection	in	humanized	mice	
(Münz	and	Speck,	respectively).	 It	will	be	 invaluable	 to	 investigate	an	 in	 vivo	model	 in	which	
HIV	 may	 compromise	 EBV	 specific	 immune	 control	 resulting	 in	 EBV	 associated	
lymphoproliferative	disease.	 Establishment	 of	 such	 a	 model	 with	 the	 capacity	 to	 recapitulate	
what	 is	 seen	 in	 HIV	 infected	 patients	 may	 pave	 the	 way	 for	 novel	 treatments	 against	 EBV	
associated	malignancies	in	HIV	infected	individuals.	
Preliminary	results	
	
Co‐infection	of	huNSG	mice	results	in	rapid	weight‐loss,	increased	EBV	viral	loads	as	well	
as	 increased	 frequency	of	 tumors.	 In	 a	 first	 pilot	 study,	 24	 huNSG	mice	were	 generated	 by	
postnatal	 irradiation	 and	 injection	 of	 CD34+	 hematopoietic	 progenitor	 cells	 derived	 from	 one	
human	 fetal	 liver	 donor.	 The	 animals	 were	 checked	 4	 months	 later	 for	 human	 leukocyte	
engraftment	in	the	peripheral	blood	by	flow	cytometry	and	split	into	four	experimental	groups	
each	with	a	similar	mean	frequency	of	lymphocyte	subtypes:	double	mock	(n=6);	HIV	(n=5);	EBV	
(n=	 7);	 EBV/HIV	 (n=6),	 animals	 were	 infected	 and	 blood/organs	 collected	 according	 to	 the	
timeline	 (Fig.	 1a).	 We	 observed	 a	 dramatic	 decline	 in	 general	 condition	 of	 some	mice	 in	 the	
EBV/HIV	infected	group	from	day	21‐29	post	infection.	The	sudden	and	significant	weight	loss	
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was	 striking	 in	 the	 co‐infected	mice	 and	 necessitated	 termination	 of	 the	 experiment	 4	weeks	
post	EBV	infection	(Fig.	1b).	This	weight	loss	was	unexpected	at	this	early	time	point	considering	
the	relatively	low	dose	of	EBV	(10e4	RGU).	Upon	sacrifice	of	the	animals,	macroscopically	visible	
tumors	(spleen,	liver	and	gut)	were	more	numerous	in	EBV/HIV	group	(Fig.	1c)	and	mice	with	
tumors	in	the	EBV/HIV	group	often	presented	with	tumors	in	multiple	organs.	The	weight	loss	
and	increased	tumor	frequency	was	accompanied	by	increased	EBV	DNA	load	detectable	in	the	
blood	of	the	EBV/HIV	cohort	at	days	21	and	29	post	infection	in	some	animals	(Fig.	1	d‐e).		
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EBV/HIV	infection	leads	to	a	loss	of	CD4+	T	cells,	expansion	of	CD8+	T	cells	and	results	in	a	
reduced	EBV	specific	IFN‐gamma	response	as	compared	to	EBV	single	infected	mice.	One	
week	before	EBV	 infection	 total	 peripheral	 blood	human	 cells,	 T	 cells,	 CD4+	 and	CD8+	T	 cells	
were	quantified	 to	 ensure	 the	 groups	were	 as	homogenous	 as	possible	 and	 indeed	only	 little	
variation	of	the	different	cell	types	for	the	different	groups	was	observed	(Fig.	2a).	All	mice	had	
a	normal	CD4+/CD8+	ratio,	i.e.	more	CD4+	compared	to	CD8+	T	cells	at	this	time	point	(Fig.	2a).		
At	termination,	the	HIV‐mono	as	well	as	the	HIV/EBV	coinfected	mice	had	a	significant	CD4+	T	
cell	loss	in	the	peripheral	blood	(Fig.	2b).	Upon	EBV	infection	irrespective	of	HIV,	we	observed	a	
marked	 expansion	 of	 CD8+	 T	 cells.	 Thus,	 HIV‐	 and	 EBV‐mono‐infected	 mice	 as	 well	 as	 the	
HIV/EBV‐co‐infected	mice	 are	 characterized	 by	 an	 unique	 pattern	 of	 CD4+	 T	 cell	 loss	 and/or	
CD8	T‐cell	expansion.	These	data	from	the	blood	were	mirrored	by	cellular	composition	of	the	
spleen	(Fig.	2c).		
In	parallel	 to	 the	 in	vivo	 infection	 experiment,	 autologous	B	 cells	 from	 the	donor	 tissue	were	
transformed	with	EBV	ex	vivo.	The	resulting	LCLs	were	co‐cultured	with	B	cell	depleted	(CD19	
MACS	 depleted)	 spleen	 cells	 from	 each	 mouse	 from	 different	 experimental	 groups	 and	 the	
amount	of	IFN‐gamma	producing	cells	was	measured	by	ELISPOT	assay.	We	observed	that	mice	
infected	with	 EBV	 had	 T	 cells	 that	 released	 IFN‐gamma	 specifically	 in	 response	 to	 the	 LCLs.	
Most	 importantly,	we	 could	 show	 that	 the	 splenic	 T	 cells	 derived	 from	mice	 in	 the	 EBV/HIV	
infected	 group	 had	 a	 significantly	 reduced	 IFN‐gamma	 response	 to	 the	 autologous	 LCLs	
compared	to	those	from	EBV	single	infected	mice	(Fig.	2d).	The	overall	IFN‐gamma	response	in	
response	to	the	unspecific	stimulus	PMA/Ionomycin	seemed	to	be	slightly	lower	in	HIV	or	HIV	/	
EBV	infected	animals	(Fig.	2e).	We	believe	that	the	loss	of	the	EBV	specific	IFN‐gamma	response	
in	the	EBV/HIV	infected	mice	could	be	due	to	CD8+	T	cell	exhaustion	due	to	the	presence	and	
replication	of	both	viruses.	T	cell	exhaustion	markers	were	analyzed	in	spleen	and	blood	(data	
not	shown)	and	there	seemed	to	be	an	increased	surface	expression	of	these	markers	on	CD8+	T	
cells	in	the	dual	infected	group.	This	could	explain	why	there	was	an	increased	EBV	viral	load	in	
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the	EBV/HIV	mice	despite	 infection	with	a	 low	EBV	dose	as	well	as	an	early	onset	of	terminal	
weight	loss	and	increased	frequency	of	spleen	and	liver	tumors.		
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Significance		
Mice	with	reconstituted	human	immune	system	components	offer	the	first	small	animal	models	
to	 study	 pathogens	 with	 an	 exclusively	 human	 tropism,	 as	 long	 as	 they	 infect	 cells	 of	 the	
human	 hematopoietic	 lineage.	 The	 interplay	 between	 EBV	 and	 HIV,	 which	 causes	 tumors	 in	
AIDS	patients,	can	now	been	studied	 in	 these	novel	 in	vivo	models.	The	 proposed	 project	will	
now	address	how	HIV	infection	changes	EBV	infection,	which	EBV	associated	tumors	form	upon	
HIV	 co‐infection,	 and	 how	 HIV	 infection	 compromises	 EBV	 specific	 immune	 control.	 These	
studies	will	not	only	characterize	the	interplay	between	these	two	important	human	pathogens	
in	 vivo,	 but	 also	 establish	 a	 model,	 which	 can	 be	 explored	 to	 test	 treatments	against	EBV	
associated	malignancies	in	HIV	infected	individuals.	
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iv)	Review	article	(In	preparation)	
	
Clinical	applications	of	genetically	modified	hematopoietic	stem	cells	
Carlo	 Jackson,a	 Renier	 Myburgh	 b,	 Karl‐Heinz	 Krause	 c,	 Roberto	 F.	 Speck	 b	 and	 Michael	 S.	
Peppera	
aDepartment	of	Immunology	and	Institute	for	Cellular	and	Molecular	Medicine,	Faculty	of	
Health	Sciences,	University	of	Pretoria,	South	Africa;	bDivision	of	Infectious	Diseases	and	
Hospital	Epidemiology,	University	Hospital	of	Zurich,	University	of	Zurich,	Switzerland,	
University	of	Geneva	Hospitals,	Geneva,	Switzerland;	c(Karl‐Heinz).	
This	is	an	on	topic	review	which	I	have	contributed	to	as	the	second	author.	This	manuscript	is	
in	preparation	and	planned	to	be	submitted	before	the	end	of	2014			
	
	
Abstract	
Autologous	and	allogeneic	hematopoietic	stem	cell	(HSC)	transplantations	have	been	performed	
globally	 in	patients	with	 various	haematological	 and	other	disorders	 for	more	 than	50	years.	
Genetic	 manipulation	 of	 HSCs	 prior	 to	 transplantation	 has	 been	 envisaged	 for	 genetic	 and	
infectious	 diseases	 to	 overcome	 limitations	 associated	 with	 naive	 HSCs.	 However,	 many	
obstacles	need	to	be	overcome	before	HSC‐mediated	gene	therapy	can	be	considered	for	routine	
therapy.	 A	 major	 concern	 is	 that	 the	 integration	 of	 the	 genetic	 elements	 might	 cause	
endogenous	gene	activation	or	deactivation	that	in	turn	lead	to	aberrant	cell	proliferation	and	
tumour	 formation.	 Many	 improvements	 have	 been	 made	 in	 vector	 construction	 aimed	 at	
overcoming	this	problem,	but	the	optimization	of	other	facets	of	the	gene	therapy	process	could	
further	increase	the	safety	of	the	treatment.	The	transduction	efficiency	of	HSCs	is	much	lower	
109	
	
than	 most	 cell	 types	 and	 is	 an	 obstacle	 to	 obtaining	 adequate	 numbers	 of	 transduced	 cells	
capable	of	engrafting	in	adult	patients.	Furthermore,	HSCs	generally	differentiate	in	culture	and	
lose	their	ability	to	engraft,	and	thus	it	is	not	a	trivial	task	to	obtain	transduced	HSCs	that	have	
not	lost	their	ability	to	provide	long	term	engraftment.	We	provide	an	overview	of	several	facets	
involved	in	HSC	gene	therapy	including	the	success	stories	and	limitations	of	clinical	trials	and	
the	latest	techniques	that	can	be	used	to	improve	the	process.	
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v)	Review	article	(Published:	Progress	in	Neurobiology.	2011.	Vol.	93.	
Pg.293‐311)	
	
The	chemokine	receptor	CCR5	in	the	central	nervous	system	
Silvia	Sorce	a,	Renier	Myburgh	a,b,	Karl‐Heinz	Krause	a,c,*	
a	Department	of	Pathology	and	 Immunology,	Faculty	of	Medicine,	University	of	Geneva,	
Rue	Michel‐Servet	1,	1211	Geneva‐4,	Switzerland,	b	Department	of	Immunology,	Faculty	
of	Health	Sciences,	University	of	Pretoria,	Prinshof	Campus,	0002	Pretoria,	South	Africa,	c	
Department	 of	 Genetic	 and	 Laboratory	 Medicine,	 Geneva	 University	 Hospitals,	
Switzerland	
This	is	a	review	which	I	was	a	contributing	author.	Various	chapters	were	my	responsibility.	
Abstract		
The	expression	and	the	role	of	the	chemokine	receptor	CCR5	have	been	mainly	studied	in	the	
context	of	HIV	 infection.	However,	 this	protein	 is	also	expressed	 in	 the	brain,	where	 it	 can	be	
crucial	 in	 determining	 the	 outcome	 in	 response	 to	 different	 insults.	 CCR5	 expression	 can	 be	
deleterious	or	protective	in	controlling	the	progression	of	certain	infections	in	the	CNS,	but	it	is	
also	emerging	that	it	could	play	a	role	in	non‐infectious	diseases.	In	particular,	it	appears	that,	in	
addition	 to	 modulating	 immune	 responses,	 CCR5	 can	 influence	 neuronal	 survival.	 Here,	 we	
summarize	 the	 present	 knowledge	 about	 the	 expression	 of	 CCR5	 in	 the	 brain	 and	 highlight	
recent	findings	suggesting	its	possible	involvement	in	neuroprotective	mechanisms.	
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vi)	Review	article	(Published:	Pharmacology	&	Therapeutics.	2012.	Vol.	133.	
Pg.	280‐290.)		
	
Cardiovascular	Pharmacogenetics	
Renier	Myburgh	a,	Warren	E.	Hochfeld	b,	Tyren	M.	Dodgen	c,	James	Ker	d,	Michael	S.	Pepper	a,e, 	
a	Department	of	 Immunology,	 Faculty	 of	Health	 Sciences,	University	of	Pretoria,	 South	
Africa,	 b	 Department	 of	 Medical	 Genetics,	 School	 of	 Clinical	 Medicine,	 Cambridge	
University,	United	Kingdom,	 c	Department	 of	Pharmacology,	 Faculty	of	Health	 Science,	
University	 of	 Pretoria,	 South	 Africa,	 d	 Department	 of	 Internal	 Medicine,	 Steve	 Biko	
Academic	Hospital	and	Faculty	of	Health	Sciences,	University	of	Pretoria,	South	Africa,	e	
Department	 of	 Genetic	Medicine	 and	 Development,	 Faculty	 of	Medicine,	 University	 of	
Geneva,	Switzerland	
Since	 my	 PhD	 project	 is	 an	 ongoing	 collaboration	 between	 three	 Universities	 (University	 of	
Zurich,	Geneva	and	Pretoria	 in	South	Africa)	 I	had	spent	 time	at	all	 three	 institutions.	Certain	
institutions	encourage	 the	writing	of	 review	articles	 for	 the	 thesis	 that	are	on	different	 topics	
than	that	of	the	main	research	focus.	For	this	reason	I	published	this	“off	topic”	review	as	first	
author	during	my	time	in	South	Africa	and	Geneva.				
Abstract	
Human	 genetic	 variation	 in	 the	 form	 of	 single	 nucleotide	 polymorphisms	 as	 well	 as	 more	
complex	 structural	 variations	 such	 as	 insertions,	 deletions	 and	 copy	 number	 variants,	 is	
partially	responsible	for	the	clinical	variation	seen	in	response	to	pharmacotherapeutic	drugs.	
This	 affects	 the	 likelihood	 of	 experiencing	 adverse	 drug	 reactions	 and	 also	 of	 achieving	
therapeutic	 success.	 In	 this	paper,	we	 review	key	 studies	 in	 cardiovascular	pharmacogenetics	
that	 reveal	 genetic	 variations	 underlying	 the	 outcomes	 of	 drug	 treatment	 in	 cardiovascular	
disease.	 Examples	 of	 genetic	 associations	 with	 drug	 efficacy	 and	 toxicity	 are	 described,	
including	the	roles	of	genetic	variability	in	pharmacokinetics	(e.g.	drug	metabolizing	enzymes)	
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and	 pharmacodynamics	 (e.g.	 drug	 targets).	 These	 findings	 have	 functional	 implications	 that	
could	lead	to	the	development	of	genetic	tests	aimed	at	minimizing	drug	toxicity	and	optimizing	
drug	efficacy	in	cardiovascular	medicine.	
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vii)	Review	article	(Published:	European	Journal	of	Cell	Biology.	2013.	Vol.	
92.	Pg.	229‐236)	
	
Adipocyte	and	adipogenesis	
Aus	Tariq	Ali	a,∗,	Warren	E.	Hochfeld	b,	Renier	Myburgh	c,	Michael	S.	Pepper	c,d	
a	 Department	 of	 Chemical	 Pathology,	 Tygerberg	 Hospital,	 Cape	 Town,	 South	 Africa,	 b	
Department	 of	 Medical	 Genetics,	 School	 of	 Clinical	 Medicine,	 Cambridge	 University,	
United	Kingdom,	 c	Department	of	 Immunology,	Faculty	of	Health	Sciences,	University	of	
Pretoria,	 South	Africa,	 d	Department	 of	Genetic	Medicine	 and	Development,	 Faculty	 of	
Medicine,	University	of	Geneva,	Switzerland	
Since	 my	 PhD	 project	 is	 an	 ongoing	 collaboration	 between	 three	 Universities	 (University	 of	
Zurich,	Geneva	and	Pretoria	 in	South	Africa)	 I	had	spent	 time	at	all	 three	 institutions.	Certain	
institutions	encourage	 the	writing	of	 review	articles	 for	 the	 thesis	 that	are	on	different	 topics	
than	that	of	the	main	research	focus.	For	this	reason	I	published	this	“off	topic”	review	as	first	
author	during	my	time	in	South	Africa	and	Geneva.				
Abstract	
Adipocytes	are	the	main	constituent	of	adipose	tissue	and	are	considered	to	be	a	corner	stone	in	
thehomeostatic	control	of	whole	body	metabolism.	Their	primary	function	is	to	control	energy	
balance	 bystoring	 triacylglycerol	 in	 periods	 of	 energy	 excess	 and	mobilizing	 it	 during	 energy	
deprivation.	Besides	theclassical	function	of	storing	fat,	adipocytes	secrete	numerous	lipid	and	
protein	factors.	Collectively	theyare	considered	constituting	a	major	endocrine	organ	which	has	
a	 profound	 impact	 on	 the	 metabolismof	 other	 tissues,	 the	 regulation	 of	 appetite,	 insulin	
sensitivity,	 immunological	 responses	 and	 vasculardisease.Adipogenesis	 is	 the	 process	 during	
which	 fibroblast	 like	preadipocytes	developed	 into	matureadipocytes.	Adipogenesis	 is	 a	well‐
orchestrated	 multistep	 process	 that	 requires	 the	 sequential	 activationof	 numerous	
transcription	 factors,	 including	 the	CCAAT/enhancer‐binding	protein	 (C/EBP)	 gene	 familyand	
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peroxisome	 proliferator	 activated	 receptor (PPAR).	 In	 order	 to	 reach	 maturity,	 these	 cells	
mustgo	 through	 two	 vital	 steps:	 adipocyte	 determination	 and	 adipocyte	 differentiation.	
Although	 many	 of	 themolecular	 details	 of	 adipogenesis	 are	 still	 unknown,	 several	 factors	
involved	 in	 this	 processes	 have	 beenidentified.	 Some	 stimulators	 include	 peroxisome	
proliferator‐activated	 receptor (PPAR),	 insulin‐likegrowth	 factor	 I	 (IGF‐l),	macrophage	colony	
stimulating	 factor,	 fatty	 acids,	 prostaglandins	 and	 glucocor‐ticoids.	 Inhibitors	 include	
glycoproteins,	transforming	growth	factor	(TGF),	inflammatory	cytokinesand	growth	hormone.	
Beside	these	factors,	there	are	others	for	example	age,	gender	and	life	style	thatmay	affect	this	
process	 in	one	way	or	another.	An	increase	in	the	number	and	size	of	adipocytes	causeswhite	
adipose	 tissue	 (WAT)	 to	 expand	 and	 this	 can	 lead	 to	 obesity.	 Adipogenesis	 can	 lead	 to	
centralobesity	 if	 it	 occurs	 in	 the	 abdominal	 fat	 depot	 and	 peripheral	 obesity	 if	 it	 occurs	 in	
subcutaneous	tissue.	
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viii)	Project	underway	
	
Development	of	an	in	vitro	and/or	in	vivo	selection	strategy	for	
positive	and	negative	selection	of	transduced	CD34+	progenitor	cells	
	
Working	Hypothesis	
We	hypothesize	that	gene	engineering	of	hematopoietic	progenitor	cells	(HPC)	can	give	rise	to	
an	HIV	resistant	 immune	system,	this	approach	applied	through	autologous	manipulation	and	
transplantation	of	HPCs	represents	a	promising	approach	 for	a	cure	of	HIV.	Gene	engineering	
will	 be	 achieved	 using	 lentiviral	 based	 self‐inactivating	 (SIN)	 vectors	 targeting	 the	 HIV	 co‐
receptor	 CCR5	 and	 eventually	 other	 viral	 targets.	 In	 addition,	 we	 hypothesize	 that	 positive	
selection	of	gene	engineered	CD34+	cells	 is	mandatory	since	 the	majority	of	progeny	cells	are	
required	to	be	resistant	to	HIV;	if	not	the	unmodified	HIV	target	cells	will	permit	establishment	
of	latent	reservoirs	and	ongoing	viral	replication	resulting	in	progressive	immunodeficiency	and	
potential	horizontal	or	vertical	HIV	transmission.	
Tumor	 cells	 are	known	 to	get	 resistant	 to	 chemotherapeutic	drugs,	which	 is	not	 the	 case	 for,	
however	 “normal”	 cells.	Therefore,	 the	expression	of	genes	 in	normal	bone	marrow	cells	 that	
increase	 their	 tolerance	 to	 drugs	 would	 allow	 for	 efficient	 negative	 selection	 of	 the		
untransduced	cells	145.		
	
Specific	Aims	
	
1.	To	study	strategies	for	in	vitro/vivo	selection	of	gene	engineered	CD34+	cells	
1.1	 To	 investigate	 the	 potential	 to	 assert	 positive	 and	 negative	 selection	 pressures	 by	
expression	of	the	human	reduced	folate	carrier	(hRFC),	and	(RRM2)	gene	in	CD34+	cells.	When	
cells	 are	 exposed	 to	 either	 Trimetrexate	 and/or	 Hydroxyurea	 as	 well	 as	 Methotrexate	 a	
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different	selective	pressure	can	be	affected.		Please	see	section	viii),	the	development	of	this	vector	
is	currently	under	submission	for	patenting.	
1.2	To	develop	a	selection	system	based	on	the	dihydrofolate	reductase	gene	(DHFR),	where	a	
mutant	version	of	this	gene	(DHFRfs)	provides	cells	over	expressing	this	gene	with	resistance	to	
Methotrexate	and	thus	allow	for	positive	selection	of	transduced	cells	137.		
Introduction	and	relevance	
In	 collaboration	 with	 the	 laboratory	 of	 Prof.	 Krause	 (UNIGE)	 we	 developed	 a	 vector	 which	
combines	an	in	vivo	selection	as	well	as	a	suicide	strategy	based	on	the	expression	of	the	human	
reduced	 folate	 carrier	 (hRFC1)	and	 the	 ribonucleotide	 reductase	 subunit	 (RRM2)	 146,147.	 Early	
gene	therapy	trials	with	retroviral	based	vectors	resulted	in	a	substantial	numbers	of	patients	
developing	 lymphomas	 due	 to	 the	 integration	 of	 the	 retroviral	 based	 vectors	 into	 proto‐
oncogenic	sites.	While	the	risk	of	such	a	serious	adverse	event	using	lentivirus	based	vectors	is	
highly	unlikely,	gene	engineering	strategies	should	include	a	suicide	strategy	for	killing	of	gene	
engineered	cells	which	might	undergo	malignant	transformation.	Since	HIV	replication	will	not	
be	controlled	when	only	a	minority	of	cells	are	resistant,	selection	is	needed	for	the	enrichment	
of	gene	engineered	cells	pre‐	or	post‐transplantation.		
1.1	 hRFC1	 is	 a	 transport	 protein	 for	 folate	 compounds	 and	 in	 particular	 also	 for	 the	 folate	
antagonist	 methotrexate.	 Thus,	 increased	 expression	 of	 hRFC1	 may	 promote	 the	 uptake	 of	
methotrexate	and	thus	the	preferential	killing	(suicide)	of	transduced	cells;	untransduced	cells	
will	be	more	resistant.	In	contrast,	trimetrexate,	another	folate	antagonist,	is	lipophilic,	and	thus	
is	 not	 dependent	 upon	 hRFC1;	 thus,	 cells	 with	 increased	 expression	 of	 hRFC1	 will	 have	 an	
increased	transport	of	folinic	acid	which	will	render	cells	resistant	to	trimetrexate	(selection);	
untransduced	 cells	 will	 be	 more	 vulnerable	 to	 this	 compound.	 In	 other	 terms,	 hRFC1	 gene	
engineered	 HPCs	 and	 their	 progeny	 cells	 should	 be	 highly	 vulnerable	 to	 the	 effect	 of	
methotrexate	(suicide)	while	being	resistant	to	trimetrexate	(selection)	146,148.		
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1.2	Human	DHFR	 is	 involved	 in	 synthesis	 of	 purines	 and	 thymidylates	 the	 basic	 components	
used	to	build	DNA.	More	specifically,	DHFR	reduces	dihydrofolic	acid	(a	vitamin	B9	derivative)	
to	 tetrahydrofolic	 acid	 which	 is	 the	 bases	 for	 synthesis	 of	 purines	 and	 pyrimidines	 149.	
Methotrexate	inhibits	DHFR	and	is	able	to	prevent	the	proliferation	and	growth	of	T	cells	150.	A	
mutant	form	of	the	DHFR	gene	has	been	described	called	DHFRfs,	which	has	normal	enzymatic	
activity	but	due	to	two	point	mutations	(Leu22	to	Phe	and	Phe31	to	Ser)	methotrexate	cannot	
bind	to	and	inhibit	the	mutant	form	of	the	enzyme	151.		
Trimetrexate	 and	 methotrexate	 are	 both	 compounds	 with	 FDA	 approval	 for	 human	 use.	
Trimetrexate	was	used	for	the	treatment	of	pneumocystis	carinii	pneumonia.	In	a	first	instance	
we	will	examine	the	in	vitro	selection/killing	by	transducing	HeLa	cells	or	SupT1	cells	with	the	
vector	encoding	hRFC1	which	then	will	be	exposed	to	either	methotrexate	or	trimetrexate.	We	
will	be	able	to	verify	enrichment	or	killing	of	transduced	cells	by	tracking	the	frequency	of	GFP	
positive	 cells	 by	 flow‐cytometry	 when	 adding	 trimetrexate	 or	 methotrexate	 since	 the	 vector	
encodes	in	addition	GFP.		
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Preliminary	results	
	 	
	
Figure	1.	Cloning	 strategy	 for	 the	DHFR	 and	DHFRfs	 selection	 project	 (please	 see	 section	 1.2	
above).	 Recombinational	 cloning	 to	 prepare	 the	 DHFR	 and	 DHFRfs	 selection	 plasmid	 which	
would	 include	 expression	 of	 the	 GFP	 reporter	 gene	 and	 the	 CCR5	 targeting	 triple	microRNA	
cassette.	 a)	 pENTR	 plasmid	 comtaining	 the	 human	 ubiquitin	 C	 promoter	 (UBI).	 This	 plasmid	
allows	 for	bacterial	 selection	with	kanamycin.	b)	pENTR	plasmid	containing	 the	GFP	reporter	
gene	 followed	 by	 the	 CCR5	 targeting	microRNAs.	 This	 plasmid	 allows	 for	 bacterial	 selection	
with	 kanamycin.	 c)	HIV‐1	 based	 self‐inactivating	 expression	 vector	which	 contains	 the	HIV‐1	
LTRs	and	other	critical	cis‐acting	elements	to	allow	packaging	of	lentivector	particles	as	well	as	
insertion	 if	 transgenes	 into	 the	 target	 cell	 genome.	 This	 plasmid	 contains	 the	 human	 PGK	
promoter	with	am	excisable	mCherry	gene	allowing	for	insertion	of	a	selection	gene	using	AgeI	
and	EcoRV	restriction	sites.	Once	an	enzymatic	LR	recombinational	reaction	is	carried	out,	the	
UBI	promoter	 and	GFP‐CCR5	microRNA	 sequences	will	 be	 inserted	 in	place	of	 the	 ccdB	 toxic	
gene.	This	plasmid	allows	for	bacterial	selection	with	Ampicillin.					
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Figure	 2:	 Administration	 of	 methotrexate	 causes	 a	 transient	 ablation	 of	 human	 cells	 in	
humanized	mice	at	a	dose	of	35mg/kg	per	mouse.	a)	Control	mice	(n=2)	and	methotrexate	mice	
(n=2)	were	injected	with	PBS	and	25mg/kg	methotrexate	respectively	at	days	0,	4	and	8.	There	
was	no	difference	in	frequency	of	human	cells	(CD45+)	in	the	peripheral	blood	during	the	course	
of	the	experiment.	The	red	dotted	line	indicates	the	last	day	of	drug	administration.	b)	Control	
mice	 (n=3)	 and	methotrexate	mice	 (n=3)	were	 injected	with	PBS	and	35mg/kg	methotrexate	
respectively	 at	 days	 1,	 4,	 8	 and	 11.	 At	 day	 15	 there	 was	 a	 further	 decrease	 in	 frequency	 of	
human	cells	(CD45+)	compared	to	day	8.	At	day	15	and	22	the	mice	receiving	methotrexate	had	
significantly	lower	frequencies	of	human	cells	(CD45+)	compared	to	the	PBS	mice.	32	days	after	
the	 last	 injection,	 the	 frequency	 of	 human	 cells	 had	 recovered	 in	 all	 mice	 that	 received	
methotrexate.	The	red	dotted	line	indicates	the	last	day	of	drug	administration.		
Outlook		
Once	 preliminary	 testing	 is	 complete	 the	 vectors	 described	 in	 this	 thesis	 would	 require	
optimization	of	the	geometry	to	produce	the	final	vector	which	will	combine	the	elements	for	in	
vivo	selection/suicide	and	two	anti‐HIV	targets.	This	will	be	conducted	in	collaboration	with	the	
laboratories	 of	 Prof.	 Karl‐Heinz	 Krause	 (UNIGE)	 and	 Prof.	 Michael	 Pepper	 (University	 of	
Pretoria,	SA)	to	initiate	a	phase	I	clinical	trial.		
120	
	
ix)	Invention	disclosures		
	
University	of	Geneva,	UNITEC:	New	design	of	micro	RNAs	(miRNAs)	for	
gene	therapy	vectors 
We	have	an	MTA	that	the	three	universities	involved	in	this	project	(University	of	Zurich,	University	
of	Pretoria	and	the	University	of	Geneva)	all	have	rights	to	use	these	inventions		
Inventors:	Renier	Myburgh	
Contributors:	Karl‐Heinz	Krause,	Patrick	Salmon	
Design	of	effective	and	improved	gene	therapy	vectors	enabling	markedly	improved	efficiency	
of	specific	gene	knockdown.	 	 Invention	circumvents	known	weak	points	 in	published	designs.		
Vectors	 enabled	 by	 the	 invention	 could	 have	 therapeutic	 applications	 in	 a	 range	 of	 diseases,	
including	treating	haematopoietic	stem	cells	for	treatment	of	malignancies	and	HIV	infection.	
	
University	of	Geneva,	UNITEC:	in	vivo	cell	selection	via	gene	therapy	
and	combination	cytotoxic	treatment 
We	have	an	MTA	that	the	three	universities	involved	in	this	project	(University	of	Zurich,	University	
of	Pretoria	and	the	University	of	Geneva)	all	have	rights	to	use	these	inventions		
Inventors:	Renier	Myburgh,	Karl‐Heinz	Krause,	David	Suter	
Contributors:	Michael	Pepper,	Patrick	Salmon	
New	 strategies	 for	 in	 vivo	 selection	 through	 the	 use	 of	 gene	 therapy	 vectors	 containing	
resistance	 genes	 against	 (more	 than	 one)	 cytotoxic	 compounds.	 Enabling	 in	 vivo	 (positive	 or	
negative)	 selection	 of	 transplanted	 cells	 concomitantly	 transformed	 by	 disease‐specific	 gene	
therapy,	thus	favouring	survival	of	cells	with	effective	therapeutic	modification.		
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DISCUSSION	
	
In	this	thesis,	we	endeavoured	to	develop	a	gene	therapy	cure	for	HIV.	We	based	our	strategy	on	
producing	CCR5‐deficient	hematopoietic	progenitor	cells,	which	are	CCR5	deficient	as	a	result	of	
constitutive	expression	of	highly	efficient	CCR5	targeting	microRNAs	(miRNAs).		
	
We	 had	 several	 reasons	 for	 using	 this	 strategy.	 First,	 HAART	 treatment	 has	 improved	 the	
outcome	 for	 HIV	 patients	 in	 general	 but	 has	 known	 disadvantages,	 such	 as	 drug	 toxicity	
(cardiovascular,	kidney,	liver	disease	as	well	as	cancer),	the	need	to	adhere	to	complicated	drug	
regimens,	and	the	emergence	of	drug‐resistant	strains	of	the	virus	152‐155.	Second,	CCR5‐deficient	
individuals	are	protected	against	HIV	 infection	yet	suffer	no	detrimental	effects	without	CCR5	
156.	Third,	in	South	Africa,	a	substantial	number	of	HIV‐infected	patients	also	have	lymphomas	in	
advanced	stages;	this	included	AIDS	defining	and	non‐AIDS	fining	cancers.	157,158.	Chemotherapy	
alone	 or	 in	 combination	with	 rituximab	will	 not	 be	 sufficient	 to	 cure	 these	 lymphomas,	 and	
these	patients	will	still	require	treatment	with	ablative	chemotherapy	and	autologous	stem	cell	
transplantation.	 This	 provides	 the	 opportunity	 to	 intervene	 and	 complement	 the	 autologous	
hematopoietic	 progenitor	 cells	 of	 these	 patients	 with	 anti‐HIV	 genes	 able	 to	 eliminate	 CCR5	
expression	to	try	and	cure	HIV	in	parallel.		
	
The	proof	of	concept	 that	CCR5	deficiency	can	be	used	as	a	 therapy	 for	HIV	 is	 the	case	of	 the	
“Berlin	 patient,”	 who	 received	 donor	 CCR5‐deficient	 hematopoietic	 progenitor	 cells	 to	 treat	
acute	myeloid	leukemia.	The	patient	became	aviraemic	soon	after	transplantation	43.	This	is	still,	
however,	a	unique	case	51,	and	it	does	not	strongly	suggest	CCR5	as	a	viable	gene	therapy	target.	
This	does	 not	mean	 that	 other	 targets	 for	HIV	 gene	 therapy	 should	be	 ignored;	 indeed	many	
groups	have	 explored	 the	potential	 of	 targeting	HIV	 genes,	 such	 as	Tat,	Nef	 and	Rev	 (only	 to	
mention	 a	 few),	with	RNA	 interference	 to	 eliminate	 expression	 of	 these	 gene	products	 159‐162.	
The	concern	with	targeting	HIV	genes	is	that	a	single	target	of	this	kind	should	not	be	used	in	
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isolation.	HIV	has	 a	 very	 high	 replication	 rate	 that	 ultimately	 results	 in	mutations	 in	 the	HIV	
RNA	that	render	the	gene	therapy	useless.		
	
Effective	and	robust	 targeting	of	HIV	genes	with	RNA	 interference	requires	 the	use	of	several	
dissimilar	 RNA	 interference	 species	 that	 target	 different	 genes.	 Furthermore,	 the	 RNA	
interference	 genes	 must	 have	 perfect	 homology	 to	 their	 HIV	 gene	 targets:	 even	 a	 single	
mutation	 in	an	HIV	gene	can	prevent	 targeting	by	 the	RNA	 interference	gene	163‐165.	Thus,	 the	
most	robust	strategy	would	be	to	target	a	host	gene,	such	as	CCR5,	as	well	as	a	single	HIV	gene	
or	multiple	 HIV	 genes,	 providing	 broad	 enough	 coverage	 to	 prevent	 HIV	 escape.	 Indeed	 this	
type	of	strategy	has	been	studied	in	humanized	mice	in	which	down‐regulation	of	CCR5	with	an	
shRNA	 was	 combined	 with	 a	 Tar	 decoy	 and	 an	 anti‐HIV	 TRIM5α	 isoform	 56.	 However,	 this	
complicated	strategy	did	not	inhibit	viral	 load	 in	vivo.	Only	when	splenocytes	from	these	mice	
were	sorted	into	anti‐HIV	transduced	and	non‐transduced	cells	did	the	authors	report	that	HIV	
replication	was	blocked	in	the	anti‐HIV	transduced	fractions	55,56,166.	
	
We	 opted	 to	 start	 with	 development	 of	 a	 CCR5‐based	 strategy	 before	 developing	 secondary	
and/or	tertiary	targets.	It	is	also	important	to	verify	the	effectiveness	of	each	single	target	54,59‐
61,167,	before	testing	multiple	targets	simultaneously	55,56,168‐170.	Silencing/knocking‐out	CCR5	by	
shRNAs	 or	 zinc‐finger	 nucleases	 has	 been	 extensively	 tested	 in	 HIV‐permissive	 humanized	
mouse	models	 54‐56,59.	Up	 to	 this	point,	miRNAs	 to	 knock‐down	CCR5	have	not	 been	 tested	 in	
humanized	mouse	models.	This	is	somewhat	surprising	since	shRNAs	cause	cellular	toxicity	in	
vivo	65,171.	The	toxicity	has	been	linked	to	shRNAs	having	to	be	expressed	from	highly	active	pol	
III	promoters,	however	these	promoters	are	usually	necessary	for	proper	expression	of	shRNAs	
as	 they	require	very	precise	ends	 to	be	correctly	processed	and	he	 initiation	and	 termination	
sites	of	pol	III	promoters	are	well	defined	172.	Furthermore,	shRNAs	bypass	DROSHA	processing	
in	the	nucleus	and	over‐saturate	exportin5,	which	affects	the	processing	of	naturally	occurring	
miRNAs	 in	 the	 cell	 65,171.	On	 the	other	hand,	miRNAs	 can	be	 expressed	 from	 less	 active	pol	 II	
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promoters	 and,	 since	 they	 follow	 the	 full	 RNA	 interference	 pathway	 (including	 DROSHA	
processing),	might	 be	 less	 likely	 to	 disrupt	 cellular	 homeostasis	 172.	 The	 rate	 of	 transduction	
must	also	be	considered	in	terms	of	causing	cellular	toxicity.	If	excessive	transduction	rates	are	
used	(over	50%),	the	resulting	high	level	of	expression	due	to	the	presence	of	multiple	copies	of	
the	 transgene	would	 likely	 result	 in	 cellular	 toxicity	even	with	miRNAs	expressed	 from	pol	 II	
promoters	89,172.		
	
Since	 these	gene	 therapies	are	aimed	at	patients,	 safety	 is	of	great	 concern,	and	 the	 choice	of	
vector	is	important.	A	previous	gene	therapy	trial	for	(SCID)	X‐1	disease	used	moloney	murine	
leukaemia	 gamma	 retrovirus	 (MLV).	 The	 resulting	 activated	 proto‐oncogenes	 caused	 T‐cell	
leukemia	in	the	patients	173,174.	The	tendency	of	gamma‐retroviruses	to	integrate	their	genomes	
near	 transcription	 start	 sites	 and	 Cpg	 islands	 was	 directly	 linked	 to	 the	 development	 of	
leukaemia.	A	further	consideration	is	level	of	transduction.	High	levels	of	transduction	increase	
the	 number	 of	 transgene	 copies	 inserted	 per	 cell	 89,	 and	 a	 combination	 of	 high	 rates	 of	
transduction	and	the	tendency	of	gamma‐retorviruses	to	integrate	in	the	same	regions	in	close	
proximity	to	known	proto‐oncogenes	increases	the	chance	of	aberrant	effects	89,132,133,173.		
	
With	safety	in	mind,	our	CCR5‐targeting	miRNA	was	cloned	into	a	self‐inactivating	HIV‐1‐based	
lentivector	system,	and	we	maintained	reasonably	low	levels	of	transduction	(<30%).	In	human	
gene	 therapy	clinical	 trials	 for	Wiskott	Aldrich	syndrome	and	metachromatic	 leukodystrophy,	
HIV‐1‐based	lentivectors	have	been,	thus	far,	safe	in	terms	of	the	integration	profile	even	when	
high	transduction	rates	were	used	132,133.	The	reason	for	this	is	lentivectors	tend	to	insert	within	
transcriptional	 units	 or	 gene‐rich	 regions	 and	 not	 close	 to	 genes	 that	 are	 associated	 with	
causing	clonal	expansion	132,133.	A	further	advantage	of	lentivectors	is	their	ability	to	transduce	
quiescent	 cells.	 HIV‐1	 lentivectors	 can	 better	 transduce	 quiescent,	 primitive	 human	
hematopoietic	progenitor	cells	than	MLV‐based	vectors.	Because	anti‐HIV	transduced	progeny	
cells	are	required	throughout	life,	HIV	gene	therapy	must	achieve	decent	levels	transduction	of	
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true	 hematopoietic	 progenitors	 175.	 The	 ability	 of	 HIV‐1‐based	 lentivectors	 to	 transduce	
quiescent	cells	 is	why	lentivectors	have	such	a	distinct	and	much	more	favourable	 integration	
profile	than	MLV	vectors.		
	
We	used	an	HIV‐1‐based	 lentivector	with	a	CCR5‐targeting	miRNA	cassette	 (three	hairpins	 in	
tandem)	and	limited	transduction	rates	to	approximately	20%	to	prevent	cells	from	containing	
more	 than	one	copy	 the	 transgene.	The	 limited	 transduction	rates	make	knock‐down	of	CCR5	
more	difficult	since	the	miRNA	needs	to	be	efficient	enough	to	achieve	high‐level	knock‐down	
despite	 the	 low	 transduction	 rate.	The	 first	miRNA	we	 tested,	miR‐30,	 resulted	 in	 suboptimal	
knock‐down	 at	 low	 transduction	 rates	 (<20%	 knock‐down).	 Since	miR‐30	was	 commercially	
available	 along	 with	 a	 well‐described	 system	 for	 target	 gene	 knock‐down	 (GIPZ	 &	 TRIPZ	
shRNAmir	 lentivector	 expression	 systems,	 Thermo	 Scientific	 Open	 Biosystems;	
http://www.bmgc.umn.edu/prod/groups/ahc/@pub/@ahc/@bmgc/documents/asset/ptripz_
technical_manual.pdf),	we	were	forced	to	find	a	way	to	significantly	improve	its	efficiency.	We	
attempted	 to	 redesign	 the	miRNA	to	 improve	 its	processing	by	endogenous	RNA	 interference	
enzymes	which	would	result	in	more	targeting	strand	being	released	in	the	cytoplasm	to	allow	
for	 greater	 knockdown	 of	 the	 target	 gene.	 It	 must	 be	 efficient	 enough	 to	 achieve	 complete	
knockdown	at	 low	 transduction	rates.	We	hypothesised	 that	 the	poor	performance	of	miR‐30	
was	due	 to	 an	 inefficient	 processing	 somewhere	 between	Drosha	 and	DICER.	 Through	 an	 in‐
depth	review	of	the	literature,	we	found	that	weaker	down	regulation	was	provided	by	miRNAs	
with	 shorter	 lower	 stem	 lengths	 and	 with	 upper	 stems	 in	 which	 the	 5’	 end	 of	 the	 targeting	
strand	was	not	thermodynamically	unstable	compared	to	the	3’	end	72.	miR‐30	miRNAs	have	a	
shorter	lower	stem	and	suboptimal	targeting	strand	thermodynamic	configuration.	We	thought	
this	 would	 negatively	 affect	 DROSHA	 processing	 and	 hamper	 release	 of	 targeting	 strand.	 To	
address	 these	 issues,	 we	 modified	 various	 structural	 features	 of	 the	 miRNA	 that	 we	 called	
(mirGE).	The	modifications	were	the	following:	the	lower	stem	length	was	increased	from	9	to	
13	nucleotides,	the	targeting	strand	was	moved	to	the	5’	side	of	the	miRNA,	and	the	5’	end	of	the	
125	
	
targeting	strand	was	designed	to	be	more	thermodynamically	unstable	than	the	3’	end,	which	
should	 facilitate	 selection	 and	 loading	 of	 the	 targeting	 strand	 into	 RISC	 rather	 than	 the	
passenger	strand.	72,93,176	.	We	also	included	a	wobble	in	the	middle	of	the	upper	stem	to	prevent	
abortive	 processing	 72.	 These	modifications	 resulted	 in	 2x	more	 CCR5	 knock‐down	 than	with	
miR‐30	at	a	similar	transduction	rate.		
	
While	 refining	 our	 design,	 we	 discovered	 that	 the	 thermodynamically	 unstable	 5’	 end	 of	 the	
targeting	strand	was	not	so	important	for	improving	knock‐down	efficiency	as	described	72,93,176.	
To	test	this,	we	developed	various	hairpins	targeting	GFP	with	lower	stem	lengths	ranging	from	
9–17	nucleotides	and	where	either	the	5’	or	3’	of	the	targeting	strands	were	thermodynamically	
unstable.	These	experiments	showed	 that	 it	was	 rather	 the	 increased	 lower	stem	 length	 (>11	
nucleotides	and	<17	nucleotides)	that		increased	GFP	knockdown	since	within	this	lower	stem	
length	range,	the	5’	targeting	strand	mismatch	did	not	significantly	 increase	GFP	knock‐down,	
compared	 to	 the	 same	 hairpins	 with	 an	 unstable	 3’	 targeting	 strand.	 These	 results	 were	
confirmed	by	sequencing	total	RNA	from	cells	transduced	with	the	miR‐30	or	mirGE	vectors.	We	
used	 next‐generation	 sequencing	 techniques	 to	 detect	 the	 siRNAs	 (targeting	 and	 passenger	
strands)	 released	 by	 DROSHA	 and	 DICER	 processing.	 The	 increased	 level	 of	 knock‐down	
capacity	of	our	mirGE	could	be	attributed	to	the	increased	lower	stem	length,	which	resulted	in	
very	accurate	DROSHA	processing	(0.027%	incorrect	cuts),	compared	to	miR‐30,	with	a	shorter	
lower	stem	in	which	DROSHA	processing	was	very	inaccurate	(21%	incorrect	cuts).	For	mirGE,	
there	 was	 very	 efficient	 release	 of	 the	 5’	 end	 of	 the	 targeting	 strand.	 For	 miR‐30,	 since	 the	
targeting	strand	was	carried	on	the	3’	end	of	the	hairpin,	DICER	was	responsible	for	releasing	of	
its	targeting	strand	5’	end	and	for	both	mirGE	and	miR‐30	DICER	was	relatively	imprecise	in	its	
cleavage.	 This	 resulted	 in	 10x	 more	 targeting	 strand	 available	 for	 RISC	 coming	 from	 mirGE	
compared	to	miR‐30.		
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The	 mirGE	 design	 proved	 successful	 during	 in	 vitro	 testing	 where	 	 with	 a	 triple	 miRNA	
expressed	as	a	cassette	we	could	achieve	>90%	CCR5	knockdown	at	low	transduction	rates	in	
HeLa	cells.	We	then	initiated	in	vivo	testing.	We	used	the	NSG	humanized	mouse	model,	where	
mice	were	 produced	with	 transduced	 human	 umbilical	 cord	 blood	 derived	 CD34+	 progenitor	
cells.	In	the	first	set	of	experiments,	we	transduced	CD34+	cells	at	<30%	with	the	CCR5	knock‐
down	vector	and	 transplanted	 the	 total	CD34+	cell	population	 into	 the	mice.	 In	 these	animals,	
less	 than	 30%	of	 the	 progeny	 cells	were	 transduced	 in	vivo,	and	no	 viral	 load	 inhibition	was	
achieved.	The	major	limiting	factor	was	the	low	frequency	of	anti‐HIV	transduced	cells.	This	was	
the	same	limiting	factor	that	hindered	various	previous	attempts	at	inhibiting	HIV	viral	load	in	
humanized	 mice	 with	 gene	 therapy	 55,56,59,177.	 Shimizu	 et	 al;	 transplanted	 mice	 in	 which	 45–
50.8%	of	CD34+	cells	were	anti‐HIV	transduced	59.	Ringpis	et	al;	transduced	the	CD34+	cells	in	a	
range	 of	 63–79%,	 however,	mice	were	 transplanted	with	 a	 50:50	mixture	 of	 transduced	 and	
untransduced	cells	55.	Walker	et	al;	did	not	indicate	the	initial	transduction	rate	of	their	CD34+	
cells,	 but	mice	 transplanted	with	 the	 anti‐HIV	 transduced	 CD34+	 cells	 had	 17.5%	of	 the	 total	
human	cells	 and	55%	of	CD4+	T	 cells	 transduced	 in	vivo	 56.	 Centlivre	 et	 al;	 transplanted	mice	
with	a	CD34+	cell	mixture	in	which	43%	of	cells	were	transduced	177.	In	all	of	these	studies,	no	
viral	load	inhibition	was	achieved	in	vivo.	However,	when	splenocytes	were	isolated	and	sorted	
into	pure	fractions	of	anti‐HIV	transduced	cells,	viral	inhibition	was	achieved.	In	our	first	set	of	
experiments	 in	 humanized	mice,	we	 transplanted	 a	mixture	 of	 untransduced	 and	 transduced	
cells	 as	described	above,	 and	we	maintained	 low	 initial	 transduction	 rates	of	 the	CD34+	 cells.	
This	low	transduction	rate	was	maintained	to	limit	the	number	of	integrated	vector	copies	per	
cell	which	has	safety	implications,	and	this	would	allow	us	to	determine	whether	there	would	
be	 any	 antiviral	 effects	 with	 the	 resulting	 low	 frequency	 of	 anti‐HIV	 cells	 in	 the	 periphery.	
Indeed	we	saw	an	expansion	of	the	anti‐HIV	transduced	CD4+	T	cells	in	the	peripheral	blood	of	
these	mice,	although	it	must	be	stated	it	was	a	rather	limited	expansion	which	did	not	translate	
into	viral	load	inhibition	in	vivo.	We	had	expected	that	in	this	scenario,	there	would	be	a	much	
stronger	 selection	of	 anti‐HIV	 transduced	cells	due	 to	 the	killing	of	untransduced	cells	by	 the	
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virus,	however	 the	continuous	renewal	of	untransduced	cells	 into	 the	periphery	coming	 from	
the	majority	of	untransduced	engrafted	human	hematopoietic	progenitor	cells	allowed	HIV	 to	
replicate	 unhindered.	 Eventually,	 a	 general	 loss	 of	 CD4+	 T	 cells	 occurred	 in	 these	 animals,	 as	
well	 as	 an	 inversion	 of	 the	 normal	 CD4/CD8	 ratio.	 Similar	 results	 were	 reported	 when	
comparable	 or	 even	 higher	 transduction	 rates	 of	 CD34+	 cells	 were	 used	 56,167,170.	 Higher	
transduction	 rates	 on	 transplanted	 CD34+	 cells	 resulted	 in	 higher	 frequencies	 of	 transduced	
progeny	cells	in	the	periphery	that,	 in	some	cases,	resulted	in	a	transient	viral	 load	inhibition,	
but	 no	 long‐term	 effect	 on	 viral	 load	 was	 achieved	 in	 vivo	 56,167,170.	 Holt	 et	 al;	 showed	 a	
significant	but	short‐term	viral	 load	 inhibition	with	their	strategy	54.	However,	 it	 is	difficult	 to	
compare	these	results	directly	since	the	authors	modified	the	CD34+	cells	by	nucleofection	and	
not	transduction	with	lentivectors.	Kitchen	et	al;		used	very	low	transduction	rates	and	reported	
some	 antiviral	 effect	 but	 again	 short	 term	 57.	 Importantly,	 they	mentioned	 above	 and	 others	
demonstrate	 complete	 or	 substantial	 HIV	 viral	 load	 inhibition	 only	 in	 ex	 vivo	 purified	
transduced	splenocytes	from	humanized	mice	transplanted	with	untransduced	and	transduced	
CD34+	 cells	 55,56,59,177.	We	 also	 demonstrated	 that	 the	 purified	 transduced	 fraction	 of	 spleens	
from	our	mice	transplanted	with	a	mixture	of	untransduced	and	transduced	CD34+	cells	resisted	
HIV	 infection	 ex	 vivo.	 Importantly,	 in	 our	 experiments,	 the	 initial	 transduction	 rate	 of	 the	
transplanted	 CD34+	 cells	 was	 <30%,	 demonstrating	 that	 our	 miRNA‐mediated	 CCR5	 knock‐
down	is	comparable	in	its	ability	to	inhibit	HIV	infection	to	recently	published	work	55,56,59,177.		
	
HIV	gene	therapy	is	more	complicated	and	difficult	to	cure	than	other	diseases,	such	as	Wiskott	
Aldrich	syndrome.	With	very	few	cells	and	very	quickly,	HIV	can	establish	a	latent	reservoir	in	
the	 mucosal	 and	 lymphoid	 compartments,	 ensuring	 its	 persistence	 even	 when	 HAART	
treatment	 is	 administered	 178.	 HIV	 establishes	 a	 permanent	 reservoir	 extremely	 early	 on	 in	
infection	 (i.e.,	within	 the	 first	days)	 178,	 and	HAART	alone	cannot	deplete	 the	 latent	 reservoir.	
Gene	 therapy	 for	 HIV	 cannot	 deplete	 the	 latent	 reservoir,	 and	 any	 untransduced	 cells	 will	
provide	 HIV	with	 an	 opportunity	 to	 replicate.	 So	 the	main	 hurdle	 is	 to	 achieve	 high	 enough	
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frequencies	 of	 transduced	 anti‐HIV	 progeny	 cells	 in	 vivo.	 Furthermore,	 HIV	 can	 evolve	 and	
develop	escape	mutants,	depending	on	the	selective	pressure	applied.	Thus,	critical	co‐factors	
or	viral	genes	that	are	targeted	must	be	completely	down‐regulated	or	blocked,	and	coverage	of	
these	 various	 targets	must	 be	 extensive	 enough	 to	 prevent	 escape.	 To	 succeed,	 any	 anti‐HIV	
vectors	must	perform	at	a	very	high	level.	On	the	other	hand,	for	other	diseases	which	are	being	
treated	 with	 gene	 therapy	 (e.g.,	 Wiskott	 Aldrich	 syndrome),	 all	 that	 is	 required	 is	 some	
expression	 of	 the	 correct	 version	 of	 a	 gene	 that	 is	 lacking	 in	 a	 proportion	 of	 the	 cells	
transplanted	back	to	the	patient.	This	level	of	transgene	expression	being	sufficient	to	provide	a	
positive	 clinical	outcome	 132,133.	 Indeed,	 in	 certain	diseases,	 cells	 expressing	 the	 transgene	are	
naturally	positively	selected	due	to	a	survival	advantage:	the	gene	in	question	is	directly	linked	
to	correct	functioning	and	survival	of	certain	immune	cells.	132,133.	
	
With	the	issue	of	frequency	of	anti‐HIV	transduced	cells	being	crucial	for	HIV	gene	therapy,	the	
aim	of	our	second	set	of	in	vivo	experiments	was	to	address	this	and	to	try	and	establish	what	
the	 threshold	 is?	What	proportion	of	 transduced	cells	 is	 required	 in	order	 to	provide	enough	
protection	to	inhibit	HIV	replication	in	vivo?	We	maintained	the	use	of	low	transduction	rates	of	
CD34+	 cells,	 eliminated	 the	 untransduced	 cells	 prior	 to	 transplantation	 by	 FACS	 and	
transplanted	only	anti‐HIV	transduced	cells	into	the	mice.	This	resulted	in	mice	with	practically	
pure	populations	of	transduced	progeny	cells	in	the	periphery.	Upon	infection,	viral	replication	
never	 reached	 the	 normal	 plateau	 and	 was	 significantly	 inhibited	 for	 an	 extended	 period	 of	
time.	Despite	 the	ongoing	 low	 levels	of	viral	 replication,	 these	animals	did	not	experience	 the	
usual	HIV‐associated	 loss	 of	 CD4+	 T	 cells.	 Furthermore,	 expansion	 of	 central	memory	 CD4+	 T	
cells,	 which	 have	 been	 suggested	 to	 contribute	 to	 enhanced	 control	 of	 HIV	 infection,	 was	
evident.	Central	memory	CD4+	T	cells	are	an	indication	of	immune	reconstitution	upon	HAART	
treatment	139,143,179.	At	this	point,	we	provided	the	first	data	showing	the	generation	of	mice	with	
pure	populations	of	transduced	cells	in	vivo	resulting	in	in	vivo	long‐term	HIV	viral	load	control.	
The	ongoing	 low	 level	 viral	 replication	observed	was	most	 likely	due	 to	 the	engraftment	of	 a	
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small	population	of	untransduced	cells	that	remained	after	the	sorting	prior	to	transplantation.	
This	population	only	represented	approximately	7%	of	 the	 total	 transplanted	cells,	and	again,	
this	illustrates	the	challenges	we	face	with	finding	a	cure	for	HIV	with	gene	therapy.	The	margin	
for	error	 is	very	small.	Our	data	 indicate	 that	practically	all	 cells	must	be	 transduced	with	an	
anti‐HIV	RNA;	indeed,	even	in	our	model,	HIV	established	itself	and	replicated.	The	main	effect	
of	our	data	is	the	proof	of	concept:	to	provide	an	effective	gene	therapy	cure	for	HIV,	either	very	
effective	ex	vivo	selection	or	in	vivo	selection	strategies	must	be	implemented	alongside	highly	
effective	anti‐HIV	transgenes.		
	
An	 aspect	 that	was	not	 examined	 in	 this	work	 is	whether	HAART	 implemented	 for	 a	 defined	
period	 of	 time	 would	 affect	 the	 ability	 of	 HIV	 to	 rebound	 in	 an	 environment	 made	 up	 of	
primarily	anti‐HIV	transduced	cells.	Furthermore,	these	studies	were	conducted	in	humanized	
mice	that	do	not	harbour	a	fully	functional	human	immune	system.	We	can	only	speculate	what	
degree	of	protection	this	 frequency	of	anti‐HIV	gene‐engineered	cells	could	provide	 in	an	HIV	
patient	 since	a	patient’s	 immune	system	can	recover	significantly	under	HAART.	Perhaps	 this	
frequency	of	anti‐HIV	engineered	cells	in	a	patient	could	provide	sufficient	protection	to	allow	
the	immune	system	to	reconstitute	itself	and	significantly	suppress	the	viral	load,	this	also	being	
the	result	of	possibly	a	much	more	efficient	selection	of	the	anti‐HIV	cells	by	HIV	in	this	setting.		
This	 would	 open	 up	 the	 possibilities	 for	 a	 range	 of	 new	 ways	 to	 treat	 HIV,	 such	 as	
complementing	 gene	 therapy	with	HAART,	HAART	 for	 limited	 periods	 of	 time,	 or	 even	more	
simplified	 HAART	 regimens,	 as	 well	 as	 possibly	 combining	 gene	 therapies	 with	 therapeutic	
vaccines.	The	major	hope	for	HIV	gene	therapy	is	to	provide	a	definitive	cure	for	HIV	or	at	least	
to	alleviate	the	burden	of	current	HAART	regimens	in	terms	of	dosage	or	duration	of	treatment.	
This	would	not	only	benefit	the	health	of	patients	worldwide	but	also	address	issues	of	cost	and	
compliance	to	life‐long	HAART.	
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OUTLOOK	
	
1) New	anti‐HIV	targets:	Since	we	have	provided	the	first	proof	of	principle	that	our	CCR5	
targeting	 strategy	 can	provide	protection	 against	HIV	 in	 humanized	mice,	 our	 lab	 has	
initiated	 the	 development	 of	 new	 lentivectors	 to	 express	 further	 anti‐HIV	 genes	 to	
compliment	 the	 anti‐CCR5	 microRNA	 cassette.	 These	 new	 anti‐HIV	 genes	 will	 act	 as	
decoy	molecules	 to	 disrupt	 the	 APOBEC‐Vif	 interaction	 in	 such	 a	way	 to	 increase	 the	
amount	of	anti‐viral	APOBEC3G.	APOBEC3G	interferes	with	the	reverse	transcription	of	
HIV	as	well	as	viral	DNA	integration.	The	HIV	Vif	protein	(viral	infectivity	factor),	blocks	
the	 antiviral	 activity	 of	 the	 human	 APOBEC3G	 enzyme,	 this	 interaction	 results	 in	 the	
ubiquitination	and	cellular	degradation	of	APOBEC3G.	There	are	3	new	vectors	planned:	
i)	Over‐expression	of	a	mutant	APOBEC3G	(D128K)	which	Vif	is	unable	to	bind	to	due	to	
the	point	mutation	180,181.	This	mutant	APOBEC3G	is	otherwise	fully	functional.	ii)	Over‐
expression	of	a	truncated	form	of	the	Vif	protein	which	cannot	bind	to	the	proteasomal	
degradation	 complex	 and	 thus	 should	 not	 be	 able	 to	 direct	 the	 degradation	 of	
APOBEC3G.	This	truncated	Vif	will	compete	with	wildtype	Vif	for	binding	to	APOBEC3G	
which	should	result	in	more	APOBEC3G	available	for	incorporation	into	newly	produced	
viral	 particles.	 iii)	 	 Over‐expression	 of	 a	 truncated	 form	 of	 Vif	 which	 cannot	 bind	 to	
APOBEC3G	 but	 is	 still	 able	 to	 bind	 to	 the	 proteasomal	 machinery.	 Excess	 of	 this	 Vif	
mutant	 should	 saturate	 the	 proteasomal	 machinery	 and	 prevent	 the	 degradation	 of	
endogenous	APOBEC3G	bound	to	wildtype	Vif.	 iv)	The	anti‐CCR5	microRNA	which	we	
called	mirGE	has	performed	extremely	well.	I	have	however	tried	to	further	improve	our	
knockdown	capabilities	by	designing	a	new	microRNA	which	I	have	called	miR‐Extreme.	
In	brief,	miR‐Extreme	has	the	same	5’	flank,	lower	stem	and	upper	stem	configuration	as	
mirGE.	 The	 loop	 has	 been	 replaced	 by	 smaller	 9	 nucleotide	 super	 loop	 182,	 and	 the	 3’	
flanking	sequence	has	been	replaced	by	a	sequence	from	a	recently	described	microRNA	
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called	miR‐E	183.	 	miR‐Extreme	has	been	designed	to	target	CCR5,	it	needs	to	be	cloned	
into	an	appropriate	vector	to	be	tested.	
Once	all	vectors	are	tested,	the	final	plan	is	to	combine	the	most	effective	decoy	Vif	or	
APOBEC3G	with	the	anti‐CCR5	microRNA	genes	in	a	single	construct.		
2) Selection	 strategies:	 I	 have	 developed	 lentivectors	 that	 express	 various	 genes	 that	
provide	resistance	or	 in	one	case	 increased	sensitivity	 to	various	drugs.	The	drugs	we	
have	 chosen	 are	 antifolate	 drugs	 used	 in	 cancer	 treatments	 (methotrexate	 and	
trimetrexate)	as	well	as	hydroxyurea	which	is	also	a	cancer	drug.	These	drugs	have	been	
or	are	used	routinely	 in	clinics.	The	reason	 for	developing	such	vectors	 is	 to	allow	 for	
the	 ex	 vivo	 or	 in	 vivo	 selection	 of	 anti‐HIV	 transduced	 cells	 as	 we	 believe	 HIV	 gene	
therapy	can	only	work	sufficiently	well	 if	 the	vast	majority	 (>90%)	of	HIV	 target	 cells	
are	transduced	with	an	anti‐HIV	genes.	Two	vectors	have	already	been	constructed	and	
testing	is	underway	 i)	Expression	of	the	human	RFC1	gene	and	RRM2	gene	in	a	single	
construct.	 Expression	 of	 hRFC1	 results	 in	 cells	 being	 resistant	 to	 trimetrexate	 which	
means	that	untransduced	cells	can	be	negatively	selected,	but	at	the	same	time	cells	are	
more	sensitive	to	methotrexate,	so	if	needed,	the	transduced	cells	can	be	eliminated.	In	
parallel,	 expression	 of	 the	 RRM2	 gene	 makes	 cells	 resistant	 to	 hydroxyurea.	 The	
possible	benefit	of	expressing	two	positive	selection	genes	simultaneously	is	that	lower	
concentrations	of	each	drug	could	be	used	if	the	two	drugs	have	a	synergistic	effect.	This	
has	 still	 to	 be	 tested.	 ii)	 Expression	 of	 a	 mutant	 form	 the	 human	 dehydrofolate	
reductase	gene	(DHFRfs).	Methotrexate	has	a	very	similar	structure	to	folic	acid,	and	has	
a	 100x	 higher	 affinity	 for	 wildtype	 DHFR	 compared	 to	 folate.	 Methotrexate	 however	
cannot	bind	to	the	mutant	DHFRfs	gene	and	therefore	cells	expressing	the	DHFRfs	gene	
are	resistant	to	methotrexarte	resulting	in	a	powerful	selection	tool.		
Once	we	 have	 determined	which	 selection	 strategy	 is	 the	most	 efficient,	 the	 ultimate	
goal	is	to	generate	a	vector	with	the	anti‐CCR5	microRNA;	a	2nd	anti‐HIV	gene	(decoy)	as	
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well	 as	 the	 selection	 gene	 or	 genes.	 This	 final	 vector	 will	 be	 tested	 in	 a	 humanized	
mouse	model	 and	 for	 this	phase	of	 testing	will	most	 likely	 include	 a	 reporter	 gene.	 It	
might	be	crucial	to	test	in	parallel	a	second	version	of	this	construct	without	a	reporter	
gene	since	we	plan	to	use	this	vector	in	a	Phase	I	clinical	trial.				
3) Phase	 I	 clinical	 trial	 in	 South	 Africa:	 The	 long	 term	 objective	 is	 to	 use	 the	 final	
lentivector	 which	 is	 the	 product	 of	 the	 work	 described	 above	 to	 produce	 lentivector	
particles	and	transduce	patient	CD34+	progenitor	cells	under	GMP	conditions.	Since	the	
advent	 of	 HAART,	 the	 frequency	 of	 AIDS‐Non‐Hodgkin’s	 lymphoma	 (HIV‐NHL)	 has	
decreased	184.	This	has	been	attributed	to	the	improved	immunity	and	decreased	risk	of	
opportunistic	infections	due	to	modern	HAART	regimens	184.	Ironically,	worldwide	there	
has	been	a	recent	and	dramatic	increase	in	the	numbers	of	HIV	patients	developing	non‐
AIDS	 defining	 cancers	 such	 as	Hodgkin’s	 lymphoma	 (HL)	 185.	 In	 South	Africa	 it	 seems	
there	is	a	different	trend,	there	has	been	a	sharp	increase	in	frequency	of	HIV	patients	
developing	HIV‐NHL	despite	HAART	as	well	as	an	increase	in	frequency	of	HIV	patients	
developing	HL	157.	Since	2002	the	numbers	of	HIV	patients	with	NHL	has	increased	from	
20–30	patients	per	year	 to	70–80	patients	per	year	 157.	During	 the	period	1995‐2004,	
19.5%	 of	 HIV	 patients	 from	 the	 Chris	 Hani	 Baragwanath	 Hospital	 near	 Johannesburg	
presented	 with	 HL.	 However	 this	 has	 now	 increased	 to	 over	 50%	 157.	 Since	 these	
patients	 require	 chemotherapy,	 the	 ultimate	 goal	 would	 be	 to	 obtain	 hematopoietic	
stem	cells	from	such	patients	from	the	peripheral	blood	following	G‐CSF	stimulation	or	
directly	from	bone	marrow	prior	to	chemotherapy.	The	stem	cells	will	be	transduced	ex	
vivo	with	the	anti‐HIV‐selection	lentivector	discussed	above.	The	autologous	transduced	
hematopoietic	stem	cells	will	be	 infused	back	 into	 the	patient	with	 the	hope	that	both	
diseases	can	be	addressed	in	this	way.	
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